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ABSTRACT	OF	THE	DISSERTATION		Synthesis	of	α-L-Threofuranosyl	Nucleosides,	Phosphoramidites,	and	Triphosphates	for	Synthetic	Biology		By		Saikat	Bala		Doctor	of	Philosophy	in	Pharmaceutical	Sciences			University	of	California,	Irvine,	2019		Professor	John	C	Chaput,	Chair		 	A	major	goal	of	synthetic	biology	is	to	recapitulate	emergent	properties	of	life.	Despite	a	significant	body	of	work,	a	longstanding	question	that	remains	to	be	answered	is	how	such	a	 complex	 system	 arose?	 In	 this	 dissertation,	 synthetic	 nucleic	 acid	 molecules	 with	alternative	sugar-phosphate	backbones	were	investigated	as	potential	ancestors	of	DNA	and	RNA.	 Threose	 nucleic	 acid	 (TNA)	 is	 capable	 of	 forming	 stable	 duplex	 structure	 with	complementary	strands	of	itself	and	RNA.	This	provides	a	plausible	mechanism	for	genetic	information	 transfer	 between	 TNA	 and	 RNA.	 Therefore	 TNA	 has	 been	 proposed	 as	 a	potential	RNA	progenitor.	Using	molecular	 evolution,	 functional	 sequences	were	 isolated	from	 a	 pool	 of	 random	 TNA	 molecules.	 This	 implicates	 a	 possible	 chemical	 framework	capable	of	crosstalk	between	TNA	and	RNA.	Further,	this	shows	that	heredity	and	evolution	are	 not	 limited	 to	 the	 natural	 genetic	 system	 based	 on	 ribofuranosyl	 nucleic	 acids.	Structurally	different	from	DNA	and	RNA,	TNA	was	further	explored	as	a	source	of	nuclease	
xxi		
resistant	 affinity	 reagents	 in	 therapeutic	 application.	 Since	 TNA	molecules	 are	 naturally	unavailable,	 synthetic	 approach	 has	 been	 developed	 previously	 for	 initial	 research	explorations.	A	detailed	synthetic	optimization	have	been	investigated	in	this	dissertation	to	provide	quantitative	amount	of	TNA	substrates	for	the	downstream	research	applications	in	Synthetic	biology.		Chapter	2	describes	a	highly	optimized	synthetic	approach	for	large	scale	preparation	of	α-L-threose	nucleoside	and	phosphoramidites	by	ten	reaction	steps	form	L-ascorbic	acid.	This	new	strategy	overcomes	several	shortcomings	from	original	method	presented	by	Dr.	Eschenmoser	 and	 co-workers	 and	 allow	 us	 to	 quantitatively	 synthesize	 several	 key	intermediate	precursors	 for	 the	α-L-threose	nucleoside	phosphoramidites	and	nucleoside	triphosphate	synthesis.	The	α-L-threose	nucleoside	phosphoramidites	are	then	used	as	the	monomers	for	the	synthesis	of	TNA	oligonucleotides	by	solid	phase	chemistry.	Chapter	 3	 discusses	 the	 stepwise	 approach	 of	 development	 for	 synthesizing	 α-L-threose	nucleoside	3’-monophosphate	and	3’-triphosphate.	3’-Secondary	hydroxyl	group	on	α-L-threose,	having	steric	encumbered	issue	from	the	neighboring	nucleobases,	presents	the	low	efficiency	in	the	phosphorylation	step	by	using	classic	P(V)	chemistry.	Introducing	P(III)	phosphitylation,	 substitution,	 and	 subsequent	 oxidation	 reaction	 together	 achieve	 high	phosphorylation	 yield	 on	 3’-hydroxyl	 group	 of	 α-L-threose	 nucleoside	 and	 facilitate	 α-L-threose	 nucleoside	 3’-monophosphate	 and	 3’-triphosphate	 synthesis	 and	 purification	 by	HPLC	 chromatography.	 The	 α-L-threose	 nucleoside	 3’-triphosphates	 are	 tested	 as	 the	substrates	for	enzymatic	TNA	oligonucleotide	synthesis	by	engineered	polymerases.	Chapter	 4	 discusses	 the	 synthesis	 of	 2’-deoxy-α-L-threose	 nucleoside	 using	 two	deoxygenation	 approaches.	 Introducing	 the	 triethylborane	 as	 the	 radical	 initiator,	 that	
xxii		
avoids	the	side	products	formation	from	the	stringent	radical	initiation	reaction	condition	required	 for	 AIBN,	 allows	 the	 deoxygenation	 reaction	 to	 process	 at	 room	 temperature	smoothly	and	efficiently.	The	following	phosphorylation	reaction	for	2’-deoxy-α-L-threose	nucleoside	triphosphate	synthesis	was	achieved	by	stepwise	approach	described	in	Chapter	2.	The	2’-deoxy-α-L-threose	nucleoside	triphosphates	are	designed	and	synthesized	as	the	chain	terminator	incorporated	by	TNA	Kod-RI	polymerase	for	crystallography	purpose.	Chapter	5	discusses	the	synthesis	of	a	novel	organic	pyrophosphate	reagent	which	was	used	to	develop	a		highly	optimized	and		HPLC	free	approach	for	gram	scale	synthesis	of	both	natural	(DNA,	RNA)	and	modified	(TNA,	L-DNA	etc.)	nucleoside	triphosphates	(NTPs).	Here	a	new		pyrene	substituted	pyrophosphate	reagent	was	developed	which		introduced	hydrophobicity	in	nucleoside	triphosphate	analogies	and	made	it	easier	to	purify	by	silica	gel	column	chromatography	and	we	can	scale	it	up	to	a	gram	synthesis	of	triphosphates.	This	is	 a	 very	 cost	 effective	 approach	 to	 obtain	 high	 quality	 triphosphates.	 The	 synthesized	products	are	comparable	to	commercial	products	in	terms	of	purity	and	biological	function.										
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Chapter	1	
Background		
1.1	Introduction	DNA	and	RNA	are	two	well-known	biopolymers	that	can	store	and	transfer	genetic	information.1-2	RNA	has	the	natural	ability	to	store	genetic	information,	as	seen	with	RNA-based	virus	genomes,3	and	to	perform	enzymatic	and	regulatory	functions,	observed	with	riboswitches,4	ribosomes,5	molecular	recognitions,6	therapeutics,7	self-replicating	introns,8	and	ribozymes.9	Since	RNA	can	perform	these	two	essential	activities	to	support	life,	it	may	be	 hypothesized	that	 life	 originated	 from	 RNA,	 commonly	 referred	 to	 as	 the	 RNA	world	hypothesis,	in	which	RNA	is	a	progenitor	in	the	origins	of	life	on	Earth.10	This	hypothesis	has	motivated	many	scientists	to	investigate	RNA	as	the	original	genetic	polymer	of	life	in	the	evolutionary	path	of	life.	Researchers	have	systematically	studied	the	chemical	structure	of	RNA	using	artificial	genetic	polymers	related	to	RNA.	Such	research	is	based	on	several	aspects	that	include	predecessors	that:	(i)	are	able	to	base-pair	with	natural	nucleic	 acid	 polymers	 (RNA	 or	 DNA)	 and	 itself	 for	 the	 transfer	 of	 genetic	 information	between	 two	 stages	 of	 life,	 (ii)	 may	 be	 synthesized	 easily	 under	 plausible	 pre-biotic	conditions	and	in	which	its	chemical	structure	is	simple,	and	(iii)	have	chemical	structures	that	are	chemically	derived	from	RNA.		The	 aims	 of	 synthetic	 genetics,	 a	 sub-discipline	 of	 synthetic	 biology	 is	 to	 develop	artificial	genetic	polymers,	termed	XNAs	(xeno	nucleic	acids),	in	which	the	letter	X	refers	to	the	sugars	or	 its	substitutes.	These	XNAs	can	replicate	 in	vitro	and	eventually	 in	a	model	protocell.11	On	the	basis	of	backbone	moiety,	there	are	different	types	of	XNAs	(Figure	1.1).	
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Figure	1.1	XNAs	are	classified	by	their	sugar	compositions	and	may	be	categorized	according	to	the	number	of	atoms,	which	include	the	4-carbon	sugar	(Threose	in	TNA,	the	“locked”	ribose	analog	in	LNA),	the	5-carbon	sugar	(Aabinose	in	ANA,	2’-Fluoroarabinose	in	FANA),	and	6-membered	sugar	(cyclohexene	in	CeNA,	anhydohexitol	in	HNA)		
	 Among	these	XNAs,	HNA	and	TNA	aptamers	were	first	discovered	in	2012.	FANA	and	ANA	are	likely	candidates	for	aptamer	validation	due	to	their	structural	similarity	to	RNA,	whereas	LNA	and	CeNA	are	not,	due	to	their	structurally	restrictive	conformation	and	the	difficulty	 in	 synthesizing	 the	 latter.12,13	Thus,	 four	XNAs	 (TNA,	HNA,	 FANA	and	ANA)	 are	viewed	as	suitable	candidates	capable	of	undergoing	evolution.	Most	XNAs	are	amenable	to	directed	 evolution	 via	 a	 process	 called	 systematic	 evolution	 of	 ligands	 by	 exponential	enrichment	(SELEX),	but	therapeutic	value	varies	based	on	the	commercial	availability	of	their	 monomers	 and	 biostability	 against	 nucleases,	 FANA	 and	 ANA	 are	 commercially	available	and	are	relatively	resistant	against	high	nuclease	degradation.	However,	TNA	and	HNA	have	shown	comparatively	better	nuclease	resistance	ability	than	FANA	and	ANA,	but	they	must	be	synthesized	chemically	in	house	from	the	starting	nucleosides.		
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In	our	lab,	we	have	focused	our	efforts	on	TNA	synthesis	and	evaluation.	TNA	is	an	artificial	genetic	polymer	that	was	developed	by	Dr.	Albert	Eschenmoser	as	part	of	his	search	for	nucleic	acid	structures	that	were	related	to	DNA/RNA.14	TNA	is	composed	of	a	repeating	four-carbon	threose	backbone	(Figure	1.2),	which	is	structurally	different	from	the	natural	five-carbon	ribose	backbone	in	DNA	and	RNA.	As	a	result,	the	backbone	linkage	is	one	atom	shorter	than	that	observed	in	DNA	and	RNA.	
	
	
	
	
	
	
	
	
Figure	1.2	Structural	differences	between	the	linearized	backbone	of	DNA	(RNA)	with	TNA.		Why	is	TNA	important?	TNA	adopts	an	A-type	helix	when	it	forms	Watson-Crick	base	pairs	with	complimentary	strands	of	DNA,	RNA,	and	itself	(Figure	1.3).15	This	implies	that	TNA	 is	 able	 to	 transfer	 genetic	 information	 between	 itself	 and	 with	 the	 natural	 genetic	polymers.	TNA	is	also	very	stable	to	biological	nucleases.16	We	have	investigated	the	stability	of	 two	different	TNA	oligonucleotides	 in	human	 liver	microsome	(HLM)	and	50%	human	serum	 (HS),	 which	 are	 biologically	 relevant	 matrices	 that	 are	 rich	 in	 nucleases	 and	 are	
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commonly	 used	 to	 test	 nucleic	 acid	 stability	 and	 nuclease	 resistance.	 TNA	 shows	 high	nuclease	resistance	ability	in	both	HLM	and	HS	(Figure	1.4).	Therefore,	TNA	can	form	strong	homo	and	hetero	duplexes	and	is	very	stable	to	biological	nucleases.17	
	
	
			 	
	
	
	
	
	
Figure	1.3	Solution	NMR	spectral	analysis	shows	that	TNA	forms	A-type	of	helix	when	it	forms	a	duplex	with	a	complimentary	strand	of	TNA.			(Figure	was	used	with	permission	from	Nature	Chemistry,	2012,4,183)			TNA	 is	 also	 capable	 of	 in	 vitro	 selection.	 Engineered	 polymerases	 can	 transcribe	functional	 TNA	 aptamers	 selected	 from	 a	 large	 number	 of	 sequences.	 Moreover,	 TNA	overcomes	the	problem	of	post-selection	modifications	that	plagues	the	field	of	RNA,	as	the	TNA	backbone	is	completely	resistant	to	nuclease	degradation.18	Unmodified	nucleic	acids	are	very	susceptible	to	nuclease	attack	and	are	therefore	generally	unsuitable	as	therapeutic	agents.	RNA	aptamers	need	different	modifications	to	avoid	nuclease	attack,	but	TNA	does	
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not	need	such	extra	modifications.	For	these	reasons,	we	are	extremely	interested	in	TNA	and	its	potential	in	biological	applications.		
(a)																																																																																																																																																		(c)	
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Figure	1.4	Comparative	nuclease	stability	assays	performed	in	human	serum	(HS)	and	human	liver	microsomes	(HLM).	(a)	TNA	polymers	remain	undigested	after	7	days	of	incubation	at	37°C	in	50%	human	serum	or	0.5	mg/mL	human	liver	microsomes.	Buf	denotes	buffer	only.	(b)	FANA	and	2’-F-RNA	both	rapidly	degrade	under	simulated	biological	conditions.	(c)	Chemical	structure	of	FANA	and	2’-F-RNA.			(Figure	was	used	with	permission	from	Bioorg.	Med.	Chem.	Lett,	2016,26,	2418-2421)			TNA	 is	 an	 unnatural	 nucleic	 acid	 that	 is	 not	 commercially	 available.	 Thus,	 we	synthesize	 TNA	monomers	 and	 polymers	 chemically	 in	 lab.	 All	 the	monomers	 shown	 in	figure	 4	 are	 used	 for	 all	 the	projects	 in	 our	 lab.	 The	 top	 row	 corresponds	 to	 the	TNA-2-phosphoramidite	 with	 3'	–O-DMT	 protection	 (tN-amidites,	 N	 =	 A,T,G,C).	 These	 listed	
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compounds	(Figure	1.5A)	are	used	for	making	TNA	oligonucleotides	on	an	automated	DNA	synthesizer	via	solid-phase	synthesis.	All	the	bases	are	protected	with	respective	protecting	groups	 to	 avoid	 side	 reactions.	 The	 compounds	 (Figure	 1.5B)	 correspond	 to	 the	 TNA	triphosphates	 (tNTPs,	N	=	A,T,G,C),	which	are	very	essential	 for	enzymatic	TNA	oligomer	synthesis,	enzyme	engineering,	and	aptamer	selection.19	
	
	
									
Figure	1.5	Different	TNA	monomers	important	for	TNA	biology	(A)	TNA-2’-	phosphoramidite	monomers	with	the	3’-OH	are	DMT	protected.	The	nucleobases	are	also	protected	with	respective	protecting	groups.	(B)	TNA-3’-triphosphates					monomers	(tNTPs)		 	In	 my	 thesis	 work,	 I	 have	 	 developed	 a	 generalizable	 approach	 to	 the	 large	 scale	synthesis	 of	 nucleoside	 triphosphates	 (NTPs).	 Natural	 and	 modified	 nucleic	 acid	triphosphates	 impact	 nearly	 every	 major	 aspect	 of	 healthcare	 research	 from	 DNA	sequencing	 to	 drug	 discovery.	 Various	 research	 groups	 in	 this	 field	 and	 literatures	 have	attempted	 to	 demonstrate	 a	 strategy	 to	 nucleoside	 triphosphate	 synthesis	 that	 is	
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generalizable,	high-yielding	and	cost-effective.	However,	this	remains	an	unsolved	problem,	as	some	methods	discovered	have	proven	to	be	effective	for	only	some	substrates	and	to	be	only	moderately	effective	for	other	substrates.	Thus	far,	not	one	synthesis	strategy	has	been	found	to	be	universally	satisfactory	for	all	substrates.		The	synthesis,	isolation,	and	storage	of	nucleoside	triphosphates	(NTPs)	are	difficult	for	several	reasons24.	(1)	Most	methods	for	the	synthesis	of	NTPs	involve	the	combination	of	charged	ionic	reagents	(e.g.,	pyrophosphates)	with	more	lipophilic	substrates	(e.g.,	protected	nucleosides).	As	a	result,	 it	 is	difficult	to	find	appropriate	solvents.	Moreover,	purification	involves	the	isolation	of	charged	water-soluble	products	from	a	mixture	of	hydrophobic	and	hydrophilic	impurities.	(2)	Nucleoside	triphosphates	(NTPs)	are	not	robust,	and	it	is	difficult	to	make	 quantitative	 generalizations	 of	 their	 rates	 of	 decomposition.	 Usually	 the	 rate	 of	hydrolysis	of	the	product	is	accelerated	in	the	presence	of	acids	or	bases,	even	if	stored	in	lower	 temperature.	 But	 most	 recently,	 we	 have	 found	 a	 protocol	 that	 can	 prevent	 the	degradation	 of	 NTPs	 for	 a	 long	 period	 of	 time.25	 Here	 we	 demonstrated	 we	 can	 store	triphosphate	products	in	Tris	buffer	(pH=	8.2)	in	-80	oC	for	more	than	6-8	months	without	any	degradation.				The	most	widely	used	approach	to	the	synthesis	of	nucleoside	triphosphates	(NTPs)	is	the	nucleophilic	attack	of	the	pyrophosphates	on	an	activated	nucleoside	monophosphate	(NMP).	There	are	several	early	works	that	describe	the	phosphorylation	of	nucleosides	and	their	activation	techniques	(Scheme	1.1).26-29	It	is	shown	that	the	treatment	of	an	inorganic	pyrophosphate	 reagent	 generates	 the	 desired	 product.	 The	 use	 of	 the	 nucleoside	
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phosphoramidates	is	one	of	the	most	useful	strategy	for	the	activation	of	monophosphates.	Here	the	products	are	purified	by	high	performance	liquid	chromatography	(HPLC)	or	strong	ion	exchange	chromatography.													
	
	
	
Scheme	1.1		Different	chemical	methods	for	the	activation	of	nucleoside	monophosphates	(NMPs)	and	the	synthesis	of	nucleoside	triphosphates	from	NMPs.	In	these	methods,		dichloro-phosphate	is	used	for	the	phosphorylation	and	synthesis	of	the	nucleoside	monophosphates.		Another	 common	 synthetic	 strategy	 is	 the	 use	 of	 activated	 phosphites	 or	
phosphoramidites	derived	from	the	nucleosides.	This	type	of	 technique	involves	an	 in	situ	ring	opening	of	cyclotriphosphate	intermediates	(Scheme	1.2).30-39	This	method	was	found	to	be	most	efficient	in	the	phosphorylation	of	the	less	reactive	hydroxyl	(-OH)	group	of	the	
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nucleoside	 (as	 seen	 with	 the	 secondary	 alcohol	 of	 TNA).	 The	 P(III)	 in	 the	 reagent	 can	phosphorylate	the	secondary	hydroxyl	group	in	a	more	facile	manner.	Experimental	 facts	demonstrate	that	the	attack	of	the	nucleophile	at	the	ring	opening	step	results	in	a	linearized	product.	Yet,	HPLC	is	the	best	way	to	isolate	the	products	further.		 											
	
	
	
	
	
Scheme	1.2		Synthesis	of	nucleoside	triphosphates	using	activated	phosphites	or	phosphoramidite	derivatives	derived	from	nucleosides.	Here	the	triphosphates	are	made	via	a	cyclotriphosphate	intermediate.		(Figure	was	adapted	from		J.	Am.	Chem.	Soc.	2019,	141,	15013-15018)		
R OH
O P
O
O
Cl
2. PPi
1.
P O R
R2N
R2N
OP
O
P O
P
O
O
O
O
O R
OP
O
P O
P
O
O
O
O
O R
O
O P
O
O
Cl
R OH
2. PPi
1.
OP
O
P O
P
O
O
O
O
NR2
R-OH
Activator
P O R
Cl
Cl
OOP
O
P O
P
O
O
O
O O
O
R O P
O
O
OH
P O P OH
O O
OH OH
PPi
Activator
R-OH
HuangFischer
PPi
Ludwig-
EcksteinJessen
LudwigTaylor &
Cummins
[O]
P(III)
P(V)
OH
10		
Most	 of	 the	 commercial	 sources	 obtain	 their	 nucleoside	 triphosphates	 (NTPs)	 via	
biocatalytic	 methods.	 These	 methods	 are	 extremely	 useful	 for	 the	 synthesis	 of	 natural	triphosphates	 (A,	 C,	 G,	 and	T).	 Such	 is	made	 possible	 by	 the	 enzymatic	 extraction	 of	 the	desired	product	from	their	natural	sources.	It	is	observed	that	adenosine	may	be	converted	into	ATP	using	a	mixture	of	three	enzymes:	adenosine	kinase,	adenylate	kinase,	and	acetate	kinase.40	 Similarly,	 deoxyribonucleic	 triphosphates	 may	 be	 extracted	 from	 the	corresponding	ribonucleotide	counterpart	with	ribonucleotide	reductase	(Scheme	1.3).								
	
	
Scheme	1.3	Different	biocatalytic	syntheses	of	deoxyribonucleoside	triphosphates	(dNTPs).		The	 methods	 discussed	 earlier	 are	 all	 beneficial	 for	 the	 synthesis	 of	 nucleoside	triphosphates,	 but	 none	 are	 sufficient	 for	 the	 synthesis	 of	 both	 natural	 and	 modified	nucleoside	triphosphates	with	equal	efficiency.	These	biocatalytic	methods	all	require	HPLC	or	strong	 ion	exchange	chromatography	for	the	purification	of	 the	desired	product.	Thus,	they	are	not	suitable	for	the	large	scalable	syntheses	of	triphosphates.	Sau.	et	al.	developed	an	iterative	synthetic	approach	for	the	synthesis	of	nucleoside	triphosphates	that	bypasses	
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HPLC	 purification	 and	 is	 scalable	 (Scheme	 1.4)41.	 Here	 they	 described	 an	 efficient	phosphytilation	to	the	nucleoside,	followed	by	oxidation,	hydrogenation,	and	the	addition	of	a	phosphate	group	one	at	a	time.	The	phosphorylated	product	can	be	purified	by	silica	gel	column	chromatography.						
	
	
	
	
	
Scheme	1.4	Schematic	synthetic	diagram	for	nucleoside	triphosphate	synthesis	using	an	iterative	synthetic	method.		(Figure	was	used	with	permission	from	Org.	Lett,	2018	,19,	4379-4382)			Using	 this	 iterative	 synthetic	 method,	 	 gram	 scale	 product	 may	 be	 obtained	 with	greater	 ease,	 as	 noted	with	 the	 lack	 of	 HPLC	 usage,	 but	 the	 overall	 synthesis	 process	 is	heavily	prolonged	and	contains	difficult	steps	that	require	silica	gel	purification.	Overall,	the	products	were	contaminated	with	heavy	metal	ions,	which	nulls	the	polymerase	activity	in	the	enzymatic	reaction.			Recently,	we	developed	a	novel	P(V)	pyrophosphate	reagent	that	can	synthesize	both	natural	 and	 unnatural	 nucleoside	 triphosphates	 on	 the	 gram	 scale.42	 The	 idea	 originates	
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from	 use	 of	 the	 activated	 monophosphate	 method	 as	 mentioned	 earlier,	 but	 here	 they	developed	the	pyrophosphate	reagent	with	a	polycyclic	aromatic	(PA)	moiety,	in	which	the	pyrene	group	attributes	hydrophobicity	 to	 the	triphosphate	precursor	(Scheme	1.5).	This	hydrophobic	precursor	aids	purification	via	silica	gel	column	chromatography.								
	
	
	
Scheme	1.5	General	synthetic	scheme	for	synthesizing	NTPs	using	the	organic	pyrophosphate	method.		In	 summary,	 methods	 for	 synthesizing	 nucleoside	 triphosphates	 initially	 evolved	rapidly	during	the	1950s,	though	efforts	since	then	have	tapered	off,	with	noticeable	languish	the	 last	 two	 decades.	 A	 revival	 of	 interest	 in	 the	 synthesis	 of	 these	 important	molecules	would	be	appropriate	and	pivotal	to	the	nucleic	acid	chemistry	field.	The	thesis	described	therein	is	the	development	of	several	novel	and	generalized	techniques	to	obtain	nucleosides	,	phosphoramidites	and	triphosphates		in	high	quality	and	large	quantity.	
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Chapter	2	
A	Scalable	Synthesis	of	α-L-Threose	Nucleic	Acid	Monomers	
 
Publication Note 
 This	paper	was	originally	published	in	the	Journal	Of	Organic	Chemistry.	Sujay	 P.	 Sau,	 Nour	 Eddine	 Fahmi,	 Jen-Yu.	 Liao,	 Saikat	 Bala	 and	 John	 C.	 Chaput.	 A	Scalable	 Synthesis	 of	 α-L-Threose	Nucleic	Acid	Monomers.	 	 J.Org.	 Chem,	2016,	 81,	 2302-2307.	Copyright	©	2016	American	Chemical	Society	
2.1 Contribution Statement 
 Fahmi,	N.	E.	and	Sau,	S.	P.	designed	the	synthetic	strategy.	All	authors	contributed	to	the	synthesis,	reaction	optimization,	and	data	collection.	Sau,	S.	P.	and	Chaput,	 J.	C.	wrote	the	manuscript	with	the	comments	from	the	rest	of	the	authors.	
2.2 Abstract of the Chapter 
 Recent	advances	in	polymerase	engineering	have	made	it	possible	to	copy	information	back	 and	 forth	 between	 DNA	 and	 artificial	 genetic	 polymers	 composed	 of	 TNA	 (α	 -L	 -threofuranosyl-	(3′	,2′	)	nucleic	acid).	This	property,	coupled	with	enhanced	nuclease	stability	relative	to	natural	DNA	and	RNA,	warrants	further	investigation	into	the	structural	and	functional	properties	of	TNA	as	an	artificial	genetic	polymer	for	synthetic	biology.	Here,	we	 report	 a	 highly	 optimized	 chemical	 synthesis	 protocol	 for	 constructing	 multigram	quantities	 of	 TNA	 nucleosides	 that	 can	 be	 readily	 converted	 to	 nucleoside	 2′	 -
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phosphoramidites	or	3′	-	triphosphates	for	solid-phase	and	polymerase-mediated	synthesis,	respectively.	 The	 synthetic	 protocol	 involves	 10	 chemical	 transformations	 with	 three	crystallization	steps	and	a	single	chromatographic	purification,	which	results	in	an	overall	yield	of	16−	23%	depending	on	the	identity	of	the	nucleoside	(A,	C,	G,	T).	
2.3 Introduction 
 TNA	(α-L-threofuranosyl-(3′,2′)-nucleic	acid)	is	an	artificial	genetic	polymer	in	which	the	natural	ribose	sugar	found	in	RNA	has	been	replaced	by	the	α-L-threose	sugar.	In	contrast	to	natural	 DNA	 and	RNA,	which	 have	 a	 six-atom	backbone	 repeat	 unit	 connected	 by	 3′,	 5′-phosphodiester	 linkages,	 TNA	 has	 five	 atoms	 (or	 covalent	 bonds)	 in	 the	 phosphodiester	backbone	with	 linkages	 occurring	 at	 the	 2′	 and	 3′	 vicinal	 positions	 of	 the	 threose	 sugar.	Despite	 this	major	difference	 in	 structure,	TNA	 is	 capable	 of	 forming	 stable	 and	 efficient	antiparallel	Watson−Crick	duplexes	with	complementary	strands	of	DNA	and	RNA.	1−3	The	ability	 to	 transfer	genetic	 information	between	TNA	and	RNA,	coupled	with	 the	chemical	simplicity	 of	 threose	 relative	 to	 ribose	 sugar,	 has	 fueled	 interest	 in	 TNA	 as	 a	 possible	progenitor	 of	 RNA	 in	 the	 pre-RNA	world	 hypothesis.4−6	 TNA	 is	 also	 being	 explored	 as	 a	catalysts	for	synthetic	biology,	source	of	nuclease	resistant	reagents,	and	molecular	affinity	medicine	 for	 biological	 targets,	 as	 the	 constitutional	 structure	 of	 TNA	 is	 stable	 under	biological	 conditions.	Ongoing	works	 in	both	of	 these	 areas	have	 inspired	 researchers	 to	develop	 the	 engineered	 polymerases	 that	 can	 “transcribe”	 DNA	 into	 TNA	 and	 other	polymerases	that	can	“reverse	transcribe”	TNA	back	into	DNA.7−12	By	including	a	selective	amplification	 step	 in	 the	 replication	 cycle,	 methods	 are	 now	 being	 developed	 to	 isolate	functional	TNA	molecules	by	in	vitro	selection.13	
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Motivated	 by	 a	 desire	 to	 study	 atomic-level	 structure	 by	 solution	 NMR	 and	 X-ray	crystallography	and	the	structural	and	functional	properties	of	TNA	by	in	vitro	selection,	we	have	 systematically	 evaluated	 the	 chemical	 synthesis	 of	 TNA	monomers	with	 the	 goal	 of	designing	a	synthetic	approach	that	is	amenable	to	large-scale	(multigram)	synthesis.	A	new	chemical	synthesis	strategy	was	necessary	because	the	original	approach	(Scheme	2-1)	first	described	by	Eschenmoser	and	colleagues	suffered	from	a	number	of	shortcomings	that	
Scheme	2.1		Original	Strategy	Developed	to	Synthesize	α-L-Threose	Nucleosides	
	 	
	
					 	(Scheme	was	used	with	permission	from		J.Org.	Chem,	2016,	81,	2302-2307)		included	 numerous	 silica	 gel	 purification	 steps,	 low	 overall	 yield	 (2−6%),	 and	 poor	regioselectivity	during	nucleoside	tritylation.	While	the	two	DMT	regioisomers	(3′	and	2′)	
2.5a	and	2.5b	can	be	separated	chromatographically,	only	trace	amounts	of	the	2′-isomer	is	obtained	in	the	case	of	adenosine	and	cytosine,	which	necessitates	an	additional	series	of	protection−deprotection	steps	to	synthesize	the	adenine	and	cytosine	threose	nucleoside	3′-	triphosphates.	Here,	we	describe	an	optimal	chemical	synthesis	strategy	for	generating	TNA	
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nucleoside	 precursors	 that	 can	 be	 readily	 converted	 to	 3′-triphosphates	 for	 polymerase-mediated	primer-extension	reactions	or	2’-phosphoramidites	for	solid-phase	synthesis.	Our	approach	 involves	a	 total	of	10	chemical	 transformations	with	 three	crystallization	and	a	single	 chromatographic	 purification	 steps	 and	 results	 in	 an	 overall	 yield	 of	 16−23%	depending	 on	 the	 identity	 of	 the	 nucleoside	 (A,	 C,	 G,	 T).	We	 demonstrate	 that	 this	 new	strategy	can	be	used	to	produce	multigram	quantities	of	TNA	monomers	for	the	downstream	exploration	in	structural	and	functional	properties	of	TNA	polymers.	
2.4	Results	and	Discussion	
 The	 synthesis	 of	 L-threonolactone	 (2.2)	 from	 L-ascorbic	 acid	 (vitamin	 C)	 has	 been	reported	 previously	 (Scheme	 2-1).	 Accordingly,	 L-ascorbic	 acid	 undergoes	 oxidative	cleavage	in	the	presence	of	hydrogen	peroxide	and	CaCO3	to	produce	the	calcium	salt	of	L-threonate	(2.6).	Compound	2.6	is	then	converted	to	the	desired	L-threonolactone	(2.2)	using	a	Dowex	cation	exchange	resin	 to	promote	acidification	and	 intramolecular	 lactonization.	However,	due	to	the	limited	solubility	of	2.6,	both	steps	require	to	remove	the	large	volumes	of	water	prior	to	cyclization	and	crystallization.	We	began	by	examining	 the	crystallization	of	2.6	 from	the	resulting	aqueous	reaction	mixture.	 Literature	 methods	 report	 to	 reduce	 the	 volume	 of	 the	 aqueous	 solution	 by	diminished-pressure	evaporation	prior	to	crystallization	with	methanol;	however,	this	is	a	tedious	process,	especially	when	the	reaction	is	performed	on	a	large	scale.	We	found	that	the	addition	of	2	volumetric	equivalents	of	methanol	directly	to	the	reaction	mixture	allowed	
2.6	 to	precipitate	 as	 a	white	 crystalline	material	 in	85%	yield.	 This	 subtle	 change	 to	 the	
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protocol	resulted	in	a	yield	that	favorably	comparable	against	previous	reports	(65−79%)	and	allowed	large-scale	reactions	to	be	performed	with	substantially	higher	throughput.		Next,	we	investigated	the	conversion	of	2.6	to	2.2	(Scheme	2-2)	with	several	 feasible	approaches.	While	 previous	 literature	methods	 apply	 the	 use	 of	 a	 Dowex	 cation	 acid.	 Of	these,	dilute	sulfuric	acid	produced	the	desired	compound	in	crystalline	form	with	yields	that	are	comparable	to	what	has	been	achieved	previously	using	Dowex.	However,	because	of	the	hygroscopic	nature	of	L-threonolactone	(2.2),	crystallization	failed	whenever	the	compound	was	not	properly	dried.	As	an	alternative	way	to	avoid	using	dilute	H2SO4,	we	tested	oxalic	acid	as	a	calcium	exchange	reagent	in	situ.	We	found	that	refluxing	a	heterogeneous	mixture	of	 2.6	 in	 acetonitrile	 with	 1	 equiv	 of	 oxalic	 acid	 and	 a	 catalytic	 amount	 of	 para-toluenesulfonic	acid	produced	the	desired	L-threonolactone	(2.2)	and	calcium	oxalate	as	an	insoluble	 side	 product	 precipitate	 that	 could	 be	 easily	 separated	 by	 filtration.	 Using	 this	approach,	pure	2.2	is	obtained	as	a	white	solid	in	93%	yield	after	co-evaporation	with	ethyl	acetate.	Additionally,	 to	eliminate	 the	need	 for	an	expensive	cation	exchange	resin,	oxalic	acid	provided	a	streamlined	method	for	obtaining	large	quantities	of	L-threonolactone	(2.2)	without	the	need	for	rigorous	drying	of	aqueous	solution	to	an	anhydrous	state.	
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Scheme	2-2.	Synthesis	of	Universal	Glycosyl	Donor	for	TNA	Nucleosides	
		
	
			
	
Reagents	and	conditions:	(a)	(i)	CaCO3,	30%	aq.	H2O2,	H2O,	18	h,	0	°C	to	rt;	(ii)	active	charcoal,	70	°C,	2	h,	85%;	 (b)	oxalic	acid,	para-toluenesulfonic	acid	 (cat),	CH3CN,	2	h,	 reflux,	93%;	 (c)	benzoyl	chloride,	1:10	pyridine−CH2Cl2,	0.5	h,	0	°C,	64%;	(d)	tert-butyldiphenylchlorosilane,	imidazole,	DMAP	(cat),	CH2Cl2,	18	h,	0	°C	to	rt;	(e)	1	M	DIBAL-H	in	toluene,	dry	1,2-	dimethoxyethane,	0.5	h,	−78	°C;	(f)	Ac2O−DMAP	(5	equiv,	1.5	equiv)	in	CH2Cl2,	2	h,	−78	°C	to	rt,	95%	from	2.7.		(Scheme		was	used	with	permission	from		J.Org.	Chem,	2016,	81,	2302-2307)		A	 major	 limitation	 of	 the	 original	 synthetic	 route	 developed	 by	 Eschenmoser	 and	colleagues	was	the	low	regioselectivity	observed	when	α-L-threofuranosyl	nucleosides	2.4	are	reacted	with	DMT-Cl	(Scheme	2-1)	in	tritylation	step.	In	most	cases,	tritylation	produced	a	 mixture	 of	 2′	 and	 3′	 regioisomers	 that	 could	 be	 separated	 by	 careful	 silica	 gel	chromatography	to	generate	pure	2.5a	and	2.5b.	In	principle,	this	synthetic	strategy	would	have	been	ideal	if	2.5a	and	2.5b	were	obtained	in	equal	amounts;	however,	in	practice,	the	tritylation	 of	 adenosine	 and	 cytosine	 α-L-threofuranosyl	 nucleosides	 yielded	 only	 trace	amounts	of	 the	2′-DMT	isomer	(2.5b).	Thus,	 in	order	to	obtain	the	precursor	compounds	
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required	 to	 synthesize	 TNA	 3′-nucleoside	 triphosphates,	 a	 cumbersome	 strategy	 of	protection	and	deprotection	was	developed	to	convert	2.5a	into	2.5b.14	In	an	effort	to	generate	antiviral	compounds	based	on	the	structural	framework	of	TNA	nucleosides,	Herdewijn	and	colleagues	developed	a	regioselective	strategy	that	defined	the	2′	 	 and	 3′	 	 hydroxyl	 positions	 early	 in	 the	 synthetic	 pathway.	 Accordingly,	 the	 authors	reported	that	2	 	could	be	selectively	converted	2.2	 to	 the	2-O	-benzoyl	L	 -threonolactone	derivative	1.7	 by	 the	 addition	 of	 benzoyl	 chloride	 to	 a	 solution	 of	2.2	 	 and	 imidazole	 in	acetonitrile	after	8	h	of	stirring	from	−	5	°	C	to	room	temperature	(Scheme	2-2).	Although	this	method	proved	unsatisfactory	in	our	hands,	selective	benzoylation	of	2.2		was	achieved	with	the	addition	of	1	equiv.	of	benzoyl	chloride	to	2.2		in	1:10	pyridine−	dichloromethane	solution	after	stirring	for	30	min	at	0	°	C.	Following	the	reaction,	we	further	discovered	that	
2.7		could	be	precipitated	as	a	pure	white	powder	in	64%	yield	after	stirring	overnight	at	4	°	C	from	a	mixture	of	dichloromethane	and	hexanes.	In	 analogy	 to	 previous	 work	 on	 threofuranosyl	 nucleosides,2.8	 compound	 2.7	 was	converted	 to	 the	 universal	 glycosyl	 donor	 2.8	 following	 three	 successive	 chemical	transformations.	 We	 introduced	 the	 tert-butyldiphenylchlorosilyl	 protection	 at	 the	 3’-hydroxy	 position	 of	2.7,	 followed	 by	DIBAL-H	 reduction	 of	 the	 lactone	 to	 the	 lactol,	 and	finally	acetylation	at	the	anomeric	position	to	give	2.8	in	96%	yield	from	2.7.	Filtration	of	
2.8	 through	 a	 short-pad	 of	 silica	 gel	 proved	 highly	 facile	 and	 efficient	 due	 to	 the	 strong	polarity	differences	between	2.8	and	the	nonwashable	reagents.	From	2.8,	we	constructed	a	complete	set	of	TNA	nucleosides	for	thymidine	(T,	2.9c),	cytidine	(C,	2.9b),	adenosine	(A,	
2.9a),	and	guanosine	(G,	2.9d)	by	applying	a	Vorbrüggen	glycosylation	(Scheme	2-3)	that	involved	heating	the	nucleobase	(in	protected	form)	with	glycosyl	donor	in	the	presence	of	
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trimethylsilyl	 trifluoromethane-sulfonate	 (TMSOTf).	 After	 workup,	 the	 3′-tert-butyldiphenylsilyl	protecting	group	was	selectively	removed	following	the	treatment	with	tetrabutylammonium	 fluoride	 for	 1	 h	 at	 0	 °C.	 Glycosylation	 and	 desilylation	 proceeded	smoothly	for	thymine,	N4-benzoyl	cytosine,	and	N2-acetyl-O6-diphenylcarbamoyl	guanine	to	give	 2.9a,	 2.9b,	 and	 2.9d,	 respectively,	 in	 64−70%	 yield	 after	 crystallization.	 However,	glycosylation	with	N6-benzoyl	adenine	resulted	in	a	3:2	mixture	of	N9-	and	N7-regioisomers.	Surprisingly,	 similar	 isomeric	 mixtures	 were	 obtained	 when	 SnCl4	 was	 substituted	 for	TMSOTf,	which	gave	exclusively	the	N9-regioisomer	for	glycosylation	with	1,2,3-tribenzoyl	threose.15	Although	the	N9-	and	N7-regioisomers	are	separable	by	silica	gel	chromatography,	we	 found	 that	 the	 crude	 isomeric	mixture	 could	 be	 converted	 to	 the	 thermodynamically	favored	N9-isomer	by	heating	the	reaction	in	anhydrous	toluene	in	the	presence	of	1	equiv	of	TMSOTf	for	1	h	at	80	°C.	Further	optimization	showed	that	glycosylation	in	toluene	at	95	°C	provided	the	desired	N9-regioisomer	as	 the	major	synthesized	product.	Crystallization	after	3’-desilylation	gave	pure	N9-adenosine	nucleoside	(2.9c)	in	43.5%	yield.	Compounds	2.9a−d	are	key	intermediates	in	the	divergent	synthesis	of	TNA	nucleoside-3′-triphosphates	 and	 2′-phosphoramidites.	 For	 L-threofuranosyl	 nucleoside	 3′-triphosphates,	compounds	2.9a−d	can	be	phosphorylated	using	the	standard	Ludwig	and	Eckstein	method,	 followed	by	 treating	 the	concentrated	NH4OH	to	remove	 the	sugar	and	nucleobase	 protecting	 groups.14	 For	 L-threofuranosyl	 nucleoside	 2′-phosphoramidites,	compounds	2.9a−d	are	tritylated	with	DMT-Cl	and	treated	with	1	N	NaOH	at	0	°C	for	20	min	deprotection	reaction	to	remove	the	2′-benzoyl	group	to	obtain	compounds	2.10a−d	
	
Scheme	2-3.	Synthesis	of	TNA	Phosphoramidite	Precursors	
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Reagents	and	conditions:	(a)thymine,	N,O-bis(trimethylsilyl)acetamide	(BSA),	trimethylsilyltriflate	(TMSOTf),	 CH3CN,	 2	 h,	 60°C;	 (b)	 N4-benzoylcytosine,	 BSA,	 TMSOTf,	 CH3CN,	 2	 h,	 60	 °C;	 (c)	 N6-benzoyladenine,	BSA,	TMSOTf,	toluene,	2.5	h,	95	°C;	(d)	(i)	N2-acetyl-	O6-diphenylcarbamoyl-guanine,	BSA,	1,2-dichloroethane,	0.5	h	70	°C	(ii)	TMSOTf,	CH3CN,	toluene,	1.5	h,	70	°C;	(e)	1	M	TBAF	in	THF,	1	h,	0	°C,	64%	for	1.9a,	70%	for	1.9b,	43.5%	for	1.9c,	69%	for	1.9d;	(f)	DMT-Cl,	DMAP,	pyridine,	18	h,	70	°C;	(g)	1	M	NaOH,	THF−MeOH,	20	min,	0	°C,	71%	for	1.10a,	65%	for	1.10b,	63%	for	1.10c;	(h)	DMT-Cl,	AgOTf,	2,4,6-	trimethylpyridine,	dry	CH2Cl2	18	h,	70	°C,	52%	for	1.10d.		 (Scheme	was	used	with	permission	from		J.Org.	Chem,	2016,	81,	2302-2307)		(Scheme	 2-3).17	 While	 the	 tritylation	 of	 2.9a−c	 proceeded	 efficiently	 under	 standard	conditions,	tritylation	of	2.9d	required	rigorous	azeotropic	removal	of	water	and	the	use	of	
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AgOTf	as	the	catalyst.	Removal	of	the	O6-diphenylcarbamoyl	(DPC)	group	with	20%	TFA	in	CH2Cl2	allowed	tritylation	to	occur	under	standard	conditions,	suggesting	that	the	bulky	DPC	group	creates	the	steric	barrier	to	limit	the	addition	of	the	DMT	group.	In	 our	 laboratory,	we	 routinely	 synthesize	 TNA	 nucleosides	2.9a−d	using	 the	 above-mentioned	methodology.	In	a	typical	synthesis	run,	125	g	of	2.1	is	converted	into	80	g	of	2.7	with	 an	 overall	 yield	 of	 49%.	 In	 contrast	 to	 previously	 methods,	 modifications	 to	 the	purification	protocol	of	2.6	and	2.2	makes	it	possible	to	generate	large	quantities	of	highly	pure	2.7	in	just	5	days.	The	conversion	of	2.7	to	2.8	is	generally	performed	with	16.5	g	of	2.7	to	obtain	35	g	of	2.8	with	an	overall	yield	of	96%	in	24	h.	The	N-glycosylation	of	2.8,	followed	by	desilylation,	affords	nucleosides	2.9a−d	 in	64−70%	yield,	with	 the	noted	exception	of	
2.9c,	which	is	obtained	in	slightly	lower	yield	(43.5%).	We	have	found	that	the	synthesis	of	
2.9a−d	 from	 2.7	 can	 be	 performed	 on	 scales	 as	 large	 as	 50	 g,	 which	 is	 a	 substantial	improvement	 in	 the	 synthesis	 of	 TNA	 nucleoside	molecules	 that	will	 help	 accelerate	 the	synthesis	and	characterization	of	TNA	polymers.	
	
2.5	Conclusion	
 In	summary,	we	provide	a	scalable	and	optimized	synthesis	protocol	for	constructing	L-threofuranosyl	 nucleosides	 that	 are	 immediate	 precursors	 for	 TNA	 triphosphates	 and	phosphoramidite	 monomers	 synthesis.	 Several	 key	 challenges	 have	 been	 resolved	 and	numbers	of	purification	steps	were	minimized	to	increase	the	yield	of	key	intermediates	and	product	 synthesis.	 The	 conversion	 of	 vitamin	 C	 to	 L-threonolactone	 was	 optimized	 to	minimize	 the	 cost	 and	 for	 generating	 a	 key	 intermediate	 in	 the	 synthesis	 pathway.	 The	
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universal	glycosyl	donor	2.8	was	prepared	 from	2.7	 in	 three	chemical	 steps,	 followed	by	filtration	through	a	short	pad	of	silica	gel.	The	complete	set	of	TNA	nucleosides	(2.9a−d)	were	synthesized	in	two	reactions	from	2.8	and	purified	by	crystallization.	Final	tritylation,	followed	 by	 debenzoylation,	 provided	 the	 desired	 compounds	 (2.10a−d)	 after	 silica	 gel	column	chromatography.	Together,	these	changes	make	it	possible	to	synthesize	multigram-scale	quantities	of	TNA	monomers	that	can	be	used	to	synthesize	TNA	polymers.	
2.6	Experimental	Details	
General	Procedures	
 Except	 as	 otherwise	 noted,	 all	 nonaqueous	 reactions	 were	 carried	 out	 in	 oven-dried	glassware	 under	 a	 balloon	 pressure	 of	 argon	 or	 nitrogen.	 Reagents	 were	 commercially	available	and	used	as	received;	anhydrous	solvents	were	purchased	as	 the	highest	grade.	Reactions	were	monitored	 by	 thin-layer	 chromatography	 using	 0.25	mm	 Silicycle	 or	 EM	silica	 gel	 60	 F254	 plates.	 Column	 chromatography	was	 performed	 using	 Silicycle	 40−60	mesh	silica	gel.	Yields	are	reported	as	isolated	yields	of	spectroscopically	pure	compounds.	1H	 and	 13C	 NMR	 spectra	 were	 obtained	 using	 400	 and	 500	 MHz	 NMR	 spectrometers.	Chemical	shifts	are	reported	in	parts	per	million	(ppm,	δ)	referenced	to	the	1H	resonance	of	TMS.	13C	 spectra	 are	 referenced	 to	 the	 residual	13C	 resonance	of	 the	 solvent	 (DMSO-d6,	39.52	ppm,	CD3OD,	49.00	ppm).	Splitting	patterns	are	designated	as	follows:	s,;	br,;	d,;	dd,;	t,;	q,;	m,.	
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	Calcium-L-threonate	(2.6).15	To	a	cold	(0−5	°C)	solution	containing	125	g	(0.71	mol)	of	L-ascorbic	acid	(2.1)	in	1	L	of	H2O	was	slowly	added	125	g	(1.3	mol)	of	CaCO3	with	a	spatula	over	30	min	(evolution	of	CO2	was	observed).	To	the	resulting	heterogeneous	slurry	was	added	250	mL	of	30%	aq.	H2O2	dropwise	over	a	period	of	ca.	1	h	with	stirring	at	0−5	°C.	The	reaction	mixture	was	allowed	to	warm	to	r.t	and	stirred	overnight.	The	heterogeneous	slurry	was	filtered,	and	the	filter	cake	was	washed	with	two-100	mL	portions	of	H2O.	The	filtrate	was	treated	with	25	g	of	activated	carbon	Darco	G-60	and	then	heated	to	50	°C,	until	peroxide	was	no	longer	detected	using	Merckoquant	1001-1	peroxide	 test	 strips.	The	hot	suspension	was	 filtered,	and	 the	solid	material	was	washed	with	two-50	mL	portions	of	H2O.	The	washings	and	the	filtrate	were	combined	and	crystallized	by	the	addition	of	2	volume	equivalents	of	methanol	while	stirring	for	16	h	at	4	°C.	The	solid	material	was	filtered,	washed	with	two-50	mL	portions	of	MeOH,	and	dried	under	high	vacuum	at	40	°C.	Calcium	L-threonate	monohydrate	(2.6)	was	obtained	as	a	white	solid:	yield	99.4	g	(85%);	1H	NMR	(400	MHz,	D2O)	δ	3.60	(dd,	1H,	J	=	11.6,	7.6	Hz),	3.66	(dd,	1H,	J	=	11.6,	5.2	Hz),	3.95	(m,	1H)	and	4.03	(m,	1H).	
	
L-Threonolactone	(2.2).19	To	a	suspension	of	calcium	L-threonate	(2.6)	(99.4	g,	0.30	mol)	in	dry	acetonitrile	(500	mL)	were	 added	 anhydrous	 oxalic	 acid	 (28.8	 g,	 0.32	mol)	 and	 para-toluenesulfonic	 acid	monohydrate	 (1.0	 g).	 The	 heterogeneous	mixture	 was	 stirred	 at	 reflux	 for	 3	 h.	 The	 hot	mixture	was	allowed	to	cool	to	room	temperature	and	filtered.	The	filter	cake	was	washed	with	 50	 mL	 of	 acetonitrile,	 and	 the	 combined	 filtrate	 was	 evaporated	 under	 reduced	pressure	to	produce	a	colorless	syrup.	The	residue	was	dissolved	in	100	mL	of	EtOAc	and	
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evaporated	to	dryness	to	give	L-threonolactone	(2.2)	as	a	white	solid:	yield	66.5	g	(93%);	silica	gel	TLC	(EtOAc):	Rf	=	0.36;	1H	NMR	(400	MHz,	CD3OD)	δ	3.93	(dd,	1H,	J	=	8.8,	7.2	Hz),	4.20	(d,	1H,	J	=	7.2	Hz),	4.29	(dd,	1H,	J	=	14.0,	6.8	Hz)	and	4.41	(dd,	1H,	J	=	9.8,	6.8	Hz),	4.82	(s,	2H).		
2-O-Benzoyl-L-threonolactone	(2.7).18	To	a	cold	(0−5	°C)	solution	containing	66.5	g	(0.56	mol)	of	L-threonolactone	(2.2)	in	1.2	L	of	CH2Cl2	and	135	mL	of	anhydrous	pyridine	under	argon	was	added	benzoyl	chloride	(72.0	mL,	0.62	mol)	dropwise.	The	mixture	was	stirred	under	argon	for	30	min	at	4	°C.	The	crude	reaction	mixture	was	then	sequentially	washed	with	1	N	HCl	(3	×	400	mL)	and	brine	(200	mL).	The	combined	aqueous	layer	was	back	extracted	with	two	100	mL	portions	of	CH2Cl2.	To	the	combined	organic	layers	was	added	2	volume	equivalents	of	hexane	over	1	h,	and	the	solution	was	left	stirring	for	16	h	at	4	°C.	The	product	was	collected	by	filtration	and	dried	under	vacuum.	2-O-benzoy-L-threonolactone	(2.7)	was	obtained	as	a	white	solid:	yield	80.1	g	(64%);	silica	gel	TLC	(1:1	hexanes−EtOAc):	Rf	=	0.30;	1H	NMR	(400	MHz,	CDCl3)	δ	3.81	(brs,	1H),	4.16	(dd,	1H,	J	=	9.2,	7.6	Hz),	4.64	(dd,	1H,	J	=	9.2,	8.0	Hz),	4.73	(q,	1H,	J	=	7.6	Hz),	5.41	(d,	1H,	J	=	6.8	Hz),	7.48	(t,	2H,	J	=	8.0	Hz),	7.64	(t,	1H,	J	=	8.0	Hz)	and	8.10	(d,	2H,	J	=	7.6	Hz).	
	
1-O-Acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose	(2.8).18	To	 a	 cold	 (0−5	 °C)	 solution	 containing	 16.5	 g	 (74.3	 mmol)	 of	 2-O-benzoyl-L-threonolactone	 (2.7),	 60	mg	of	DMAP	and	10.2	 g	 (150	mmol)	 of	 imidazole	 in	160	mL	of	CH2Cl2	 was	 added	 dropwise	 tert-butyldiphenylchlorosilane	 (20	 mL,	 75.0	 mmol).	 The	reaction	mixture	was	warmed	 to	 r.t.	 and	 stirred	 under	 argon	 for	 16	 h.	 The	 solvent	was	
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evaporated	under	reduced	pressure,	and	the	residue	was	dissolved	in	300	mL	of	hexane.	The	organic	phase	was	sequentially	washed	with	1	N	HCl	(100	mL),	H2O	(100	mL),	and	brine	(100	mL).	The	organic	layer	was	dried	over	MgSO4	and	evaporated	to	give	2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threonolactone	as	a	colorless	syrup	(35	g).	The	crude	material	was	used	directly	without	further	purification;	silica	gel	TLC	(3:1	hexanes−EtOAc)	Rf	=	0.5.	To	a	cold	(−78	°C,	acetone/dry	ice)	solution	containing	35.0	g	of	crude	2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threonolactone	in	150	mL	of	1,2-dimethoxyethane	was	added	a	1	M	solution	of	DIBAL-H	in	toluene	(100	mL,	100	mmol)	dropwise	over	a	10	min	period.	The	mixture	was	stirred	under	argon	for	an	additional	20	min	at	−78	°C.	TLC	showed	the	reaction	to	be	complete	(Rf	0.35	 in	3:1	hexanes−EtOAc).	A	premade	solution	containing	Ac2O	(367	mmol)	and	DMAP	(115	mmol)	in	CH2Cl2	(Ac2O/DMAP/CH2Cl2	=	35	mL/14.0	g/40	mL)	was	then	added	dropwise	at	−78	°C.	After	10	min,	the	reaction	mixture	was	removed	from	the	dry	ice	bath	and	allowed	to	stir	for	1.5	h	while	warming	to	r.t.	The	mixture	was	then	diluted	with	200	mL	of	hexanes	and	poured	into	a	cold	stirring	1	N	aq.	HCl	solution	(200	mL).	The	organic	layer	was	separated	and	washed	with	H2O	(100	mL),	sat.	aq.	NaHCO3	(100	mL),	and	brine	(100	mL).	The	organic	 layer	was	dried	over	MgSO4	and	evaporated	to	give	 	42	g	of	crude	product	as	a	yellow	syrup.	The	product	was	suspended	 in	25	mL	of	10%	EtOAc	 in	hexanes,	passed	 through	a	short	pad	of	 silica	 (50	g),	and	washed	out	with	10%	EtOAc	 in	hexanes	 (200	 mL).	 An	 anomeric	 mixture	 of	 1-O-acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threo-furanose	 (2.8)	was	 obtained	 as	 a	 colorless	 syrup:	 yield	 36.0	 g	(96%);	silica	gel	TLC	(3:1	hexanes−EtOAc):	Rf	=	0.5.		
1-(2′-O-Benzoyl-α-L-threofuranosyl)thymine	(2.9a).	
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To	 a	 solution	 containing	 34.0	 g	 (67.4	 mmol)	 of	 1-O-acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose	 (2.8)	 and	8.9	 g	 (70.5	mmol)	 of	 thymine	 in	140	mL	of	anhydrous	acetonitrile	was	added	45	mL	(145	mmol)	of	BSA,	and	the	mixture	was	stirred	for	30	 min	 at	 60	 °C.	 TMSOTf	 (20.0	 mL,	 108	 mmol)	 was	 added	 dropwise,	 and	 stirring	 was	continued	 for	 another	 2	 h	 at	 60	 °C,	 after	 which	 time	 TLC	 analysis	 (1:1	 hexanes−EtOAc)	showed	the	reaction	to	be	complete.	The	mixture	was	cooled	to	r.t,	diluted	with	300	mL	of	EtOAc,	and	poured	into	200	mL	of	cold	sat.	aq.	NaHCO3	solution	with	stirring.	The	organic	layer	was	separated	and	washed	with	H2O	(100	mL)	and	brine	(100	mL),	dried	over	MgSO4,	and	concentrated	under	reduced	pressure.	The	crude	nucleoside	was	obtained	as	a	white	foam	 (41	 g)	 and	 was	 used	 directly	 without	 further	 purification;	 silica	 gel	 TLC	 (1:1	hexanes−EtOAc):	Rf	=	0.37.	To	 a	 cold	 (0−5	 °C)	 solution	 containing	 41	 g	 of	 crude	 1-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)thymine	in	THF	(250	mL)	was	added	dropwise	TBAF	(1	M	solution	in	THF,	70.0	mL,	70.0	mmol),	and	the	mixture	was	stirred	for	1	h	at	0−5	°C.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	residue	was	dissolved	in	300	mL	of	EtOAc.	The	organic	layer	was	separated	and	washed	twice	with	H2O	(100	mL)	and	brine	(100	mL),	dried	over	MgSO4,	and	concentrated	under	reduced	pressure	to	give	20	g	of	the	crude	 nucleoside	 as	 a	 yellow	 syrup.	 The	 syrup	 was	 dissolved	 in	 50	 mL	 of	 CH2Cl2	 and	crystallized	 by	 the	 addition	 of	 50	 mL	 of	 hexanes.	 1-(2′-O-Benzoyl-α-L-threofuranosyl)-thymine	 (2.9a)	 was	 obtained	 as	 a	 white	 solid:	 yield	 14.44	 g	 (64%);	 silica	 gel	 TLC	 (1:2	hexanes−EtOAc):	Rf	=	0.35;	1H	NMR	(400	MHz,	CDCl3)	δ	1.90	(s,	3H),	4.05	(brs,	1H),	4.20	(dd,	1H,	J	=	4.4,	10.0	Hz),	4.29	(d,	1H,	J	=	10.0	Hz),	4.51	(brs,	1H),	5.43	(s,	1H),	5.87	(d,	1H,	J	=	2.0	Hz),	7.36	(s,	1H),	7.47	(t,	2H,	J	=	7.6	Hz),	7.61	(t,	1H,	J	=	7.2	Hz),	8.02	(d,	2H,	J	=	8.2	Hz)	and	
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8.90	(brs,	1H);	13C	NMR	(125	MHz,	CD3OD):	δ	12.5,	74.7,	76.5,	83.9,	91.4,	111.2,	129.7,	130.4,	130.8,	134.8,	138.7,	152.3,	166.4,	166.6;	HRMS	(ESI-TOF):	[M	+	Na]+	calcd	for	C16H16N2O6Na,	355.0906;	found,	355.0910.		
N4-Benzoyl-1-(2′-O-benzoyl-α-L-threofuranosyl)cytosine	(2.9b).	To	 a	 solution	 containing	 33.5	 g	 (66.3	 mmol)	 of	 1-O-acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose	(2.8)	and	15.0	g	(70.0	mmol)	of	N4-benzoylcytosine	in	150	mL	of	anhydrous	acetonitrile	was	added	40.0	mL	(154	mmol)	of	BSA,	and	the	mixture	was	stirred	 for	30	min	at	60	 °C.	TMSOTf	 (38.0	mL,	199	mmol)	was	added	dropwise,	and	stirring	was	continued	at	60	°C	for	another	2	h,	after	which	time	TLC	(1:1	hexanes−EtOAc)	showed	the	reaction	to	be	complete.	The	mixture	was	cooled	to	room	temperature,	diluted	with	200	mL	of	EtOAc,	and	poured	into	200	mL	of	sat.	aq.	NaHCO3	solution	with	stirring.	The	white	suspension	was	filtered	over	Celite		and	the	organic	layer	was	separated	and	washed	with	H2O	(150	mL)	and	brine	(150	mL),	dried	over	MgSO4,	and	concentrated	under	reduced	pressure.	The	crude	nucleoside	was	obtained	as	a	white	foam	(36.0	g)	and	was	used	directly	without	further	purification;	silica	gel	TLC	(EtOAc):	Rf	=	0.75.	To	a	cold	(0−5	°C)	solution	containing	36.0	g	of	crude	N4-benzoyl-1-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)-cytosine	in	THF	(200	mL)	was	added	dropwise	TBAF	(1	M	solution	in	THF,	70.0	mL,	70.0	mmol),	and	the	mixture	was	stirred	at	0−5	°C	for	1	h.	The	solvent	was	evaporated	under	diminished	pressure,	and	the	residue	was	dissolved	in	500	mL	of	EtOAc.	The	organic	layer	was	washed	with	1	N	aq.	HCl	(150	mL)	and	H2O	(150	mL),	and	then	was	stirred	with	brine	(150	mL)	at	r.t.	to	precipitate	the	product.	N4-Benzoyl-1-(2′-O-benzoyl-α-L-threofuranosyl)cytosine	 (2.9b)	 was	 obtained	 as	 a	 white	 solid:	 yield	
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19.4	g	(70%);	silica	gel	TLC	(1:2	hexanes−EtOAc):	Rf	=	0.40;	1H	NMR	(400	MHz,	DMSO-d6)	δ	4.3	(m,	3H),	5.39	(s,	1H),	5.85	(d,	1H,	J	=	2.8	Hz),	5.99	(s,	1H),	7.41	(d,	1H,	J	=	7.2	Hz),	7.50−7.64	(m,	5H),	7.72	(t,	1H,	J	=	7.2	Hz),	8.03	(t,	4H,	J	=	7.6	Hz),	8.22	(d,	1H,	J	=	7.6	Hz),	and	11.27	(s,	1H);	13C	NMR	(125	MHz,	DMSO-d6):	δ	72.4,	76.6,	81.5,	90.9,	95.7,	128.5,	128.9,	129.5,	132.8,	133.2,	 133.9,	 145.7,	 154.5,	 163.4,	 164.5,	 167.4;	 HRMS	 (ESI-TOF):	 [M	 +	 Na]+	 calcd	 for	C22H19N3O6Na,	444.1172;	found,	444.1180.		
N6-Benzoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)adenine	(2.9c).18	A	mixture	of	40.5	g	(80.0	mmol)	of	1-O-acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose	(2.8)	and	19.1	g	(80.0	mmol)	of	N6-benzoyladenine	was	co-evaporated	with	50	mL	of	anhydrous	toluene	and	then	suspended	in	160	mL	of	anhydrous	toluene.	To	the	suspension	was	added	42.0	mL	(163.8	mmol)	of	BSA,	and	the	mixture	was	stirred	for	30	min	at	95	°C.	Once	all	the	suspension	was	dissolved,	TMSOTf	(22.2	mL,	118.8	mmol)	was	added	dropwise,	and	stirring	was	continued	at	95	°C	 for	another	2.5	h,	after	which	TLC	showed	complete	 consumption	 of	 the	 starting	 material	 and	 more	 polar	 major	 products	corresponding	 to	 the	N9	 glycosides.	 The	mixture	was	 cooled	 to	 room	 temperature,	 then	poured	into	a	stirring	mixture	of	150	g	of	ice	and	150	mL	of	sat.	aq.	NaHCO3	solution	and	stirred	for	30	min.	The	organic	layer	was	separated	and	washed	with	H2O	(50	mL)	and	brine	(50	mL),	dried	over	MgSO4,	and	concentrated	under	reduced	pressure.	The	crude	nucleoside	was	obtained	as	a	yellow	foam:	yield	54.3	g.	To	a	cold	(0−5	°C)	solution	(ice-bath)	containing	54.3	g	of	N6-benzoyl-9-(2′-O-benzoyl-3′-
O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	in	THF	(160	mL)	was	added	dropwise	TBAF	(1	M	solution	in	THF,	80.0	mL,	80.0	mmol),	and	the	mixture	was	stirred	at	0−5	°C	for	
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30	 min.	 The	 solvent	 was	 evaporated	 under	 diminished	 pressure,	 and	 the	 residue	 was	dissolved	in	200	mL	of	EtOAc.	The	organic	layer	was	washed	with	H2O	(50	mL)	and	brine	(50	mL).	The	combined	aqueous	layer	was	back-extracted	with	EtOAc	(2	×	50	mL).	The	combined	organic	layer	was	dried	over	MgSO4	and	concentrated	under	reduced	pressure.	The	resulting	crude	material	was	dissolved	in	150	mL	of	1%	methanol	in	CH2Cl2	and	crystallized	by	slow	addition	 of	 120	 mL	 of	 hexanes.	 N6-Benzoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)adenine	(2.9c)	was	obtained	as	a	white	solid:	yield	15.5	g	(43.5%);	silica	gel	TLC	(EtOAc):	Rf	=	0.35;	1H	NMR	(400	MHz,	CDCl3)	δ	4.30	(dd,	1H,	J	=	4.0,	10.0	Hz),	4.39	(d,	1H,	J	=	10.0	Hz),	4.67	(d,	1H,	J	=	3.2	Hz),	5.63	(s,	1H),	6.07	(d,	1H,	J	=	1.6	Hz),	7.56	(m,	6H),	8.04	(t,	4H,	J	=	8.1	Hz),	8.27	(s,	1H),	and	8.81	(s,	1H).		
N2-Acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-α-L-threo-furanosyl)guanine	2.9d).	To	a	solution	containing	8.45	g	(26.1	mmol)	of	N2-acetyl-O6-diphenylcarbamoyl	guanine	in	200	mL	of	a	mixture	of	anhydrous	dichloroethane	and	toluene	(1:2	v/v)	was	added	15.8	mL	(64.6	mmol)	of	N,O-bis(trimethylsilyl)acetamide,	and	the	mixture	was	stirred	for	30	min	at	70	°C.	The	solvent	was	removed	under	reduced	pressure,	and	the	residue	was	dissolved	in	 55	 mL	 of	 anhydrous	 toluene.	 1-O-Acetyl-2-O-benzoyl-3-O-tert-butyldiphenyl-silyl-L-threofuranose	(2.8)	(11	g,	21.8	mmol)	in	65	mL	of	anhydrous	toluene	was	added	dropwise	using	a	canula,	and	the	mixture	was	heated	to	70	°C.	TMSOTf	(8.5	mL,	45.9	mmol)	was	then	added	dropwise,	and	the	mixture	was	stirred	at	70	°C	for	another	1.5	h,	after	which	TLC	(1:1	hexanes−EtOAc)	showed	complete	consumption	of	(2.8).	The	mixture	was	cooled	to	room	temperature,	 diluted	with	300	mL	of	 EtOAc,	 and	poured	 into	 150	mL	of	 sat.	 aq.	NaHCO3	solution	with	stirring,	resulting	in	a	purple	suspension.	The	suspension	was	filtered,	and	the	
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organic	layer	was	separated	and	washed	with	H2O	(150	mL)	and	brine	(150	mL),	dried	over	MgSO4,	and	concentrated	under	reduced	pressure.	The	crude	nucleoside	was	obtained	as	a	purple	foam	(16.12	g)	and	was	used	directly	without	further	purification;	silica	gel	TLC	(1:2	hexanes−EtOAc):	Rf	=	0.7.	To	a	cold	(0−5	°C)	solution	containing	16.12	g	of	crude	N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)	 guanine	 in	 THF	 (50	 mL)	was	added	dropwise	TBAF	(1	M	solution	in	THF,	19.0	mL,	19.0	mmol),	and	the	mixture	was	stirred	at	0−5	°C.	After	15	min,	TLC	was	checked	and	another	9	mL	of	TBAF	was	added,	and	the	mixture	was	stirred	for	45	min.	The	solvent	was	evaporated	under	diminished	pressure,	and	the	residue	was	dissolved	in	250	mL	of	EtOAc.	The	organic	layer	washed	with	1	N	aq.	HCl	(50	mL),	H2O	(50	mL),	and	brine	(50	mL),	was	dried	over	MgSO4,	and	concentrated	under	reduced	 pressure.	 The	 resulting	 crude	 product	 was	 dissolved	 in	 CH2Cl2	 (30	 mL)	 and	crystallized	by	addition	of	an	equal	amount	of	hexanes.	N2-Acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)-guanine	(2.9d)	was	obtained	as	a	white	solid:	yield	8.9	g	(69%);	silica	gel	TLC	(1:2	hexanes−EtOAc):	Rf	=	0.25;	1H	NMR	(400	MHz,	DMSO-d6)	δ	2.20	(s,	3H),	4.32	(dq,	2H,	J	=	3.6,	7.6	Hz),	4.60	(m,	1H),	5.78	(t,	1H,	J	=	2.0	Hz),	5.96	(d,	1H,	J	=	4.0	Hz),	6.31	(d,	1H,	J	=	1.6	Hz),	7.33	(t,	2H,	J	=	6.0	Hz),	7.43−7.60	(m,	10H),	7.72	(t,	1H,	J	=	6.0	Hz),	8.03	(dd,	1H,	J	=	0.8,	6.4	Hz),	8.60	(s,	1H),	and	10.81	(s,	1H);	13C	NMR	(125	MHz,	DMSO-
d6)	δ	24.6,	73.2,	74.8,	82.3,	87.9,	120.1,	128.7,	128.9,	129.5,	129.6,	134.0,	141.6,	144.3,	150.1,	152.3,	 154.2,	 155.3,	 165.0,	 169.2;	 HRMS	 (ESI-TOF):	 [M	 +	 Na]+	 calcd	 for	 C31H26N6O7Na,	617.1761;	found,	617.1750.	
1-(3′-O-Dimethoxytrityl-α-L-threofuranosyl)thymine	(2.10a).15	
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A	mixture	containing	3.2	g	 (9.6	mmol)	of	1-(2′-O-benzoyl-α-L-threofuranosyl)thymine	(2.9a),	4.88	g	(14.4	mmol,	1.5	equiv)	of	DMT-Cl,	and	100	mg	of	DMAP	(0.82	mmol)	was	co-evaporated	twice	with	20.0	mL	of	anhydrous	pyridine.	The	mixture	was	dissolved	in	40	mL	of	anhydrous	pyridine	and	stirred	under	argon	at	80	°C	for	16	h.	The	solvent	was	evaporated	under	diminished	pressure,	and	the	residue	was	partitioned	between	EtOAc	(50	mL)	and	H2O	 (50	 mL).	 The	 organic	 layer	 was	 washed	 with	 brine	 (50	 mL),dried	 (MgSO4)	 and	evaporated.	The	residue	was	dissolved	in	a	mixture	of	38	mL	of	THF	and	30.5	mL	of	MeOH,	and	then	cooled	to	0	°C.	To	the	cold	solution	was	added	15.0	mL	of	ice-cold	1	N	aq.	NaOH	while	stirring.	After	30	min,	the	reaction	was	quenched	by	addition	of	100	mL	of	water.	The	volatile	solvent	was	removed	under	diminished	pressure,	and	the	residual	aqueous	solution	was	extracted	with	EtOAc	(3	×	50	mL).	The	combined	organic	layer	was	dried	(MgSO4)	and	evaporated.	The	residue	was	purified	on	a	silica	gel	column	(50	g	silica	bed),	eluting	with	50−100%	EtOAc	in	hexanes	containing	2%	Et3N	in	steps	of	5%	increase	in	EtOAc	for	every	200	 mL.	 1-(3′-O-Dimethoxytrityl-α-L-threofuranosyl)thymine	 (2.10a)	 was	 obtained	 as	 a	white	foam:	yield	3.6	g	(71%);	1H	NMR	(400	MHz,	CDCl3):	δ	1.82	(s,	3H),	3.30	(d,	1H,	J	=	9.6	Hz),	3.67	(s,	3H),	3.71	(s,	3H),	3.91	(d,	1H,	J	=	13.6	Hz),	4.19	(s,	1H),	4.23	(s,	1H),	5.72	(s,	1H),	6.79	(m,	4H),	7.12−7.38	(m,	9H),	7.44	(s,	1H)	and	10.92	(s,	1H).	
	
N4-Benzoyl-1-(3′-O-dimethoxytrityl-α-L-threofuranosyl)-cytosine	(2.10b).15	A	 mixture	 of	 3.18	 g	 (7.7	 mmol)	 of	 N4-benzoyl-1-(2′-O-benzoyl-α-L-threofuranosyl)cytosine	 (2.9b),	 3.84	 g	 (11.3	mmol,	 1.5	 equiv)	 of	DMT-Cl,	 and	 120	mg	 of	DMAP	(0.99	mmol,	0.1	equiv)	was	coevaporated	twice	with	15.0	mL	of	anhydrous	pyridine.	The	residue	was	suspended	in	50	mL	of	anhydrous	pyridine	and	stirred	under	argon	for	16	
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h	 at	 80	 °C.	The	 solvent	was	 evaporated	under	diminished	pressure,	 and	 the	 residue	was	partitioned	between	EtOAc	(50	mL)	and	H2O	(50	mL).	The	organic	layer	was	washed	with	brine	(50	mL),	dried	(MgSO4),	and	evaporated.	The	residue	was	dissolved	in	a	mixture	of	38	mL	of	THF	and	30.5	mL	of	MeOH,	and	then	cooled	to	0	°C.	To	the	cold	solution	was	added	7.7	mL	of	ice-cold	1	N	aq.	NaOH	while	stirring.	After	10	min,	another	7.7	mL	of	ice-cold	1	N	aq.	NaOH	was	 added.	 Ten	minutes	 after	 the	 second	 addition,	 the	 reaction	was	 quenched	 by	addition	 of	 40	 mL	 of	 10%	 NH4Cl	 in	 water.	 The	 volatile	 solvent	 was	 removed	 under	diminished	pressure,	and	the	residue	was	diluted	by	addition	of	50	mL	of	EtOAc.	The	organic	layer	 was	 separated,	 washed	 with	 H2O	 (50	mL)	 and	 brine	 (50	mL),	 dried	 (MgSO4),	 and	evaporated.	The	residue	was	purified	on	a	silica	gel	column	(50	g	silica	bed),	eluting	with	70−100%	EtOAc	in	hexane	containing	1%	Et3N	in	steps	of	5%	increase	in	EtOAc	for	every	200	 mL.	 N4-Benzoyl-1-(3′-O-dimethoxytrityl-α-L-threofuranosyl)cytosine	 (2.10b)	 was	obtained	as	a	white	foam:	yield	3.12	g	(65%);	1H	NMR	(400	MHz,	CDCl3):	δ	3.32	(d,	1H,	J	=	10.0	Hz),	3.71	(d,	1H,	J	=	4.0	Hz),	3.74	(s,	6H),	4.25	(s,	1H),	4.33	(s,	1H),	5.70	(s,	1H),	6.79	(m,	4H),	6.75−7.35	(m,	9H),	7.47−7.67	(m,	4H),	7.94	(d,	2H,	J	=	8.0	Hz),	8.05	(d,	1H,	J	=	8.0	Hz),	and	9.10	(brs,	1H).	
	
N6-Benzoyl-9-(3′-O-dimethoxytrityl-α-L-threofuranosyl)adenine	(2.10c).15	A	 mixture	 of	 3.39	 g	 (7.6	 mmol)	 of	 N6-benzoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)adenine	(2.9c),	3.86	g	(11.4	mmol,	1.5	equiv)	of	DMT-Cl,	and	93	mg	(0.76	mmol,	0.1	equiv)	of	DMAP	was	co-evaporated	twice	with	7.0	mL	of	anhydrous	pyridine.	The	residue	was	dissolved	in	35	mL	of	anhydrous	pyridine,	and	the	mixture	was	stirred	at	75	°C	under	 argon	 for	 16	 h.	 The	 solvent	 was	 evaporated	 under	 diminished	 pressure,	 and	 the	
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residue	was	partitioned	between	EtOAc	(50	mL)	and	H2O	(50	mL).	The	organic	layer	was	washed	with	brine	(50	mL),	dried	(MgSO4),	and	evaporated.	The	residue	was	dissolved	in	a	mixture	of	38	mL	of	THF	and	30.5	mL	of	MeOH,	and	then	cooled	to	0	°C.	To	the	cold	stirred	solution	was	added	7.6	mL	of	ice-cold	1	N	aq.	NaOH	solution.	After	10	min,	another	7.6	mL	of	ice-cold	 1	 N	 aq.	 NaOH	 solution	 was	 added.	 Ten	 minutes	 after	 the	 second	 addition,	 the	reaction	was	quenched	with	40	mL	of	 10%	aq.	NH4Cl.	 The	 volatile	 solvent	was	 removed	under	diminished	pressure,	and	the	aqueous	residue	was	diluted	with	50	mL	of	EtOAc.	The	organic	layer	was	separated,	washed	with	H2O	(50	mL)	and	brine	(50	mL),	dried	(MgSO4),	and	evaporated.	The	residue	was	purified	on	a	silica	gel	column	(70	g	silica	bed),	eluting	with	30−80%	EtOAc	in	hexanes	containing	1%	Et3N.	Stepwise	elution	was	performed	with	10%	increases	 in	 EtOAc	 for	 each	 200	 mL	 volume.	 N6-Benzoyl-9-(3′-O-dimethoxytrityl-α-L-threofuranosyl)adenine	(1.10c)	was	obtained	as	a	white	foam:	yield	3.6	g	(63%);	1H	NMR	(400	MHz,	DMSO-d6)	3.45	(dd,	1H,	J	=	5.2,	9.6	Hz),	3.59	(dd,	1H,	J	=	3.2,	9.6	Hz),	3.73	(s,	6H),	4.17	(m,	1H),	4.50	(m,	1H),	5.91	(d,	1H,	 J	=	2.8	Hz),	5.93	(d,	1H,	 J	=	4.8	Hz),	6.86	(m,	4H),	7.13−7.33	(m,	9H),	7.56	(t,	2H,	J	=	7.6	Hz),	7.65	(t,	1H,	J	=	7.2	Hz),	8.06	(d,	2H,	J	=	7.2	Hz),	8.56	(s,	1H),	8.75	(s,	1H),	11.22	(brs,	1H).		
N2-Acetyl-O6-diphenylcarbamoyl-9-(3′-O-dimethoxytrityl-α-L-threofuranosyl)	
guanine	(2.10d).15	5.2	 g	 (8.74	 mmol)	 of	 N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)guanine	(2.9d)	was	coevaporated	with	20	mL	of	anhydrous	pyridine	under	reduced	pressure,	and	the	solid	residue	was	dried	under	vacuum	for	18	h.	To	the	residue	was	added	5.92	g	(17.48	mmol,	2	equiv)	of	DMT-Cl,	anhydrous	dichloromethane	(60	mL),	2.3	mL	
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of	2,4,6-trimethylpyridine	(17.48	mmol,	2	equiv),	and	675	mg	(2.62	mmol,	0.3	equiv)	of	silver	triflate.	The	mixture	was	stirred	under	nitrogen	for	18	h.	TLC	(3:1	hexanes−EtOAc)	showed	the	reaction	to	be	complete.	The	solvent	was	removed	under	diminished	pressure,	and	the	residue	was	dissolved	in	150	mL	of	dichloromethane.	The	organic	layer	was	washed	with	0.2	(N)	HCl	(300	mL),	brine	(60	mL),	dried	(MgSO4),	and	evaporated.	The	residue	was	purified	on	a	silica	gel	column	(4	×15	cm),	eluting	with	100	mL	of	99:1	DCM−Et3N	to	300	mL	of	97:2:1		DCM−MeOH−Et3N.	 The	 product	 was	 obtained	 as	 a	 pale	 yellow	 powder:	 yield	 5.8	 g	(74.3%).The	compound	 (3.0	g,	3.34	mmol)	was	dissolved	 in	45	mL	of	THF−MeOH−water	(5:4:1)	and	cooled	to	0−5	°C	in	a	water-ice	bath.	Ice-cold	1	N	aq.	NaOH	(2.1	mL)	was	added	dropwise	to	the	mixture,	and	the	mixture	was	stirred	for	10−15	min.	TLC	(hexane−EtOAc	2:1)	showed	that	the	reaction	was	not	complete.	Another	2.1	mL	of	cold	1	N	aq.	NaOH	was	added	dropwise,	and	stirring	continued	for	another	15−20	min.	The	reaction	was	quenched	with	15	mL	of	10%	aq.	NH4Cl,	and	the	crude	product	was	extracted	with	EtOAc	(2	×50	mL).	The	combined	organic	layer	was	dried	over	MgSO4	and	evaporated	under	reduced	pressure.	The	residue	was	purified	on	a	silica	gel	column	(4	×	15	cm)	using	a	gradient	elution	with	100	mL	 of	 (85:14:1)	 hexane−EtOAc−Et3N,	 followed	 by	 100−300	 mL	 of	 (75:24:1)	hexane−EtOAc−Et3N	and	(65:34:1)	hexane−EtOAc−Et3N.	N2-Acetyl-O6-diphenylcarbamoyl-9-(3′-O-dimethoxytrityl-α-L-threofuranosyl)guanine(2.10d)	was	obtained	as	a	pale	yellow	powder:	yield	1.9	g	(71%);	1H	NMR	(400	MHz,	CDCl3):	δ	2.17	(s,	3H),	2.73	(s,	1H),	3.42	(s,	2H),	3.71	(s,	6H),	4.33	(m,	1H),	4.45	(s,	1H),	5.83	(d,	1H,	J	=	2.4	Hz),	6.78	(m,	4H),	7.12−7.45	(m,	19H),	8.19	(s,	1H),	8.81	(s,	1H).		
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Chapter	3	
Synthesis	of	α-L-Threofuranosyl	Nucleoside	3′-Monophosphates,	
3′-Phosphoro(2-Methyl)imidazolides,	and	3′-Triphosphates		
	
Publication	Note	This	paper	was	originally	published	in	the	Journal	Of	Organic	Chemistry.	Saikat	Bala†,	Jen-Yu	Liao†,	Hui	Mei,	and	John	C.	Chaput*	Synthes	 is	 of	 α-L-Threofuranosyl	 Nucleoside-3′-Monophosphates,	 3′-Phosphoro(2-Methyl)imidazolides,	 and	 3′-Triphosphates.	 	 J.	 Org.	 Chem,	 2017,	 82,	 5910−5916.	 (†	 equal	contribution)	Copyright	©	2017	American	Chemical	Society		
3.1	Contribution	Statement		Bala,	S.	and	Chaput,	J.	C.	designed	the	synthetic	strategy.	All	authors	contributed	to	the	synthesis,	 optimization,	 and	 characterization	 of	 the	 synthetic	 compounds.	 All	 authors	contributed	to	the	manuscript	writing	with	the	comments	from	Mei,	H.		
3.2	Abstract	of	the	Chapter	α-L-Threofuranosyl	 nucleic	 acid	 (TNA)	 is	 an	 artificial	 genetic	 polymer	 composed	 of	vicinal	2′,3′-phosphodiester	bonds	 linking	adjacent	 to	 threofuranosyl	nucleosides.	TNA	 is	one	of	a	small	number	of	genetic	polymers	that	capable	of	cross-pairing	with	DNA	and	RNA	and	are	resistant	to	nuclease	digestion.	Although	an	efficient	approach	has	been	reported	for	
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synthesizing	 TNA	 nucleosides,	 very	 few	 advances	 have	 been	 made	 in	 the	 synthesis	 of	phosphorylated	 TNA	 compounds.	 Here,	 we	 describe	 an	 highly	 efficient	 method	 for	synthesizing	α-L-threofuranosyl	nucleoside	3′-monophosphates	(tNMPs),	3′-phosphoro(2-methyl)imidazolides	(2-MeImptNs),	and	3′-triphosphates	(tNTPs)	bearing	the	four	genetic	bases	 of	 adenine	 (A),	 cytosine	 (C),	 thymine	 (T),	 and	 guanine	 (G).	 We	 suggest	 that	 this	strategy,	which	provides	access	to	grams	of	tNMPs,	hundreds	of	milligrams	of	2-MeImptNs,	and	 tens	 of	 milligrams	 of	 tNTPs,	 will	 help	 advance	 the	 use	 of	 TNA	 monomers	 in	 the	downstream	exobiology	and	biotechnology	applications.		
	
3.3	Introduction		Nucleoside	 triphosphates	 are	 indispensable	 reagents	 for	 a	 broad	 range	 of	 synthetic	biology,	 molecular	 biology	 and	 biotechnology	 applications.1−3	 Particularly,	 modified	nucleoside	 triphosphates	 that	 carry	new	chemical	moieties	 at	 the	 sugar,	 nucleobase,	 and	phosphate	positions	are	critical	to	many	therapeutic	and	diagnostic	applications,4−7	as	well	as	 fundamental	 studies	 intended	 for	 evaluating	 the	 specificity	 of	 natural	 enzymes	 or	identifying	emergent	properties	of	life	either	here	on	Earth	or	elsewhere	in	the	universe.8	Unfortunately,	despite	extensive	efforts	to	develop	chemical	and/or	enzymatic	strategies	for	producing	nucleoside	triphosphates,	no	universal	strategy	has	been	developed	that	can	be	applied	to	all	nucleosides.9	This	is	especially	true	for	chemically	modified	analogues	where	a	 large	 number	 of	 synthetic	 methods	 have	 been	 developed	 to	 accommodate	 the	idiosyncrasies	 of	 different	 nucleoside	 chemistries.10−14	 As	 expected,	 each	 strategy	 comes	with	its	own	strengths	and	weaknesses	that	must	be	evaluated	on	a	case-by-case	basis.15	In	general,	 enzymatic	 strategies	 suffer	 from	poor	substrate	 specificity,	 scale,	 yield,	 and	cost,	
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whereas	chemical	approaches	struggle	with	functional	group	compatibility,	regiochemistry,	yield,	and	purification.	15	Synthesizing	nucleoside	triphosphates	of	α-L-threofuranosyl	nucleic	acid	(TNA)	requires	phosphorylating	the	3′-hydroxyl	position	on	the	furanose	ring.16	However,	the	3′-hydroxyl	position	of	α-L-threofuranosyl	nucleosides	is	substantially	less	reactive	than	the	5′-	hydroxyl	position	of	DNA	and	RNA	nucleosides	because	secondary	alcohols	are	less	nucleophilic	than	primary	 alcohols	 and	 the	 3′-position	 is	more	 sterically	 encumbered	 than	 the	 normal	 5′-hydroxyl	position	of	ribose	sugar	(Figure	3-1).								
	
Figure	3-1.	Molecular	structure	of	TNA	and	RNA.		Given	the	importance	of	TNA	building	blocks	in	many	exobiology	and	synthetic	biology	projects,	a	concerted	effort	has	been	made	to	develop	synthetic	approaches	for	constructing	phosphorylated	TNA	compounds	(Scheme	3-1)	on	the	scales	required	to	meet	the	needs	of	current	downstream	applications.17−20	Early	efforts	by	our	laboratory	and	others	applying	the	 Yoshikawa	method	with	 POCl3	 proved	 unsuccessful	 due	 to	 unwanted	 side	 reactions.	
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Szostak	and	co-workers	overcame	this	problem	using	the	classic	Ludwig−Eckstein	method,	which	was	achieved	all	 four	TNA	 triphosphates	 synthesis	 from	 their	 corresponding	2′-O-DMT	protected	nucleosides.21	Although	 a	 detailed	 protocol	 was	 subsequently	 established,22	 this	 method	 proved	cumbersome	due	to	the	poor	regioselectivity	observed	when	TNA	nucleosides	are	tritylated	on	3’-OH	with	DMT.21	As	an	alternative	strategy,	we	developed	a	one-pot	four-step	synthesis	of	TNA	triphosphates	from	their	2′-O-benzoyl	derivatives	that	is	considerably	less	sensitive	
27	 to	 moisture	 than	 traditional	 approaches.23	 Using	 this	 method,	 H-phosphonate	intermediates	 are	 oxidized	 in	 situ	 with	 N-chlorosuccinimide	 (NCS)	 to	 produce	chlorophosphate	intermediates	that	are	treated	with	pyrophosphate	to	generate	the	desired	nucleoside	triphosphates.23	Although	TNA	nucleoside	3′-triphosphates	generated	in	this	way	are	easy	to	purify	by	HPLC,	the	NCS	method	suffers	from	low	overall	yield	(∼10%	isolated	yield)	 due	 to	 an	 undesired	 side	 reaction	 that	 produces	 large	 quantities	 of	 the	 3′-monophosphate	derivatives	as	the	major	product.										
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Scheme	3-1.	Previous	Strategies	for	Synthesizing	TNA	Triphosphates	
	
(Scheme	was	used	with	permission	from	.		J.	Org.	Chem,	2017,	82,	5910−5916)	
	 To	overcome	the	shortcomings	of	previous	methods,	we	developed	a	robust	strategy	for	generating	TNA	nucleoside	monophosphates,	monophosphate	derivatives,	and	nucleoside	triphosphates	 that	 is	 straightforward	 to	 perform	 and	 could	 be	 transferrable	 to	 other	modified	 nucleosides.	 Our	 approach	 consists	 of	 four	 synthetic	 steps	 to	 generate	 TNA	 28		monophosphates	 from	 a	 TNA	 nucleoside	 intermediate	 that	 can	 be	 produced	 in	 large	quantities	 from	 L-ascorbic	 acid.24	 TNA	 3′-monophosphates	 are	 then	 converted	 to	 3′-phosphoro(2-methyl)imidazolides,	 which	 are	 reacted	 with	 pyrophosphate	 to	 produce	nucleoside	3′-triphosphates.	HPLC	analysis	of	the	crude	reaction	mixture	indicates	that	the	
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phosphorylation	steps	proceed	cleanly	with	high	yield	of	the	desired	compounds.	We	suggest	that	the	current	strategy	will	be	useful	for	constructing	TNA	nucleotides	for	a	wide	range	of	molecular	biology	and	biotechnology	applications,	as	TNA	nucleoside	3′-monophosphates,	3′-monophosphate	derivatives,	 and	3′-triphosphates	 are	obtained	 as	 isolated	 compounds	that	can	be	stored	for	long	periods	of	time	without	degradation.		
3.4	Results	and	Discussion			 We	 designed	 a	 synthetic	 approach	 (Scheme	 3-2)	 for	 constructing	 3′-phosphorylated	TNA	compounds	from	2′-O-benzoyl	TNA	nucleosides	3.1a−d.	TNA	nucleosides	3.1a−d	were	obtained	 from	 L-ascorbic	 acid	 using	 known	 methodology	 (Scheme	 3-2	 and	 3-3)	 that	involves	 eight	 chemical	 transformations	with	 three	 crystallization	 steps.24	While	 several	phosphorylation	 reagents	 were	 evaluated	 as	 possible	 routes	 to	 α-L-threofuranosyl	 3′-monophosphates	 (3.4a−d),	 a	 stepwise	 process	 that	 invoked	 the	 synthesis	 of	 a	 3′-phosphoramidite	intermediate	proved	highly	efficient	for	each	of	the	four	TNA	nucleosides.	Accordingly,	2′-O-benzoyl	nucleosides	3.1a−d	were	converted	to	their	corresponding	3′-O-phosphoramidite	 derivatives	 3.2a−d	 upon	 treatment	 with	 2-cyanoethoxy-N,N-diisopropylchlorophosphine	in	the	presence	of	Hunig’s	base	and	DMAP.	A	slight	excess	of	the	chlorophosphoramidite	reagent	was	crucial	for	obtaining	3′-O-phosphoramidites	3.2a−d	in	high	 yield.	 Intermediates	 3.2a−d	 were	 subsequently	 activated	 by	 1H-tetrazole	 and	converted	to	their	corresponding	trialkyl	phosphite	by	replacing	the	N,N-diisopropylamino	group	with	a	base-labile	cyanoethoxy	group.	The	trialkyl	phosphite	was	then	oxidized	with	H2O2	to	obtain	the	phosphate	triesters	3.3a−d,	which	were	purified	by	silica	gel			
47		
Scheme	3-2.	Synthesis	of	TNA	Triphosphates	Using	Activated	TNA	Monophosphates									
	
	
	
	
	
	
	
	
Reagents	and	conditions:	(a)	2-cyanoethyl	N,N-diisopropylchlorophophoramidite,	DMAP,	DIPEA,	CH2Cl2,	rt,	30−45	min,	68−75%;	(b)	3-hydroxypropionitrile,	tetrazole,	acetonitrile,	rt,	1	h;	(c)	30%	H2O2,	rt,	15	min,	71−75%	(2	steps);	(d)	30−33%	NH4OH,	38	°C,	18	h,	91−98%;	(e)	2-methylimidazole,	triphenylphosphine,	2,2′-dipyridyldisulfide,	DMSO,	 triethylamine,	 rt,	6−8	h;	 (f)	 tributylammonium	pyrophosphate,	tributylamine,	DMF,	10−12	h,	81−87%	(2	steps).	(Scheme	was	used	with	permission	from	.		J.	Org.	Chem,	2017,	82,	5910−5916)			chromatography.	The	resulting	TNA	nucleoside	3′-monophosphates	3.4a−d	were	obtained	as	 an	 ammonium	 salt	 following	 deprotection	 with	 30%	 aqueous	 ammonium	 hydroxide.	Although	this	strategy	is	more	cumbersome	than	traditional	monophosphate	reactions,25	
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we	 30	 found	 that	 the	 higher	 reactivity	 of	 the	 chlorophosphoramidite	 reagent	 by	 P(III)	chemistry,	coupled	with	the	ability	to	purify	the	nucleoside	monophosphate	precursor	3.3a-
d	by	silica	gel	chromatography,	provided	an	efficient	method	for	obtaining	large	quantities	(grams)	of	highly	pure	TNA	3′-monophosphates.	Next,	TNA	monophosphates	3.4a−d	were	converted	to	their	3′-phosphoro(2-	methyl)-imidazolide	 derivatives	 3.5a−d	 using	 classic	 methodology	 previously	 developed	 by	Mukaiyama	 and	 co-workers.26	 Accordingly,	 a	 Mitsunobu-like	 reaction	 is	 performed	 by	incubating	3.4a−d	with	excess	2-methylimidazole	and	triphenylphosphine	in	the	presence	of	2,2′-dipyridyldisulfide	under	basic	reaction	condition.	In	some	cases,	complete	conversion	of	 the	starting	material	required	the	addition	of	excess	amount	of	2-methylimidazole	and	triphenylphosphine.	 The	 desired	 TNA	 nucleoside	 3′-phosphoro-(2-methyl)imidazolides	
3.5a−d	were	isolated	as	a	sodium	salt	by	precipitating	the	reaction	with	excess	of	sodium	perchlorate	 in	 acetone	 solution.	 The	 reactions	 were	monitored	 by	 analytical	 HPLC	 until	>90%	conversion	of	the	starting	material	to	the	desired	product	was	observed	(Figure	3-2)		Interestingly,	we	found	that	the	phosphorimidazolide	reaction	proceeds	more	efficiently	when	the	monophosphates	are	precipitated	as	the	ammonium	salt	rather	than	the	sodium	salt.							
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Figure	3-2.	HPLC	analysis	of	the	crude	reaction	for	tGMP,	2-MeImptG,	and	tGTP.	
(Figure	was	used	with	permission	from	.		J.	Org.	Chem,	2017,	82,	5910−5916)	
	TNA	nucleoside	3′-triphosphates	3.6a−d	were	synthesized	from	the	activated	nucleoside	monophosphates	3.5a−d	by	displacing	the	activated	2-methylimidazole	leaving	group	with	pyrophosphate.	 In	 these	 reactions,	 TNA	 nucleosides	 3.5a−d	 were	 incubated	tributylammonium	pyrophosphate	and	tributylamine	in	a	DMF	solution	for	8−12	h	at	room	temperature.	The	reaction	was	monitored	by	analytical	HPLC,	and	additional	pyrophosphate	and	tributylamine	were	added	as	needs	to	drive	the	reaction	to	completion	(Figure	3-2).	In	
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all	 cases,	 >90%	 of	 the	 starting	 nucleoside	was	 consumed	within	 12	 h.	 The	 desired	 TNA	nucleoside	 triphosphates	3.6a−d	were	 purified	 by	 reverse-phase	 HPLC,	 concentrated	 to	dryness,	resuspended	in	methanol,	and	precipitated	as	the	sodium	salt	from	acetone.	During	the	concentration	step,	we	noticed	that	the	pH	of	the	solution	dropped	due	to	a	buildup	of	acetic	acid	from	the	ammonium	acetate	running	buffer.	If	left	unchecked,	this	change	in	pH	leads	to	unwanted	acid-catalyzed	degradation	of	the	nucleotide	triphosphate.	Fortunately,	this	problem	is	easily	overcome	by	addition	the	triethylamine	for	pH	adjustment	as	needed.	Next,	we	evaluated	the	thermal	stability	of	TNA	triphosphates	(3.6a−d)	bearing	the	four	genetic	bases	of	adenine	(A),	cytosine	(C),	thymine	(T),	and	guanine	(G).	In	this	assay,	the	stability	of	each	TNA	triphosphate	was	monitored	by	analytical	HPLC	using	small	32	aliquots	of	TNA	solutions	that	were	stored	at	temperatures	of	4,	24,	and	37	°C.	A	time	course	analysis	performed	over	8	days	(Table	3-1)	revealed	that	tNTPs	are	resistant	to	thermal	degradation	when	stored	in	a	buffered	solution	containing	10	mM	Tris	(pH	8.0).	Even	after	8	days	at	37	°C,	>70%	of	tGTP	and	>80%	of	tATP,	tCTP,	and	tTTP	remained	undegraded.	This	result	 is	consistent	with	previous	thermal	stability	studies	of	tNTPs	performed	under	standard	PCR	conditions.23	
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Table	3-1.	Thermal	Stability	of	Purified	TNA	Triphosphatesa	
(Table		was	used	with	permission	from	.		J.	Org.	Chem,	2017,	82,	5910−5916.)		To	confirm	that	tNTPs	synthesized	using	our	new	strategy	can	function	as	substrates	for	an	engineered	TNA	polymerase,	we	performed	a	standard	primer-extension	assay	in	which	a	library	of	DNA	templates	were	copied	into	TNA	product.	To	date,	the	polymerase	that	most	efficiently	 uses	 tNTP	 substrates	 is	 Kod-RI,	 a	 polymerase	 that	 was	 developed	 through	 a	combination	 of	 directed	 evolution	 and	 scaffold	 sampling.20,27	 Kod-RI	 functions	 with	 a	catalytic	rate	of	∼1	nucleotide	per	minute	and	is	able	to	copy	most	DNA	templates	into	TNA.27	As	a	demonstration,	an	IR-labeled	DNA	primer	was	annealed	to	a	degenerate	DNA	library	and	 incubated	with	Kod-RI	 in	 the	presence	of	 chemically	 synthesized	of	 tNTP	substrates.	Analysis	of	the	primer-extension	reaction	by	denaturing	polyacrylamide	gel	electrophoresis	(Figure	3-3)	reveals	that	the	primer	is	extended	to	full-length	product	after	a	3	h	incubation	at	55	°C.	This	result,	which	is	consistent	with	the	known	activity	of	Kod-RI,27	demonstrates	that	 the	 new	 synthetic	 approach	 produces	 TNA	 triphosphates	 that	 are	 recognized	 by	 an	engineered	TNA	polymerase.								
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Figure	3-3.	Primer-extension	analysis	
(Figure	was	used	with	permission	from	.		J.	Org.	Chem,	2017,	82,	5910−5916.)	A	5′-IR-labeled	DNA	primer	annealed	to	a	DNA	template	was	extended	with	70	sequential	TNA	 residues.	 Polymerization	 reaction	 was	 performed	 at	 55	 °C	 for	 3	 h	 using	 Kod-RI	 TNA	polymerase	 and	 chemically	 synthesized	 tNTPs.	 The	 reaction	 was	 analyzed	 by	 denaturing	polyacrylamide	gel	electrophoresis.			
	
3.5 Conclusion		In	 summary,	 we	 report	 a	 novel	 synthetic	 route	 for	 constructing	 TNA	 nucleotide	 3′-monophosphates,	 3′-monophosphate	 derivatives,	 and	 3′-triphosphates	 bearing	 all	 four	nucleobases	(A,	T,	G,	C).	This	strategy	overcomes	the	poor	phosphorylation	reaction	of	the	3′-hydroxyl	 group	 on	 the	 threose	 sugar	 by	 introducing	 a	 more	 convenient	 one-pot	phosphitylating	 reagent	 with	 following	 oxidation	 reaction.	 Our	 approach	 involves	 five	chemical	transformations	with	one	silica	gel	purification,	two	precipitation	steps,	and	one	HPLC	 purification.	 The	 overall	 isolated	 yield	 of	 the	 purified	 tNTP	 compounds	 from	 their	starting	nucleosides	is	36−49%	depending	on	the	identity	of	nucleoside	(A,	T,	G,	C).	Finally,	we	show	that	the	resulting	TNA	substrates	are	thermally	stable	and	function	as	substrates	for	an	engineered	TNA	polymerase.	We	suggest	that	the	simplicity	of	this	approach,	coupled	with	 the	 ability	 to	 monitor	 the	 phosphorylation	 reaction	 and	 isolate	 intermediate	compounds,	provides	a	general	approach	that	could	be	applied	to	the	facile	synthesis	for	the	phosphorylation	of	other	modified	nucleotides.		
3.6 	Experimental	Details		
General	Procedures	
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All	 non-aqueous	 reactions	 were	 performed	 using	 oven-dried	 glassware	 under	 an	atmosphere	of	 argon	or	nitrogen.	All	 chemicals	were	commercially	available	and	used	as	received.	 Anhydrous	 solvents	 were	 purchased	 as	 the	 highest	 grade	 from	 Sigma-Aldrich.	Reactions	were	monitored	by	thin	layer	chromatography	using	UV-activated	TLC	plates	with	silica	 gel	 60	 F254	 and	 aluminum	 backing	 (Sigma-Aldrich,	 St.	 Louis,	 MO).	 Flash	 column	chromatography	was	performed	using	SiliCycle	40−60	mesh	silica	gel	(SiliCycle	Inc.,	Quebec	City,	Canada).	Yields	are	reported	as	isolated	yields	of	pure	compounds.	UV	quantification	data	are	analyzed	on	Nano	Drop	2000c	using	Beer’s	Law.	1H,	13C,	and	31P	NMR	spectra	were	analyzed	on	400	and	500	MHz	NMR	spectrometers	 (Bruker,	Billerica,	MA).	 1H	values	are	reported	 in	 parts	 per	 million	 relative	 to	 Me4Si	 or	 corresponding	 deuterium	 solvents	 as	internal	 standard.	 13C	 values	 are	 reported	 in	 parts	 per	million	 relative	 to	 corresponding	deuterium	solvents	as	internal	standards.	31P	NMR	values	are	reported	in	parts	per	million	relative	to	an	external	standard	of	85%	H3PO4.	Splitting	patterns	are	designated	as	follows:	s,	 singlet;	 d,	 doublet;	 dd,	 doublet	 of	 doublets;	 t,	 triplet;	m,	multiplet.	 HPLC	 analysis	 was	performed	on	a	reverse-phase	C18	150	×	4.6	mm	column	with	5	μm	particle	size,	and	TNA	triphosphate	was	purified	on	a	preparative	 reverse-phase	C18	250	×21.2	mm	column	35	(Thermo	Scientific,	USA)	using	a	mobile	phase	of	100	mM	triethylammonium	acetate	buffer	(pH	7.0)/acetonitrile.		
1-(2′-O-Benzoyl-3′-O-[bis(2-cyanoethyoxy)phosphoryl]-α-L-threofuranosyl)thymine	
(3.3a).		To	a	stirring	solution	containing	1	g	(3.01	mmol)	of	1-(2′-O-benzoyl-α-L-threofuranosyl)	thymine	(3.1a)24	and	360	mg	(3.01	mmol)	of	DMAP	in	12	mL	anhydrous	CH2Cl2	was	added	
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1	mL	(7.53	mmol)	of	N,N′-diisopropylethylamine	followed	by	the	addition	of	0.81	mL	(3.61	mmol)	of	2-cyanoethoxy-N,N’-diisopropylchlorophosphoramidite.	After	being	stirred	for	40	min	 at	 room	 temperature,	 the	 reaction	 mixture	 was	 diluted	 with	 40	 mL	 of	 CH2Cl2	 and	extracted	twice	with	50	mL	of	saturated	aqueous	NaHCO3,	washed	with	brine,	dried	over	MgSO4,	 and	 evaporated	 under	 reduced	 pressure.	 The	 crude	 1-[2′-O-benzoyl-3′-O-(N,N-diisopropylamino-2-cyanoethoxyphosphinyl)-α-L-threofuranosyl]-thymine	 (3.2a)23	 was	used	without	further	purification.	To	a	stirring	solution	containing	crude	1-[2′-O-benzoyl-3′-O-(N,N’-diisopropylamino-2-cyanoethoxyphosphinyl)-α-L-threofuranosyl]-thymine	 (3.2a)23	 in	 10	 mL	 of	 anhydrous	acetonitrile	 was	 added	 0.62	 mL	 (9.0	 mmol)	 of	 3-hydroxypropionitrile	 followed	 by	 the	addition	of	26.8	mL	of	tetrazole	(0.45	M	solution	in	anhydrous	acetonitrile,	12.0	mmol).	The	reaction	mixture	was	stirred	 for	1.5	h	at	 room	temperature	with	monitoring	by	TLC	(1:1	hexanes−EtOAc).	After	complete	consumption	of	the	starting	material,	to	the	reaction	was	added	10	mL	of	30%	H2O2	and	left	to	stir	for	20	min	at	room	temperature.	The	crude	product	was	evaporated	under	reduced	pressure	and	dissolved	in	50	mL	of	ethyl	acetate.	The	organic	layer	was	washed	with	brine	and	water,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	was	purified	with	silica	gel	column	chromatography	affording	1-(2′-O-	benzoyl-3′-O-[bis(2-cyanoethyoxy)phosphoryl]-α-L-threofuranosyl)thymine	 (3.3a)	 as	 a	white	foam:	yield	0.87	g	(56%);	silica	gel	TLC	(DCM/MeOH,	9:1)	Rf	=	0.35;	1H	NMR	(500	MHz,	CDCl3)	δ	9.74	(s,	1H),	8.02	(d,	2H,	J	=	5	Hz),	7.61	(t,	2H,	J	=	7.5	Hz),	7.46	(t,	2H,	J	=	7.5	Hz),	7.30	(s,	1H),	6.11	(d,	1H,	J	=	2	Hz),	5.62	(s,	1H),	5.10	(m,	1H),	4.53	(m,	1H),	4.30−4.39	(m,	5H),	2.82	(t,	4H,	J	=	6	Hz),	1.92	(s,	3H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	165.2,	164.1,	150.5,	135.3,	134.1,	130.0,	128.7,	128.3,	116.6,	116.6,	111.0,	89.5,	80.4	(d,	JC,P	=	6.5	Hz),	79.6	(d,	JC,P	=5.2	Hz),	73.5	
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(d,	JC,P	=	4.7	Hz),	63.1	(d,	JC,P	=	5.0	Hz),	63.0	(d,	JC,P	=5.0	Hz),	19.7	(d,	JC,P	=	7.4	Hz),	19.7	(d,	JC,P	=	7.2	Hz),	12.7;		31P	NMR	(162	MHz,	CDCl3)	δ	−2.14;	HRMS	(ESI-TOF)	calcd	for	C22H23N4O9PNa	[M	+	Na]+	541.1100;	found	541.1094.		
N4-(2′-O-Benzoyl-3′-O-[bis(2-cyanoethyoxy)phosphoryl]-α-L-threofuranosyl)-
cytosine	(3.3b).	To	 a	 stirring	 solution	 containing	 1	 g	 (2.3	 mmol)	 of	 N4-benzoyl-1-(2′-O-benzoyl-α-L-threofuranosyl)cytosine	 (3.1b)24	 and	 290	mg	 (2.3	mmol)	 of	 DMAP	 in	 12	mL	 anhydrous	CH2Cl2	was	added	1	mL	(5.9	mmol)	of	N,N′-diisopropylethylamine	followed	by	the	addition	of	 1.05	 mL	 (4.7	 mmol)	 of	 2-cyanoethoxy-N,N’-diisopropylchlorophosphoramidite.	 After	being	stirred	for	40	min	at	room	temperature,	the	reaction	mixture	was	diluted	with	40	mL	of	CH2Cl2	and	extracted	twice	with	50	mL	of	saturated	aqueous	NaHCO3,	washed	with	brine,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	N4-benzoyl-1-[2′-O-benzoyl-3′-O-(N,N’-diisopropylamino-2-cyanoethoxy-phosphinyl)-α-L-threofuranosyl]cyto-	sine	(3.2b)23	was	used	without	further	purification.	To	 a	 stirring	 solution	 containing	 crude	 N4-benzoyl-1-[2′-O-benzoyl-3′-O-(N,N’-diisopropylamino-2-cyanoethoxyphosphinyl)-α-L-threofuranosyl]	 cytosine	 (2.2b)23	 in	 10	mL	 of	 anhydrous	 acetonitrile	 was	 added	 0.65	 mL	 (7.1	 mmol)	 of	 3-hydroxypropionitrile	followed	by	the	addition	of	21.07	mL	of	tetrazole	(0.45	M	solution	in	anhydrous	acetonitrile,	9.48	mmol).	The	reaction	mixture	was	stirred	for	1.5	h	at	room	temperature	with	monitoring	by	TLC	(1:1	hexanes−EtOAc).	After	complete	consumption	of	 the	starting	material,	 to	 the	reaction	was	added	10	mL	of	30%	H2O2	and	left	to	stir	for	20	min	at	room	temperature.	The	crude	product	 solution	was	 evaporated	 to	 dryness	 and	 re-dissolved	with	50	mL	of	 ethyl	
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acetate.	 The	 organic	 layer	 was	 washed	 with	 brine	 and	 water,	 dried	 over	 MgSO4,	 and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	with	silica	gel	column	chromatography	 affording	 N4-(2′-O-benzoyl-3′-O-[bis(2-cyanoethyoxy)phosphoryl]-α-L-threofuranosyl)cytosine	 (3.3b)	 as	 a	 white	 foam:	 yield	 0.68	 g	 (47.2%);	 silica	 gel	 TLC	(DCM/acetone,	10:1)	Rf	=	0.35;	1H	NMR	(400	MHz,	DMSO-d6)	δ	11.30	(s,	1H),	8.21	(d,	1H,	J	=	7.2	Hz),	8.00−8.07	(m,	4H),	7.73	(t,	1H,	J	=	7.6	Hz),	7.57−7.65	(m,	3H),	7.52	(t,	2H,	J	=	7.2	Hz),	7.44	(d,	1H,	J	=	6.4	Hz),	6.07	(d,	1H,	J	=	1.2	Hz),	5.73	(d,	1H,	J	=	1.2	Hz),	5.21	(m,	1H),	4.63	(d,	1H,	J	=	10.4	Hz),	4.47	(dd,	1H,	J	=	3.6,	10.4	Hz),	4.23	(m,	4H),	2.94	(m,	4H);	13C	NMR	(100.6	MHz,	DMSO-d6)	δ	167.4,	164.4,	163.7,	154.5,	145.1,	134.1,	133.2,	132.8,	129.7,	128.9,	128.6,	128.5,	118.1,	118.0,	96.3,	90.9,	79.5	(d,	JC,P	=	6.3	Hz),	78.2	(d,	JC,P	=	5.0	Hz),	74.1	(d,	JC,P	=	3.8	Hz),	63.1	(d,	JC,P	=	4.9	Hz),	63.1	(d,	JC,P	=	4.9	Hz),	19.1	(d,	JC,P	=	7.4	Hz),	19.0	(d,	JC,P	=	7.5	Hz);	31P	NMR	(162	MHz,	DMSO-d6)	δ	−2.61;	HRMS	(ESI-TOF)	calcd	for	C28H26N5O9Pna	[M	+	Na]+	630.1366;	found	630.1382.		
N6-(2′-O-Benzoyl-3′-O-[bis(2-cyanoethyoxy)phosphoryl]-α-L-threofuranosyl)adeni-
ne	(3.3c).	To	 a	 stirring	 solution	 containing	 1	 g	 (2.2	 mmol)	 of	 N6-benzoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)	 adenine	 (3.1c)24	 and	 273	mg	 (2.2	mmol)	 of	 DMAP	 in	 12	mL	 anhydrous	CH2Cl2	 was	 added	 0.78	 mL	 (4.4	 mmol)	 of	 N,N′-diisopropylethylamine	 followed	 by	 the	addition	of	0.85	mL	(3.8	mmol)	of	2-cyanoethoxy-N,N’-diisopropylchlorophosphoramidite.	After	being	stirred	for	40	min	at	room	temperature,	the	reaction	mixture	was	diluted	with	40	mL	of	CH2Cl2	and	extracted	twice	with	50	mL	of	saturated	aqueous	NaHCO3,	washed	with	brine,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	N6-benzoyl-9-
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[2′-O-benzoyl-3′-O-(N,N-diisopropylamino-2-cyanoethoxyphosphinyl)-α-L-threofuranosyl]	adenine	(3.2c)23	was	used	without	further	purification.	To	 a	 stirring	 solution	 containing	 crude	 N6-benzoyl-9-[2′-O-benzoyl-3′-O-(N,N’-diisopropylamino-2-cyanoethoxy-phosphinyl)-α-L-threofuranosyl]	 adenine	 (2.2c)23	 in	 10	mL	 of	 anhydrous	 acetonitrile	 was	 added	 0.6	 mL	 (6.7	 mmol)	 of	 3-hydroxypropionitrile	followed	by	the	addition	of	19.9	mL	of	tetrazole	(0.45	M	solution	in	anhydrous	acetonitrile,	8.96	mmol).	The	reaction	mixture	was	stirred	for	1.5	h	at	room	temperature	with	monitoring	by	TLC	(1:1	hexanes−EtOAc).	After	complete	consumption	of	 the	starting	material,	 to	 the	reaction	was	added	10	mL	of	30%	H2O2	and	left	to	stir	for	20	min	at	room	temperature.	The	crude	product	 solution	was	 evaporated	 to	 dryness	 and	 re-dissolved	with	50	mL	of	 ethyl	acetate.	 The	 organic	 layer	 was	 washed	 with	 brine	 and	 water,	 dried	 over	 MgSO4,	 and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	with	silica	gel	column	chromatography	 affording	 N6-(2′-O-benzoyl-3′-O-[bis(2-cyanoethyoxy)phosphoryl]-α-L-threofuranosyl)adenine	 (3.3c)	 as	 a	 white	 foam:	 yield	 0.65	 g	 (46%);	 silica	 gel	 TLC	(DCM/MeOH,	9:1)	Rf	=	0.35;	1H	NMR	(400	MHz,	DMSO-d6)	δ	8.80	(s,	1H),	8.62	(s,1H),	8.06	(m,	4H),	7.72	(m,	1H),	7.66	(m,	1H),	7.57	(m,	4H),	6.52	(d,	1H,	J	=	2.8	Hz),	6.29	(t,	1H,	J	=	2.8	Hz),	5.45	(m,	1H),	4.6	(dd,	1H,	J	=	4,	10.4	Hz),	4.52	(dd,	1H,	J=	4.8,	10.4	Hz),	4.24	(m,	4H),	2.96	(m,	4H);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	165.6,	164.7,	152.0,	151.9,	150.5,	143.0,	134.1,	133.3,	132.5,	129.7,	128.9,	128.5,	128.5,	128.4,	125.8,	118.2,	118.1,	87.5,	79.7,	78.6	(d,	JC,P	=	6.9	Hz),	72.1	(d,	JC,P	=	4.5	Hz),	63.1	(d,	JC,P	=	5.0	Hz),	63.0	(d,	JC,P	=	5.0	Hz),	19.1	(d,	JC,P	=	7.3	Hz),	19.0	(d,	
JC,P	=	7.2	Hz);	31P	NMR	(162	MHz,	DMSO-d6)	δ−2.25;	HRMS	(ESI-TOF)	calcd	for	C29H26N7O8Pna	[M	+	Na]+	654.1485;	found	654.1478.		
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N2-Acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-3′-O-[bis-(2-cyanoethyoxy)phos-		
phoryl]-α-L-threofuranosyl)	guanine(3.3d).	To	a	stirring	solution	containing	1	g	(1.7	mmol)	of	N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)	guanine	(3.1d)24	and	210	mg	(1.68	mmol)	of	DMAP	in	12	mL	 anhydrous	 CH2Cl2	 was	 added	 0.58	 mL	 (3.4	 mmol)	 of	 N,N′-diisopropylethylamine	followed	 by	 the	 addition	 of	 0.821	 mL	 (3.7	 mmol)	 of	 2-cyanoethoxy-N,N’-diisopropylchlorophosphoramidite.	After	being	stirred	for	40	min	at	room	temperature,	the	reaction	 mixture	 was	 diluted	 with	 40	 mL	 of	 CH2Cl2	 and	 extracted	 twice	 with	 50	 mL	 of	saturated	aqueous	NaHCO3,	washed	with	brine,	dried	over	MgSO4,	and	evaporated	under	reduced	 pressure.	 The	 crude	 N2-acetyl-O6-diphenylcarbamoyl-9-[2′-O-benzoyl-3′-O-(N,N’-diisopropylamino-2-cyanoethoxyphosphinyl)-α-L-threofuranosyl]guanine	 (3.2d)23	 was	used	without	further	purification.	To	a	stirring	solution	containing	crude	N2-acetyl-O6-diphenylcarbamoyl-9-[2′-O-benzoyl-3′-O-(N,N’-diisopropylamino-2-cyanoethoxy-phosphinyl)-α-L-threofuranosyl]	 guanine	(3.2d)23	 in	 10	 mL	 of	 anhydrous	 acetonitrile	 was	 added	 0.36	 mL	 (5.0	 mmol)	 of	 3-hydroxypropionitrile	 followed	by	the	addition	of	14.9	mL	of	 tetrazole	(0.45	M	solution	 in	anhydrous	 acetonitrile,	 6.7	 mmol).	 The	 reaction	 mixture	 was	 stirred	 for	 1.5	 h	 at	 room	temperature	with	monitoring	by	TLC	(1:1	hexanes−EtOAc).	After	complete	consumption	of	the	starting	material,	to	the	reaction	was	added	10	mL	of	30%	H2O2	and	left	to	stir	for	20	min	at	 room	 temperature.	 The	 crude	 product	 solution	 was	 evaporated	 to	 dryness	 and	redissolved	with	50	mL	of	ethyl	acetate.	The	organic	layer	was	washed	with	brine	and	water,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	with	silica	gel	column	chromatography	affording	N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O_-
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benzoyl-3′-O-[bis(2-cyanoethyoxy)-phosphoryl]-α-L-threofuranosyl)guanine	 (3.3d)	 as	 a	white	foam:	yield	0.59	g	(45%);	silica	gel	TLC	(DCM/acetone,	10:1)	Rf	=	0.35;	1H	NMR	(500	MHz,	DMSO-d6)	δ	10.78	(s,	1H),	8.55	(s,	1H),	8.03	(d,	2H,	J=	7.5	Hz),	7.71	(t,	1H,	J	=	7.5	Hz),	7.44−7.57	(m,	10H),	7.33	(t,	2H,	J	=	6.5	Hz),	6.39	(s,	1H),	6.21	(s,	1H),	5.41	(s,	1H),	4.75	(m,	1H),	4.47	(m,	1H),	4.24	(m,	4H),	2.94	(m,	4H),	2.20	(s,	3H);	13C	NMR	(125.8	MHz,	DMSO-d6)	
δ	_168.9,	164.8,	155.3,	154.2,	152.4,	150.1,	144.0,	141.6,	134.1,	129.7,	129.5,	128.9,	128.4,	127.4,	120.3,	118.2,	118.0,	116.7,	87.3,	79.5	(d,	J	C,P	=	7.0	Hz),	78.0	(d,	J	C,P	=	4.3	Hz),	71.6	(d,	J	
C,P	=	3.8	Hz),	63.0	(d,	J	C,P	=	5.0	Hz),	63.0	(d,	J	C,P	=	5.0	Hz),	24.7,	19.0	(d,	J	C,P	=	7.9	Hz),	19.0	(d,	
J	 C,P	 =	 7.7	 Hz);	 31P	 NMR	 (162	 MHz,	 DMSO-d6)	 δ	 −2.24;	 HRMS	 (ESI-TOF)	 calcd	 for	C37H33N8O10PH	[M+	H]+	780.2281;	found	780.2296.		
α-L-Threofuranosyl	nucleoside	3′-monophosphates	(3.4a−d).	In	 a	 sealed	 tube,	 1-(2′-O-benzoyl-3′-O-[bis(2-cyanoethyoxy)-phosphoryl]-α-L-threofuranosyl)	nucleosides	(0.32	mmol)	(3.3a−d)	were	combined	with	10	mL	of	saturated	NH4OH.	 The	 reaction	 was	 stirred	 at	 37	 °C	 for	 16	 h.	 The	 mixture	 was	 cooled	 to	 room	temperature,	and	the	solvent	was	evaporated	to	dryness.	The	residue	was	resuspended	in	3	mL	 of	methanol	 at	 40	 °C	with	 stirring.	 The	 40	mL	 of	 acetone	was	 dropwise	 added	 into	mixture	 to	 precipitate	 the	 product	 as	 ammonium	 salt.	 The	 precipitate	 was	 collected	 by	centrifugation	at	4400	rpm	at	room	temperature	for	15	min,	and	the	resulting	pellet	was	washed	 twice	 with	 30	 mL	 of	 acetone	 and	 dried	 under	 high	 vacuum.	 The	 product	 α-L-	threofuranosyl	nucleoside	3′-monophosphates	(3.4a−d)	were	obtained	as	the	ammonium	salt	(white	solid)	in	near	quantitative	yield.		
60		
α	-L-Threofuranosyl	thymine-3′-monophosphate	(3.4a).	Product	yield:	90.8	mg	(98.3%,	ε267	=	9600);	1H	NMR	(400	MHz,	D2O)	δ	7.61	(d,	1H),	5.82	(s,	1H),	4.62	(s,	1H),	4.46	(m,	2H),	4.34	(m,	1H),	1.90	(s,	3H);	13C	NMR	(100.6	MHz,	D2O)	δ	166.9,	151.8,	138.1,	110.5,	92.0,	79.3	(d,	J	C,P	=	4.4	Hz),	78.2	(d,	J	C,P	=	4.2	Hz),	75.1	(d,	J	C,P	=	4.7	Hz),	11.9;	31P	NMR	(162	MHz,	D2O)	δ	0.21;	HRMS	(ESI-TOF)	calcd	for	C9H13N2O8Pna	[M	+	Na]+	331.0307;	found	331.0311.	
	
α-L-Threofuranosyl	cytosine-3′-monophosphate	(3.4b).		Product	yield:	84.4	mg	(96%,	ε280	=	13100);	1H	NMR	(400	MHz,	DMSO-d6)	δ	7.65	(d,	1H,	J	=	7.2	Hz),	5.83	(d,	1H,	J	=	6.8	Hz),	5.65	(s,	1H),	4.38	(s,	1H),	4.28	(s,	2H),	4.07	(d,	1H,	J	=	7.6	Hz);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	163.8,	153.4,	143.1,	93.8,	92.7,	78.8,	78.3,	75.1;	31P	NMR	(162	MHz,	DMSO-d6)	δ	−0.65;	HRMS	(ESI-TOF)	calcd	for	C8H11N3O7P	[M	–	H]−	292.0326;	found	292.0335.		
α-L-Threofuranosyl	adenine-3′-monophosphate	(3.4c).	Product	yield:	88.5	mg	(93%,	ε259	=	15200);	1H	NMR	(400	MHz,	DMSO-d6)	δ	8.30	(s,	1H),	8.16	(s,	1H),	5.91	(d,	1H,	J	=	1.6	Hz),	4.57	(s,	2H),	4.23	(d,	1H,	J	=	8	Hz),	4.12	(dd,	1H,	J	=	5.2,	4.0	Hz);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	156.0,	153.0,	149.5,	140.2,	118.6,	89.3,	79.3	(d,	J	C,P	=	5.2	Hz),	78.2	(d,	J	C,P	=	4.7	Hz),	73.5	(d,	J	C,P	=	4.8	Hz),	75.1;	31P	NMR	(162	MHz,	DMSO-d6)	δ	1.49;	HRMS	(ESI-TOF)	calcd	for	C9H11N5O6P	[M	–	H]−	316.0479;	found	316.0447.	
α-L-Threofuranosyl	guanine-3′-monophosphate	(3.4d).	Product	yield:	90.9	mg	(91%,	ε253	=	13700);	1H	NMR	(400	MHz,	DMSO-d6)	δ	7.88	(s,	1H),	5.68	(s,	1H),	4.45	(d,	2H,	J	=	26.4	Hz);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	157.0,	154.1,	151.2,	
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136.3,	116.0,	88.6,	79.2	(d,	J	C,P	=	4.8	Hz),	78.0	(d,	J	C,P	=	3.6	Hz),	73.1	(d,	J	C,P	=	4.0	Hz);	31P	NMR	(162	MHz,	DMSO-d6)	δ	−0.17;	HRMS	 (ESI-TOF)	 calcd	 for	 C9H11N5O7P	 [M	 –	H]−	 332.0407;	found	332.0396.		
α-L-Threofuranosyl	nucleosides	3′-phosphor-2-methylimidazolides	(3.5a−d).		To	 a	 solution	 containing	 α-L-threofuranosyl	 thymidine-3′-monophosphate	 (3.4a−d)	(0.27	mmol)	and	2-methylimidazole	(2.7	mmol)	 in	5	mL	of	anhydrous	DMSO	were	added	triethylamine	(2.7	mmol),	triphenylphosphine	(1.1	mmol),	and	2,2′-dipyridyldisulfide	(1.08	mmol).	The	reaction	was	stirred	under	a	nitrogen	atmosphere	for	6−8	h	at	room	temperature	with	monitoring	by	analytical	HPLC.	After	consumption	of	the	starting	material,	the	product	was	 precipitated	 by	 the	 dropwise	 addition	 of	 the	 reaction	mixture	 to	 a	 stirring	 solution	containing	80	mL	of	acetone,	60	mL	of	diethyl	ether,	5	mL	of	 triethylamine,	and	5	mL	of	saturated	NaClO4	in	acetone.	The	precipitate	was	collected	by	centrifugation	at	4400	rpm	for	15	min	at	room	temperature.	The	pellet	was	washed	twice	with	30	mL	of	washing	solution	(acetone/diethyl	ether	1:1)	and	dried	under	high	vacuum	to	afford	the	α-L-threofuranosyl	nucleoside	3′-phosphor-2-methylimidazolides	(3.5a−d)	as	the	sodium	salt.	
	
α	-L-Threofuranosyl	thymine-3′-phosphor-2-methylimidazolide	(3.5a).		Product	yield:	97.9	mg	(97.4%,	ε267	=	9600);	31P	NMR	(162	MHz,	D2O)	δ	−7.88;	HRMS	(ESI-TOF)	calcd	for	C13H17N4O7Pna	[M	+	Na]+	395.0732;	found	395.0717.	
α-L-Threofuranosyl	cytosine-3′-phosphor-2-methylimidazolide	(3.5b).	Product	yield:	93.1	mg	(96.6%,	ε280	=	13100);	31P	NMR	(162	MHz,	D2O)	δ	−8.07;	HRMS	(ESI-TOF)	calcd	for	C12H16N5O6Pna	[M	+	Na]+	380.0736;	found	380.0735.	
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α-L-Threofuranosyl	adenine-3′-phosphor-2-methylimidazolide	(3.5c).	Product	yield:	100.5	mg	(97.7%,	ε259	=	15200);	31P	NMR	(162	MHz,	D2O)	δ	−8.37;	HRMS	(ESI-TOF)	calcd	for	C13H16N7O5Pna	[M	+	Na]+	404.0848;	found	404.0847.	
α-L-Threofuranosyl	guanine-3′-phosphor-2-methylimidazolide	(3.5d).	Product	yield:	104	mg	(97%,	ε253	=	13700);	31P	NMR	(162	MHz,	D2O)	δ	−8.40;	HRMS	(ESI-TOF)	calcd	for	C13H16N7O6Pna	[M	+	Na]+	420.0797,	found	420.0807.		
α-L-Threofuranosyl	nucleosides	3′-Triphosphates	(3.6a−d).21−23	To	 a	 solution	 containing	 0.1	 mmol	 of	 α-L-threofuranosyl	 nucleosides	 3′-phosphor-2-methylimidazolides	(3.5a−d)	and	2	mL	of	in	anhydrous	DMF	were	added	tributylamine	(0.2	mmol)	and	tributylammonium	pyrophosphate	(0.2	mmol).	The	reaction	mixture	was	then	stirred	 under	 nitrogen	 atmosphere	 for	 8−12	 h	 at	 room	 temperature	with	monitoring	 by	analytical	HPLC.	After	the	reaction	was	finished,	the	reaction	mixture	was	added	dropwise	to	a	stirring	solution	containing	30	mL	of	acetone	and	5	mL	of	saturated	NaClO4	in	acetone.	The	precipitate	was	collected	by	centrifugation	at	4400	rpm	for	15	min	at	room	temperature	and	 dried	 under	 vacuum	 for	 1	 h.	 The	 crude	 precipitate	was	 dissolved	 in	 3	mL	 of	 0.1	M	triethylammonium	 acetate	 buffer	 and	 purified	 by	 a	 semipreparative	 HPLC.	 Fractions	containing	triphosphates	were	collected	and	concentrated,	pH	adjusted	by	triethylamine	to	7.0,	and	lyophilized	to	afford	the	product	as	a	triethylammonium	salt.	The	solid	product	was	resuspended	in	3	mL	of	methanol	and	was	added	dropwise	to	a	solution	containing	40	mL	of	acetone	and	2	mL	of	saturated	NaClO4	in	acetone.	The	solution	was	centrifuged	at	4400	rpm	for	15	min	at	room	temperature.	The	supernatant	was	discarded,	and	the	pellet	was	washed	with	 30	 mL	 of	 acetone	 and	 dried	 under	 vacuum	 for	 1	 h.	 The	 resulting	 white	 solid	 was	
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dissolved	 in	 Rnase-free	 water	 containing	 10	 mM	 of	 Tris	 pH	 8.0	 to	 afford	 the	 α-L-threofuranosyl	nucleotide	3′-triphosphate	(3.6a−d)	solution.	
α	-L-Threofuranosyl	thymine-3′-triphosphate	(3.6a).		Product	yield	after	HPLC	purification:	42.6	mg	(91.1%,	ε267	=	9600).		
α	-L-Threofuranosyl	cytosine-3′-triphosphate	(3.6b).		Product	yield	after	HPLC	purification:	40	mg	(88.3%,	ε280	=	13100).		
α	-L-Threofuranosyl	adenine-3′-triphosphate	(3.6c).		Product	yield	after	HPLC	purification:	43	mg	(90.1%,	ε259	=	15200).		
α	-L-Threofuranosyl	guanine-3′-triphosphate	(3.6d).		Product	yield	after	HPLC	purification:	44.2	mg	(89.7%,	ε253	=	13700).		
Thermal	Stability	Analysis	of	TNA	Triphosphates.	A	small	volume	(30	μL)	of	4	mM	of	6a−d	in	10	mM	of	Tris	buffer	(pH	8)	was	maintained	at	different	temperatures	(4,	24,	and	37	°C)	for	a	period	of	8	days.	At	specific	time	periods	(1,	5,	 and	8	days),	5	μL	of	 sample	was	 transferred	 to	150	μL	of	HPLC	running	buffer	 [0.1	M	triethylammoniumacetate	 (TEAA)],	 and	 the	 samples	 (50	μL)	were	 analyzed	by	 analytical	reverse-phase	HPLC	with	a	gradient	of	0	to	7%	acetonitrile	in	0.1	M	TEAA	buffer	over	40	min.	Analytical	HPLC	traces	were	analyzed,	and	relative	peak	areas	are	reported	in	Table	2-1.	
Polymerase-Mediated	Primer	Extension.	The	primer	extension	experiment	was	done	in	a	single	PCR	tube	with	100	μL	of	reaction	volume	containing	a	DNA	primer−template	complex	(50	pmol).	The	complex	was	 labeled	with	 an	 IR800	 dye	 at	 the	 5′-end	 of	 the	 DNA	 primer.	 The	 primer−template	 complex	was	annealed	in	1Å~	thermoPol	buffer	(20	mM	Tris·HCl,	0	mM	(NH4)2SO4),	10	mM	KCl,	2	mM	
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MgSO4,	0.1%	Triton	X-100,	pH	8)	by	heating	for	5	min	at	95	°C	and	cooling	for	10	min	at	4	°C.	An	engineered	polymerase,	KOD-RI	(10	μL),	was	pretreated	with	MnCl2	(1	mM)	and	added	to	the	reaction	mixture.	Newly	formed	2.6	a−d	(100	μM)	were	then	added	to	the	reaction	mixture,	 and	 the	 solution	was	 incubated	 for	 3	 h	 at	 55	 °C.	 The	 reaction	was	 analyzed	 by	denaturing	polyacrylamide	gel	electrophoresis.		
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Chapter	4	
Synthesis	of	2′-Deoxy-α-L-threofuranosyl	Nucleoside	Triphosphates		
	
Publication	note		This	paper	was	originally	published	in	the	Journal	of	Organic	Chemistry.	Saikat	Bala†,	 Jen-Yu	Liao†,	 Li	 Zhang,	 Chantel	N.	 Tran,	Nicholas	 Chim,	 and	 John	C.	 Chaput.	Synthesis	of	2′-Deoxy-α-L-threofuranosyl	Nucleoside	Triphosphates.	J.	Org.	Chem.	2018,	83,	8840−8850.	(	†	Equal	Contribution)		Copyright	©	2018,	American	Chemical	Society			
4.1	Contribution	Statement		Bala,	S.	and	Liao,	J.-Y.	designed	the	synthetic	strategy.	Bala,	S.	and	Liao,	J.-Y.	performed	the	 synthesis,	 optimization,	 and	 compounds	 characterization.	 Li	 Zhang	 performed	 the	primer-extension	 assay.	 Chantel	 N.	 Tran,	 and	 Nicholas	 Chim	 performed	 the	 protein	crystallization.	 Liao,	 J.-Y.	 and	 Bala,	 S.	 involved	 in	 the	 experimental	 section	 writing	 and	supporting	information	compiling.	Liao,	J.-Y.,	Bala,	S.	and	Chaput,	J.	C.	wrote	the	manuscript.		
4.2	Abstract	of	the	Chapter	α-L-Threofuranosyl	nucleic	acid	(TNA)	is	an	artificial	genetic	polymer	in	which	the	five-carbon	 ribose	 sugar	 found	 in	RNA	has	been	 replaced	with	 an	 four-carbon	 threose	 sugar.	Despite	 a	 difference	 in	 sugar−phosphate	 backbone,	 TNA	 is	 capable	 of	 forming	 stable	antiparallel	Watson−Crick	duplex	with	complementary	strands	of	DNA	and	RNA	and	itself.	This	property	of	intersystem	base	pairing,	coupled	with	the	chemical	simplicity	of	threose	
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relative	to	ribose,	provides	support	for	the	hypothesis	that	TNA	is	the	potential	candidate	of	RNA	progenitor	in	the	evolution	of	life.	In	an	effort	to	evaluate	the	functional	properties	of	TNA	by	in	vitro	evolution,	engineered	polymerases	have	been	developed	that	are	capable	of	copying	genetic	information	back	and	forth	between	DNA	and	TNA.	However,	the	current	developed	 TNA	 polymerases	 function	 with	 reduced	 activity	 relative	 to	 their	 natural	counterparts,	which	limits	the	evaluation	of	TNA	as	a	primordial	genetic	material.	Here,	we	describe	the	synthesis	of	2′-deoxy-α-L-threofuranosyl	nucleoside	3′-triphosphates	(dtNTPs)	as	 chain-terminating	 substrates	 in	 a	 polymerase-mediated	 TNA	 synthesis	 reaction.	 The	synthesis	of	dtNTPs	should	make	it	possible	to	investigate	the	mechanism	of	TNA	synthesis	by	X-ray	crystallography	by	trapping	the	polymerase	in	the	catalytically	active	conformation.		
4.3	Introduction		TNA	 (α-L-threofuranosyl	 nucleic	 acid)	 is	 an	 artificial	 genetic	 polymer	 developed	 by	Eschenmoser	and	colleagues	as	part	of	an	investigation	into	the	chemical	etiology	of	RNA.1	Unlike	most	 of	 the	 other	RNA	 analogues	 examined	 in	 their	 study,2	 TNA	was	 found	 to	 be	capable	 of	 adopting	 stable	 Watson−Crick	 duplex	 structures	 with	 itself	 and	 with	complementary	 strands	 of	 DNA	 and	 RNA.3	 This	 property	 of	 intersystem	 base	 pairing	provides	a	mechanism	for	 the	 transfer	of	genetic	 information	between	sequential	genetic	polymers	in	the	evolution	of	life.4	In	an	effort	to	broaden	the	concept	of	information	transfer	beyond	 the	 hybridization	 of	 short	 chemically	 synthesized	 oligonucleotides,	 engineered	polymerases	 were	 developed	 to	 replicate	 TNA	 by	 copying	 information	 back	 and	 forth	between	TNA	and	DNA.5,6	These	enzymes	were	used	to	produce	the	first	examples	of	TNA	aptamers	 isolated	by	 in	vitro	selection.7−9	Since	TNA	is	refractory	to	nuclease	digestion,10	
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TNA	 affinity	 reagents	 and	 catalysts	 have	 practical	 value	 in	 diagnostic	 and	 therapeutic	applications	that	require	high	biological	stability.11,12	Detailed	 kinetic	 studies	 measuring	 the	 rate	 of	 TNA	 synthesis	 by	 an	 engineered	 TNA	polymerase	 indicate	 that	 TNA	 synthesis	 occurs	 at	 a	 rate	 that	 is	 vastly	 inferior	 to	 DNA	synthesis	with	natural	DNA	polymerases.13	Insight	into	this	problem	was	recently	obtained	when	the	X-ray	crystal	structure	of	a	laboratory-evolved	TNA	polymerase	was	solved	for	the	apo,	 binary,	 open	 and	 closed	 ternary	 complexes,	 and	 the	 translocated	 product	postcatalysis.14	Analysis	of	the	enzyme	active	site	in	the	closed	ternary	structure	suggests	that	the	slow	rate	of	catalysis	was	due	to	a	suboptimal	binding	geometry	of	the	incoming	TNA	 nucleoside	 triphosphate	 (tNTP).14	 Although	 this	 data	 provided	 a	 key	 piece	 of	information	 that	 could	 be	 used	 as	 a	 framework	 for	 engineering	 new	 TNA	 polymerase	variants,	 solving	 the	 structures	 of	 future	 TNA	 polymerases	 isolated	 along	 the	 same	evolutionary	 trajectory	would	make	 it	 possible	 to	 uncover	 important	 structural	 features	required	to	shape	the	design	of	a	polymerase	active	site	that	is	perfectly	contoured	for	TNA	substrates.	Although	 some	 unnatural	 nucleotide	 triphosphates	 are	 better	 substrates	 for	 DNA	polymerases	 than	 are	 natural	 dNTPs,15	most	 unnatural	 substrates	 function	with	 reduced	activity	relative	to	their	natural	counterparts.16,17	We	therefore	reasoned	that	an	iterative	process	of	directed	evolution	and	X-ray	crystallography	could	provide	valuable	insight	into	the	 general	 principles	 that	 govern	 polymerase	 specificity.18	 While	 our	 polymerase	engineering	endeavors	have	focused	primarily	on	TNA,	information	gained	from	this	process	could	be	applied	 to	other	polymerase	engineering	efforts	 currently	underway	 to	develop	polymerases	that	can	replicate	other	types	of	unnatural	genetic	polymers.19,20	A	critical	step	
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in	this	process	is	to	synthesize	substrates	that	can	trap	the	enzyme	in	the	catalytic	state	of	phosphodiester	bond	formation.	Although	our	previous	efforts	utilized	a	DNA	primer	lacking	a	2′-hydroxyl	group	on	the	terminal	TNA	residue,	this	approach	was	difficult	to	implement	and	often	leads	to	an	open	ternary	structure	that	captures	the	substrate	binding	step	rather	than	the	desired	catalytic	step	observed	in	the	closed	ternary	complex.14	An	 alternative	 approach	 is	 to	 use	 chain-terminating	 nucleoside	 triphosphates	 that	undergo	a	cycle	of	catalysis	prior	to	crystallization.	This	strategy	has	been	used	successfully	to	 capture	 the	 closed	 ternary	 structures	 of	 DNA	 polymerases	 by	 trapping	 the	 second	incoming	 DNA	 nucleoside	 triphosphate	 in	 the	 catalytically	 active	 conformation.21,22	However,	applying	this	approach	to	laboratory-evolved	TNA	polymerases	requires	chemical	synthesis,	as	TNA	substrates	(amidites	and	triphosphates)	are	not	available	commercially.	Here,	 we	 report	 the	 chemical	 synthesis	 of	 2′-deoxy-α-L-threofuranosyl	 nucleoside	 3′-	triphosphates	(dtNTPs)	bearing	the	four	genetic	bases	of	adenine	(A),	cytosine	(C),	guanine	(G),	and	thymine	(T).	The	resulting	substrates	were	obtained	in	eight	chemical	steps	from	advanced	intermediates	described	in	a	previously	published	chemical	synthesis	pathway.23	All	 four	 dtNTPs	 exhibit	 efficient	 site-specific	 chain	 termination	 in	 a	 TNA	 polymerization	reaction	 and	 protein	 crystallization	 studies,	with	 dtATP	 leading	 to	 the	 formation	 of	 high	quality	protein	crystals	that	diffracted	to	2.6−2.8	Å	resolution.			
4.4	Results	and	Discussions	We	 have	 previously	 described	 an	 efficient	 synthesis	 of	4.1a−d,	 which	 involves	 eight	chemical	 transformations	 and	 avoids	 the	 need	 for	 silica	 gel	 purification.23	 This	 strategy	makes	 use	 of	 a	 highly	 efficient	 regioselective	 2′-OH	 protection	 strategy	 developed	 by	
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Herdewijn	and	colleagues,24	which	simplifies	the	synthesis	of	TNA	monomers	relative	to	an	earlier	 strategy	 that	 required	 additional	 protection	 and	 deprotection	 steps.25	 Using	 this	approach,	 protected	 nucleosides	 4.1a−d	 were	 generated	 (Scheme	 1-2)	 as	 the	 starting	compounds	 for	 synthesizing	 the	 desired	 dtNTPs	 (4.9a−d)	 analogues	 described	 in	 the	current	study.	
Scheme	4-1.	Synthesis	of	2′-Deoxy	TNA	Nucleosides	4.4a−d′		
		 													
(Scheme	was	used	with	permission	from	.		J.	Org.	Chem.	2018,	83,	8840−8850)	
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	We	 began	 by	 selectively	 deprotecting	 the	 2′-benzoyl	 group	 from	 compounds	4.1a−d	using	 a	 1	 N	 NaOH	 solution	 that	 was	 added	 dropwise	 to	 the	 protected	 TNA	 nucleosides	(Scheme	 4-1).	 Nucleosides	4.2a−d	were	 then	 treated	with	 phenyl	 isothiocyanate	 under	basic	 conditions	 to	 synthesize	 2′-phenyl	 isothiocyanate	 derivatives	4.3a−d’,	 which	 were	used	 as	 the	 precursors	 for	 a	 Barton	 deoxygenation	 reaction.	 This	 reaction	 proceeded	efficiently	 for	 each	 nucleoside	 with	 the	 exception	 of	 guanosine	 analogue	 4.2d,	 which	experienced	significant	loss	of	the	diphenylcarbamoyl	(DPC)	group.	To	avoid	the	occurrence	of	a	partially	deprotected	guanine	base,	we	removed	the	DPC	group	prior	to	the	synthesis	of	
4.3d′.27	This	chemical	substitution	enabled	us	to	synthesize	all	four	TNA	nucleosides	as	2′-deoxy	 analogues	 in	 protected	 form.	 Using	 standard	 deoxygenation	 conditions	 with	 α,α′-azobisisobutyronitrile	(AIBN)	as	a	radical	initiator	and	the	tributylstannane	as	the	proton	source	and	 thione	 scavenger,	we	observed	efficient	 conversion	of	4.3a−d′	 to	4.4a−d′	 for	each	 nucleoside,	 except	 protected	 TNA	 cytidine	 derivative	 4.3b.14,26,27	 In	 this	 case,	 the	reaction	 consistently	 produced	 a	 mixture	 of	 compounds	 that	 included	 4.2b	 as	 a	 side	product.28	In	an	effort	to	avoid	this	problem,	we	pursued	milder	reaction	conditions	that	included	the	use	of	triethylborane	and	tris(trimethylsilyl)silane	as	alternative	reagents	for	the	homolytic	deoxygenation	of	the	2′-hydroxyl	group.29,30	Dry	oxygen	was	introduced	into	the	reaction,	which	triggered	a	radical	cascade	and	resulted	in	the	clean	synthesis	of	4.4a−d′	within	30	min	at	room	temperature.	The	 desilylation	 of	 4.4a−d′	 with	 1	 M	 tetrabutylammoniumfluoride	 (TBAF)	 in	 THF	afforded	TNA	nucleoside	derivatives	4.5a−d′	(Scheme	3-2).	To	confirm	that	our	synthesis	strategy	yielded	the	correct	nucleoside	analogue,	the	molecular	structure	of	4.5c	was	solved	
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by	small-molecule	X-ray	crystallography	(Figure	4-1).	The	observed	electron	density	and	torsion	angles	are	consistent	with	the	formation	of	a	2′-deoxy	analogue	with	the	3′-OH	group	occupying	 the	 β	 conformation	 on	 the	 furanose	 ring.	 Moreover,	 no	 electron	 density	 was	observed	for	the	2′	hydroxyl	moiety.		
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(Scheme	was	used	with	permission	from	.		J.	Org.	Chem.	2018,	83,	8840−8850)		Next,	 3′-monophosphate	 triesters	 4.6a−d′	were	 synthesized	 using	 a	 known	 one-pot	phosphitylation−oxidation	strategy.31	Accordingly,	compounds	4.5a−d′	were	treated	with	dibenzyl	 phosphoramidite	 and	 tetrazole	 to	 convert	 the	 3′-hydroxyl	 group	 into	 a	phosphitylated	 P(III)	 derivative	 that	 was	 oxidized	 to	 P(V)	 with	 30%	 aqueous	 H2O2.	Nucleosides	 4.6a−d′	were	 purified	 by	 flash	 column	 chromatography	 and	 hydrogenated	using	0.1−0.2	mass	equivalents	of	10%	palladium	on	charcoal.	Following	the	removal	of	the	catalyst	 by	 filtration	 and	 solvent	 evaporation,	 the	 base	 protecting	 groups	were	 removed	upon	treatment	with	33%	ammonium	hydroxide	(NH4OH)	for	18	h	at	37	°C.	Deprotection	afforded	 desired	 2′-deoxy	 TNA	 nucleoside	monophosphates	4.7a−d	 in	 >90%	 yield	 from	
4.6a−d′.						
	
	
Figure	4.1	X-ray	crystal	structure	of	6-benzoyl-2′-deoxy-α-L-threofuranosyl	
adenosine	nucleoside	4.5c.	
(Figure	was	used	with	permission	from	.		J.	Org.	Chem.	2018,	83,	8840−8850)	
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Although	 numerous	 strategies	 have	 been	 developed	 to	 synthesize	 nucleoside	triphosphates,32−34	we	 chose	 to	 follow	 a	 general	 strategy	 that	 has	worked	 previously	 for	TNA.35	 The	 desired	 dtNTPs	 were	 generated	 from	 activated	 monophosphates	 4.8a−d	 by	displacing	 the	 activated	 2-methylimidazole	 leaving	 group	 with	 pyrophosphate.	 TNA	monophosphates	 4.7a−d	 were	 converted	 to	 their	 3′-phosphoro-2-methylimidazole-activated	 derivatives	 using	 a	 Mitsunobu-like	 reaction	 of	 4.7a−d	 with	 excess	 2-methylimidazole	 and	 triphenylphosphine	 in	 the	 presence	 of	 2,2′-dipyridyl	 disulfide.35	Nucleoside	phosphoro-2-methylimidazolides	(4.8a−d)	were	precipitated	as	a	sodium	salt	with	10	equiv	of	sodium	perchlorate	in	an	ether/acetone	solution.	Compounds	4.8a−d	were	then	converted	to	the	desired	2′-deoxy	nucleoside	triphosphates	4.9a−d	by	treating	4.8a−d	with	tributylammonium	pyrophosphate	and	tributylamine	in	DMF.	The	reaction	progress	of	
4.7a−d,	4.8a−d,	 and	4.9a−d	was	monitored	by	 analytical	HPLC,	 and	 compounds	4.9a−d	were	purified	by	preparative	HPLC.		Next,	we	used	 a	 primer	 extension	 assay	 to	 compare	 the	 ability	 of	 each	2′-deoxy	TNA	triphosphate	to	terminate	TNA	synthesis	on	a	DNA	primer−template	complex	(Figure	4-2).		Primer−template	complexes	T1−T4	were	designed	to	inhibit	TNA	synthesis	midstream	using	one	of	four	chemically	synthesized	dtNTP	substrates	4.9a−d	(Figure	4-2A)	that	would	site-specifically	incorporate	at	a	central	position	in	the	growing	TNA	strand.	In	each	case,	a	5′-IR	labeled	DNA	primer	annealed	to	a	DNA	template	was	incubated	with	Kod-RI	TNA	polymerase	and	the	corresponding	dtNTP	solution	for	60	min	at	55	°C.	Four	different	dtNTP	solutions	were	prepared	in	which	one	of	the	four	normal	tNTP	residues	was	individually	replaced	with	the	corresponding	dtNTP	analogue.	The	chain-terminating	analogues	were	compared	to	the	normal	tNTPs,	which	were	used	as	positive	control	for	the	full-length	product.	An	analysis	of	
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the	resulting	primer	extension	reactions	by	denaturing	polyacrylamide	gel	electrophoresis	revealed	 that	all	 four	dtNTP	substrates	mediate	complete	and	efficient	chain	 termination	during	TNA	synthesis	by	producing	a	truncated	product	at	the	designated	site	in	the	template	(Figure	4-2B).	This	result	shows	that	the	dtNTP	substrates	are	recognized	and	processed	by	a	 laboratory-evolved	 TNA	 polymerase	 to	 produce	 a	 chain-terminated	 TNA	 extension	product.										
Figure	4-2.	Sequence	and	primer	extension	results.	(A) DNA	primer−template	 complexes	were	 used	 to	 assess	 chain	 termination	 efficiency	 of	dtNTP	substrates.	(B)	Primer	extension	experiments	were	performed	using	5′-IR	labeled	DNA	primers	annealed	to	DNA	templates	T1−T4	that	were	incubated	with	the	desired	TNA	triphosphate	solution	and	Kod-RI	TNA	polymerase	for	60	min	at	55	°C.	Reactions	were	quenched	and	analyzed	by	denaturing	polyacrylamide	gel	electrophoresis		(Figure	was	used	with	permission	from	.		J.	Org.	Chem.	2018,	83,	8840−8850.)		 Next,	we	assessed	the	feasibility	of	using	dtNTP	substrates	for	X-ray	crystallography.	A	binary	 complex	 of	 Kod-RI	 TNA	 polymerase	 bound	 to	 a	 primer−template	 duplex	 was	
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incubated	 initially	 with	 excess	 2′-deoxy-α-L-threofuranosyl	 adenosine	 nucleoside	triphosphate	4.9c	to	promote	a	single	turnover	event,	followed	by	excess	tTTP	to	capture	the	polymerase	 in	 a	precatalytic	 state	with	 the	 incoming	TNA	 triphosphate	bound	 in	 the	enzyme	active	site.	The	resulting	reaction	mixture	was	utilized	for	crystallization	trials,	and	the	most	promising	crystals	were	selected	for	further	optimization.	A	2.6	Å	resolution	X-ray	diffraction	data	set	from	the	best	crystal	form	(Figure	4.3),	belonging	to	a	space	group	of	C2	with	unit	cell	parameters	a	=	147.74	Å,	b	=	107.99	Å,	and	c	=	70.71	Å,	α	=	γ	=	90°,	β	=	102.67,	was	collected.	Molecular	replacement	using	our	previously	solved	Kod-RI	ternary	complex	(ref	16)	as	a	search	model	was	unsuccessful,	suggesting	that	the	structure	will	have	to	be	determined	 by	 experimental	 phasing.	 Nevertheless,	 this	 result	 provides	 confidence	 that	dtNTPs	offer	a	new	route	to	ternary	complexes	of	TNA	polymerases	developed	by	laboratory	evolution.	The	chemical	synthesis	of	chain-terminating	TNA	triphosphates	provides	an	opportunity	to	study	the	mechanism	of	TNA	synthesis	by	laboratory-evolved	TNA	polymerases.	Previous	structures	 reveal	 that	 Kod-RI	 recognizes	 the	 incoming	 tNTP	 substrates	 in	 a	 suboptimal	geometry.14	This	conformation	is	believed	to	account	for	the	slow	rate	of	TNA	synthesis	as	compared	to	natural	DNA	polymerases.	Using	chain-terminating	TNA	substrates,	it	may	be	possible	to	improve	our	understanding	of	the	principles	that	govern	polymerase	specificity.	Such	knowledge	would	improve	our	basic	understanding	of	polymerase	function	and	help	close	 the	 gap	 in	 catalytic	 activity	 between	 engineered	 polymerases	 and	 their	 natural	counterparts.			
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Figure	4-3.	X-ray	crystallography	of	Kod-RI	bound	to	4.9c.	(A) schematic	illustration	showing	the	addition	of	the	chain-terminating	dtATP	substrate	(9c,	red)	to	the	primer−template	duplex	by	Kod-RI.	In	the	subsequent	step,	the	tTTP	(green)	is	trapped	in	the	precatalytic	state	to	form	the	ternary	complex.	(B,C)	The	optimization	of	ternary	Kod-RI	complex	cocrystals.	(D)	The	2.6	Å	resolution	X-ray	iffraction	pattern	of	an	optimized	ternary	Kod-RI	crystal.		(Figure	was	used	with	permission	from	.		J.	Org.	Chem.	2018,	83,	8840−8850.)		
4.5	Conclusions	In	 summary,	 we	 describe	 the	 chemical	 synthesis	 of	 2′-deoxy-α-L-threofuranosyl	nucleoside	3′-triphosphates	(dtNTPs)	bearing	all	four	genetic	bases.	We	suggest	that	these	substrates	could	find	immediate	use	as	chain-terminating	reagents	in	applications	related	to	the	mechanism	of	TNA	synthesis	by	a	TNA	polymerase.	Structural	information	gained	from	these	studies	could	be	used	to	develop	new	polymerase	variants	with	greater	TNA	synthesis	activity.		
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4.6	Experimental	Details		
General	Information	All	 reactions	 were	 carried	 out	 in	 anhydrous	 solvents	 under	 an	 argon	 or	 nitrogen	atmosphere	 unless	 mentioned	 otherwise.	 All	 reagents	 and	 solvents	 were	 obtained	 from	commercial	 sources	 and	 used	 without	 further	 purification:	 Sublimed	 tetrazole	 in	 dry	acetonitrile	was	 obtained	 from	Glen	Research,	 dibenzyl	 diisopropylphosphoramidite	was	obtained	from	Combi-Blocks,	10%	palladium	on	activated	carbon	(reduced,	dry	powder)	was	obtained	 from	 Strem	 Chemicals,	 and	 5.5	 M	 tert-butyl	 hydroperoxide	 in	 decane	 over	molecular	 sieves	 was	 obtained	 from	 Sigma-Aldrich.	 Hydrogen	 and	 nitrogen	 gases	 were	purchased	as	USP	grade.	Reaction	progress	was	monitored	by	thin	 layer	chromatography	using	 glass-backed	 analytical	 SiliaPlate	 with	 UV-active	 F254	 indicator.	 Flash	 column	chromatography	was	performed	with	SiliaFlash	P60	silica	gel	(40−63	μm	particle	size).	The	
1H,	 13C,	 or	 31P	 nuclear	 magnetic	 resonance	 (NMR)	 spectra	 were	 recorded	 at	 room	temperature	 on	 either	 a	 Bruker	DRX	 400	 or	 500	MHz	 spectrometer	 at	 the	University	 of	California,	Irvine,	NMR	Facility.	The	1H	and	13C	NMR	chemical	shifts	(δ)	are	reported	in	parts	per	million	(ppm)	with	tetramethylsilane	or	deuterium	solvent	as	an	internal	reference.	The	31P	NMR	chemical	shifts	are	proton	decoupled	and	reported	in	parts	per	million	relative	to	an	external	 standard	of	85%	H3PO4.	Peaks	multiplicity	are	designated	with	 the	 following	abbreviations:	s,	singlet;	d,	doublet;	dd,	doublet	of	doublets;	t,	triplet;	m,	multiplet;	br,	broad.	HPLC	analysis	was	performed	on	a	reverse-phase	C18	150	×	4.6	mm2	column	with	5	μm	particle	 size,	 and	 nucleoside	 triphosphates	 were	 purified	 on	 a	 semipreparative	 reverse	phase	C18	250	×	9.4	mm2	column	(Thermo	Scientific,	USA)	using	a	mobile	phase	of	100	mM	triethylammonium	 acetate	 buffer	 (pH	 7.0)/acetonitrile.	 Purified	 molecules	 that	 contain	
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phosphate	 groups	 were	 converted	 into	 their	 corresponding	 Na+	 salt	 using	 the	 Dowex	Marathon	 C	 Na+-form	 of	 resin	 before	 recording	 mass	 spectra.	 High	 resolution	 mass	spectrometry	 (HRMS)	data	were	acquired	using	 the	electrospray	 ionization	 time-of-flight	(ESI-TOF)	method	at	 the	University	 of	California,	 Irvine,	Mass	 Spectrometry	Facility.	The	nucleoside	monophosphates,	 phosphorimidazolides	 and	 triphosphates	were	 dissolved	 in	RNase-free	 water	 with	 10	 mM	 Tris	 pH	 8.0	 and	 quantified	 by	 Nanodrop	 2000	 (Thermo	Scientific,	USA)	using	Beer’s	law.	(T,	ε267:	9600	M−1cm−1.	C,	ε271:	91	00	M−1cm−1.	G,	ε259:	15200	M−1cm−1.	A,	ε259:	15400	M−1cm−1.		
1-(2'-O-Benzoyl-3'-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)-thymine(4.1a).	Product	4.1a	was	prepared	as	described	previously.24	The	crude	product	was	purified	on	silica	gel	with	eluents	(EtOAc/hexane,	from	80	to	100%)	to	afford	the	1-(2′-O-benzoyl-3′-O-
tert-butyldiphenylsilyl-α-L-threofuranosyl)thymine	 (4.1a)	 as	 a	white	 solid:	 silica	 gel	 TLC	(hexane/EtOAc,	1:1)	Rf	=	0.35;	1H	NMR	(400	MHz,	CDCl3)	δ	8.42	(s,	1H),	7.93	(d,	2H,	J	=	6.4	Hz),	7.66−7.65	(m,	5H),	7.57−7.55	(m,	1H),	7.47−7.34	(m,	8H),	5.47	(s,	1H),	5.46	(s,	1H),	4.41	(d,	1H,	J	=	4	Hz),	4.16	(d,	1H,	J	=	8	Hz),	3.92	(dd,	1H,	J	=	5.2,	2.8	Hz),	1.91	(s,	3H),	1.11	(s,	9H);	
13C	NMR	(125.8	MHz)	δ	164.8,	163.7,	150.2,	136.4,	135.8,	133.7,	132.7,	131.8,	130.5,	130.0,	129.0,	128.6,	111.1,	89.8,	82.7,	75.6,	27.0,	13.3,	12.7;	HRMS	(ESI-TOF)	C32H34N2O6SiNa	[M	+	Na]+	593.2084;	found	593.2089.	
	
N4-Benzoyl-1-(2'-O-benzoyl-3'-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	
(4.1b).	
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Product	4.1b	was	prepared	as	described	previously.24	The	crude	product	was	purified	on	silica	 gel	with	 eluents	 (EtOAc/CH2Cl2,	 from	20	 to	 35%)	 to	 afford	 the	N4-benzoyl-1-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	 (4.1b)	 as	 a	 white	 solid:	silica	gel	TLC	(hexane/EtOAc,	1:1)	Rf	=	0.35;	1H	NMR	(400	MHz,	CDCl3)	δ	8.25	(d,	1H,	J	=	7.6	Hz),	7.97	(d,	2H,	J	=	7.6	Hz),	7.93	(d,	2H,	J	=	7.6	Hz),	7.64−7.36	(m,	18	H),	6.21	(s,	1H),	5.67	(s,	1H),	4.40	(d,	1H,	J	=	2.4	Hz),	4.17	(d,	1H,	J	=	10	Hz),	4.07	(d,	1H,	J	=	10,	3.2	Hz),	1.07	(s,	3H);	
13C	NMR	(125.8	MHz,	CDCl3)	δ	164.5,	136.0,	135.8,	133.6,	133.3,	132.7,	131.7,	130.4,	130.4,	130.0,	129.2,	129.2,	128.5,	128.1,	128.1,	127.7,	91.4,	82.1,	77.0,	75.8,	27.0,	19.2;	HRMS	(ESI-TOF)	C38H37N3O6SiNa	[M	+	Na]+	682.2349;	found	682.2339.		
N6-Benzoyl-9-(2'-O-benzoyl-3'-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	
(4.1c).	Product	4.1c	was	prepared	as	described	previously.24	The	crude	product	was	purified	on	silica	gel	with	eluents	 (EtOAc/hexane,	 from	33	 to	50%)	 to	afford	 the	N6-benzoyl-9-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	 (4.1c)	 as	 a	 white	 solid:	silica	gel	TLC	(hexane/EtOAc,	1:1)	Rf	=	0.40;	1H	NMR	(400	MHz,	CDCl3)	δ	8.25	(d,	1H,	J	=	7.6	Hz),	7.97	(d,	2H,	J	=	7.6	Hz),	7.93	(d,	2H,	J	=	7.6	Hz),	7.64−7.36	(m,	18	H),	6.21	(s,	1H),	5.67	(s,	1H),	4.40	(d,	1H,	J	=	2.4	Hz),	4.17	(d,	1H,	J	=	10	Hz),	4.07	(d,	1H,	J	=	10,	3.2	Hz),	1.07	(s,	3H);	
13C	NMR	(125.8	MHz,	CDCl3)	δ	162.7,	145.5,	136.2,	136.0,	136.0,	135.9,	133.4,	132.8,	131.8,	130.5,	130.4,	129.2,	129.1,	128.2,	128.2,	128.1,	127.8,	126.0,	75.8,	66.0,	27.2,	19.3;	HRMS	(ESI-TOF)	C39H37N5O5SiNa	[M	+	Na]+	706.2462;	found	706.2471.	
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N2-Acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-
threofuranosyl)guanine	(4.1d).	Product	4.1d	was	prepared	as	described	previously.24	The	crude	product	was	purified	using	flash	column	chromatography	on	a	silica	gel	with	eluents	(EtOAc/hexane,	from	80	to	100%)	 to	 afford	 N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)guanine	 (4.1d)	 as	 a	 yellow	 foam:	 silica	 gel	 TLC	(hexane/EtOAc,	1:1)	Rf	=	0.65;	1H	NMR	(400	MHz,	CDCl3)	δ	8.42	(s,	1H),	7.95−7.90	(m,	3H),	7.62−7.55	(m,	5H),	7.44−7.34	(m,	15H),	7.31−7.23	(m,	5H),	6.16	(d,	1H,	J	=	1.2	Hz),	5.81	(s,	1H),	4.57	(m,	1H),	4.22	(dd,	1H,	J	=	12,	7.6	Hz),	4.11	(dd,	1H,	J	=	14.4,	5.6	Hz),	2.50	(s,	3H),	1.03	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	_164.8,	156.5,	154.6,	152.4,	150.4,	142.4,	135.8,	134.0,	132.5,	131.9,	130.5,	130.0,	128.7,	128.1,	120.9,	88.8,	82.5,	76.2,	75.9,	27.0,	25.3,	19.1;	HRMS	(ESI-TOF)	C47H44N6O7SiNa	[M	+	Na]+	855.2938;	found	855.2960.		
1-(3′-O-tert-Butyldiphenylsilyl-α-L-threofuranosyl)	thymine	(4.2a).	To	 a	 solution	 containing	 4.73	 g	 (6.5	 mmol)	 of	 1-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)thymine	(4.1a)	in	12	mL	of	THF	and	5	mL	of	MeOH	at	0	°C	was	added	6.54	mL	(6.5		mmol)	of	ice-cold	1	N	NaOH(aq)	dropwise	while	stirring.	After	15	min,	additional	3.27	mL	(3.3	mmol)	of	ice-cold	1	N	NaOH(aq)	was	added	to	the	reaction	for	an	additional	1	h	of	stirring,	at	which	time	TLC	(hexane/EA,	1:1)	showed	the	complete	consumption	of	the	starting	material,	the	reaction	was	quenched	with	the	dropwise	addition	of	5	mL	of	1	N	HCl(aq)	at	0	°C.	The	solution	was	condensed	to	a	20	mL	volume	under	reduced	pressure,	and	the	crude	product	was	diluted	with	50	mL	of	EtOAc.	The	organic	 layer	was	washed	with	50	mL	of	H2O	and	then	50	mL	of	brine,	dried	over	MgSO4,	and	evaporated	under	
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reduced	pressure.	The	residue	was	purified	on	silica	gel	with	eluents	(MeOH/CH2Cl2,	from	0	to	 5%).	 Product	4.2a	was	obtained	 as	 a	white	 foam:	 yield	2.17	 g	 (72.1%);	 silica	 gel	 TLC	(CH2Cl2/MeOH,	20:1)	Rf	=	0.65;	1H	NMR	(400	MHz,	CDCl3)	δ	10.76	(s,	1H),	7.60	(dd,	2H,	J	=	5.2,	4.0	Hz),	7.59	(d,	1H,	J	=	1.2	Hz),	7.52	(dd,	2H,	J	=	8.0,	1.2	Hz),	7.43−7.41	(m,	1H),	7.39−7.32	(m,	5	H),	5.74	(s,	1H),	5.28	(d,	1H,	J	=	7.2	Hz),	4.39	(s,	1H),	4.28	(d,	1H,	J	=	2	Hz),	4.17	(d,	2H,	J	=	3.2	Hz),	1.87	(s,	3H),	1.01	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	164.9,	151.1,	136.8,	135.8,	132.9,	130.3,	128.1,	109.9,	94.2,	81.5,	77.7,	26.9,	19.1,	12.8;	HRMS	(ESI-TOF)	C25H30N2O5SiNa	[M	+	Na]+	489.1822;	found	489.1822.		
N4-Benzoyl-1-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	(4.2b).	A	stirring	solution	containing	6.8	g	(10.3	mmol)	of	N4-benzoyl-1-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	(4.1b)	in	51	mL	of	THF	and	51	mL	of	MeOH	was	cooled	to	0	°C.	The	solution	was	added	to	10.3	mL	(10.3	mmol)	of	ice-cold	1	N	NaOH(aq)	dropwise	while	stirring.	After	30	min,	another	10.3	mL	(10.3	mmol)	of	ice-cold	1	N	NaOH(aq)	was	added	dropwise	to	the	solution	for	an	additional	30	min	of	stirring,	at	which	time	the	TLC	showed	the	reaction	was	finished;	the	solution	was	quenched	by	adding	10.3	mL	of	1	N	HCl(aq)	 at	 0	 °C.	 The	 crude	 product	was	 condensed	 to	 50	mL	 of	 solution	 under	 reduced	pressure,	and	the	solution	was	poured	into	200	mL	of	EtOAc.	The	organic	layer	was	washed	with	200	mL	of	brine	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	 The	 crude	 product	was	 purified	 by	 flash	 column	 chromatography	with	 eluents	(MeOH/CH2Cl2,	from	1.6	to	2.5%)	to	afford	N4-benzoyl-1-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	 (4.2b)	 as	 a	 white	 solid:	 yield	 3.84	 g	 (67.1%);	 silica	 gel	 TLC	(MeOH/CH2Cl2,	1:40)	Rf	=	0.45;	1H	NMR	(400	MHz,	CDCl3)	δ	8.19	(d,	1H,	J	=	7.6	Hz),	7.94	(d,	
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2H,	J	=	7.2	Hz),	7.65−7.56	(m,	5H),	7.52−7.48	(m,	4H),	7.44−7.32	(m,	8H),	5.73	(s,	1H),	4.39	(s,	1H),	4.30	(m,	1H),	4.15	(m,	2H),	0.98	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	162.7,	156.0,	145.0,	135.8,	135.7,	133.3,	133.1,	132.9,	132.6,	130.3,	130.2,	129.1,	128.0,	128.0,	127.9,	127.8,	96.4,	95.1,	81.9,	77.1,	26.9,	19.1;	HRMS	(ESI-TOF)	C31H33N3OSiNa	[M	+	Na]+	578.2087;	found	578.2092.		
N6-Benzoyl-9-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	(4.2c).	A	 stirring	 solution	 containing	 4.0	 g	 (5.8	 mmol)	 of	 N6-benzoyl-9-(3′-O-tert-butyldiphenylsilyl-2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	(4.1c)	in	29	mL	of	THF	and	29	mL	of	MeOH	was	cooled	to	0	°C.	To	the	solution	was	added	5.8	mL	(5.8	mmol)	of	ice-cold	1	N	NaOH(aq)	dropwise	while	stirring.	After	30	min,	another	5.8	mL	(5.8	mmol)	of	ice-cold	1	N	NaOH(aq)	was	added	dropwise	to	the	solution	for	an	additional	1	h	of	stirring,	at	which	time	the	TLC	showed	the	reaction	was	finished;	the	solution	was	quenched	by	adding	5.8	mL	of	1	N	HCl(aq)	at	0	°C.	The	crude	product	was	condensed	to	25	mL	of	solution	under	reduced	pressure,	and	the	solution	was	poured	into	200	mL	of	EtOAc.	The	organic	 layer	was	washed	with	200	mL	of	brine	and	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	by	flash	column	chromatography	with	eluents	(EtOAc/	CH2Cl2,	from	30	to	60%)	to	afford	N6-benzoyl-9-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	(4.2c)	as	a	white	solid:	yield	2.6	g	(76.7%);	silica	gel	TLC	(EtOAc/CH2Cl2,	2:1)	Rf	=	0.33;	1H	NMR	(400	MHz,	CDCl3)	δ	9.23	(s,	1H),	8.78	(s,	1H),	8.42	(s,	1H),	8.01	(d,	2H,	J	=	6.4	Hz),	7.60−7.55	(m,	3H),	7.49	(t,	2H,	J	=	6.4	Hz),	 7.44−7.43	 (m,	 3H),	 7.39−7.35	 (m,	 3H),	 7.28−7.25	 (m,	 2H),	 6.05	 (s,	 1H),	 4.65	 (s,	 1H),	4.23−4.21	(m,	1H),	4.16	(dd,	1H,	J	=	4.4,	3.2	Hz),	0.94	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	
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164.7,	152.6,	150.9,	149.7,	141.5,	135.8,	135.7,	133.8,	132.9,	132.6,	132.5,	130.3,	130.3,	129.0,	128.1,	128.0,	128.0,	123.2,	92.1,	81.6,	77.6,	76.3,	26.9,	19.0;	HRMS	(ESI-TOF)	C32H33N5O4SiNa	[M	+	Na]+	602.2200;	found	602.2216.		
N2-Acetyl-O6-diphenylcarbamoyl-9-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)	
guanine	(4.2d).	To	 a	 solution	 containing	6.0	 g	 (7.2	mmol)	 of	N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)	guanine	(4.1d)	in	25	mL	of	THF	and	5	mL	MeOH	at	0	°C	was	added	8.6	mL	of	ice-cold	1	N	NaOH(aq)	dropwise	while	stirring.	After	20	min	of	stirring,	an	additional	4.3	mL	of	ice-cold	1	N	NaOH(aq)	was	added	dropwise	to	the	reaction	for	another	1.5	h	of	stirring,	at	which	TLC	(hexane/EA,	1:1)	showed	the	complete	consumption	of	the	starting	material.	The	solution	was	quenched	by	adding	8	mL	of	1	N	HCl	(aq)	at	0	°C.	The	crude	product	was	condensed	to	15	mL	of	solution	under	reduced	pressure,	and	the	solution	was	poured	into	150	mL	of	EtOAc.	The	organic	layer	was	washed	with	100	mL	of	brine	and	then	100	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	by	flash	column	chromatography	with	eluents	(EtOAc/hexane,	from	25	to	55%	with	5%	CH2Cl2)	to	afford	product	4.2d	as	a	yellow	solid:	yield	3.8	g	(72.4%);	silica	gel	TLC	(EtOAc/CH2Cl2,	2:1)	Rf	=	0.33;	1H	NMR	(400	MHz,	CDCl3)	δ	8.46	(s,	1H),	8.26	(s,	1H),	7.58	(d,	4H,	J	=	6.4	Hz),	7.41−7.30	(m,	14H),	7.25−7.23	(m,	2H),	5.86	(s,	1H),	4.56	(s,	1H),	4.41	(s,	1H),	3.97	(m,	2	H),	2.18	(s,	3H),	1.00	(s,	9H);	13C	NMR	(125.8	MHz,	CD3OD)	δ	156.1,	154.2,	151.6,	150.7,	142.4,	135.9,	135.8,	133.2,	132.6,	130.1,	129.4,	128.0,	128.0,	121.6,	92.3	82.5,	77.3,	 74.9,	 27.0,	 25.1,	 19.2;	 HRMS	 (ESI-TOF)	 C40H40N6O6SiNa	 [M	 +	 Na]+	 751.2676;	 found	751.2681.	
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N2-Acetyl-9-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)-guanine	(4.2d′).		To	a	cooled	solution	of	27	mL	of	20%	trifluoroacetic	acid	in	CH2Cl2	was	added	3.59	g	(4.9	mmol)	 of	 N2-acetyl-O6-diphenylcarbamoyl-9-(3′	 -O-	 tert-butyldiphenylsilyl	 -α-L	 -	threofuranosyl)guanine	(4.2d),	and	it	was	stirred	at	0	°C	for	1	h.	The	reaction	mixture	was	evaporated	to	dryness	under	reduced	pressure,	and	the	resulting	crude	product	was	purified	by	silica	gel	column	chromatography	with	eluents	(MeOH/CH2Cl2)	to	afford	N2-acetyl-9-	(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)guanine	 (4.2d′)	 as	 a	 pale-yellow	 solid:	 yield	2.4	g	(77%);	TLC	(MeOH/CH2Cl2,	1:10)	Rf	=	0.45;	1H	NMR	(400	MHz,	CDCl3)	δ	12.07	(s,	1H),	9.27	(s,	1H),	8.30	(s,	1H),	7.59−7.53	(m,	3H),	7.45−7.34	(m,	6H),	7.26	(d,	2H,	J	=	8	MHz),	6.09	(s,	1H),	4.57	(s,	1H),	4.01−3.99	(m,	1H),	2.47−2.44	(m,	1H),	2.28	(s,	3H),	1.02	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	172.1,	148.4,	147.6,	138.5,	136.1,	133.2,	133.1,	130.6,	130.5,	128.4,	128.3,	121.6,	84.3,	80.0,	72.5,	41.5,	27.2,	24.9,	19.3;	HRMS	(ESI-TOF)	C27H31N5O5SiNa	[M	+	Na]+	556.1992;	found	556.2003.		
1-(2′-O-Phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)		
thymine	(4.3a).	To	 a	 solution	 containing	 3.72	 g	 (8.0	 mmol)	 of	 1-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)thymine	(4.2a)	and	0.52	g	(21.8	mmol)	of	NaH	in	60	mL	of	anhydrous	THF		was	added	dropwise	1.40	mL	(11.3	mmol)	of	phenyl	 isothiocyanate,	and	the	mixture	was	stirred	for	1.5	h	in	room	temperature.	When	TLC	(hexane/EtOAc,	3:2)	showed	the	reaction	was	completed,	the	reaction	was	quenched	with	the	addition	of	10	mL	of	water	at	0	°	C.	The	volatile	solution	was	evaporated	under	reduced	pressure,	and	the	residue	was	dissolved	in	
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100	mL	of	EtOAc.	The	organic	layer	was	washed	with	200	mL	of	brine	and	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	residue	was	purified	on	silica	gel,	eluting	with	60−80%	EtOAc	in	hexane	in	steps	of	5%	increase	in	EtOAc	for	every	200	mL.	 Product	4.3a	was	 obtained	 as	 a	 white	 solid:	 yield	 4.01	 g	 (83%);	 silica	 gel	 TLC	(hexane/EtOAc,	 1:1)	 Rf	 =	 0.35;	 1H	 NMR	 (400	 MHz,	 CDCl3)	 δ	 9.47	 (s,	 1H),	 7.67	 (m,	 5H),	7.51−7.34	(m,	6H),	7.25−7.24	(m,	2H),	7.12−7.02	(m,	1H),	6.08	(s,	1H),	5.92	(s,	1H),	4.45	(s,	1H),	4.05	(d,	1H,	J	=	10	Hz),	3.84	(m,	1H),	3.78	(m,	1H),	1.86	(s,	3H),	1.10	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	164.2,	150.7,	 136.0,	 135.7,	 132.8,	 130.4,	 129.0,	 126.0,	 128.1,	 111.4,	89.5,75.0,	 27.0,	 19.3,	 12.5;	HRMS	 (ESI-TOF)	 C32H35N3O5SSiNa	 [M	 +	Na]+	 624.1964;	 found	624.1959.	
N4-Benzoyl-1-(2′-O-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-
threofuranosyl)cytosine	(4.3b).	To	 a	 stirring	 solution	 containing	 2.60	 g	 (4.7	 mmol)	 of	 N4-benzoyl-1-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	(4.2b)	and	319	mg	(12.6	mmol)	of	NaH	in	47	mL	of	anhydrous	THF	was	added	dropwise	813	μL	(6.6	mmol)	of	phenyl	isothiocyanate	at	0	°C.	The	reaction	was	stirring	at	room	temperature	for	1.5	h,	at	which	time	the	TLC	shows	that	the	reaction	was	finished.	The	mixture	was	quenched	slowly	at	0	°C	by	adding	dropwise	2	mL	of	water	followed	by	8	mL	of	1	N	HCl(aq).	The	crude	mixture	was	condensed	to	20	mL	of	solution	under	reduced	pressure,	and	the	solution	was	poured	into	200	mL	of	EtOAc.	The	organic	layer	was	washed	with	200	mL	of	brine	and	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	by	flash	column	chromatography	with	eluents	(EtOAc/CH2Cl2,	from	13	to	25%)	to	afford	product	4.3b	as	a	white	solid:	yield	3.1	g	(95.9%);	silica	gel	TLC	(EtOAc/CH2Cl2,	1:4)	Rf	=	0.4;	1H	NMR	(400	
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MHz,	CDCl3)	δ	8.24	(d,	1H,	J	=	6.8	Hz),	7.93	(d,	2H,	J	=	7.6	Hz),	7.64−7.26	(m,	18H),	7.13	(t,	1H,	
J	=	7.2	Hz),	5.99	(s,	1H),	4.50	(d,	1H,	J	=	2.4	Hz),	4.12	(d,	1H,	J	=	10	Hz),	1.04	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	165.0,	152.8,	151.8,	149.6,	141.9,	135.9,	135.7,	133.7,	132.7,	132.5,	131.7,	130.3,	 128.8,	 128.1,	 128.0,	 126.1,	 123.0,	 87.9,	 75.3,	 29.7,	 26.9,	 19.1;	 HRMS	 (ESI-TOF)	C38H38N4O5SSiNa	[M	+	Na]+	713.2230;	found	713.2205.		
N6-Benzoyl-9-(2′-O-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-
threofuranosyl)adenine	(4.3c).	To	 a	 stirring	 solution	 containing	 3.3	 g	 (5.69	 mmol)	 of	 N6-benzoyl-9-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	(4.2c)	and	368	mg	(15.36	mmol)	of	NaH	in		57	mL	of	anhydrous	THF	was	added	dropwise	917	μL	(7.40	mmol)	of	phenyl	isothiocyanate	at	0	°C.	The	reaction	was	stirred	at	room	temperature	for	1.5	h,	at	which	time	the	TLC	shows	that	the	reaction	was	finished.	The	mixture	was	quenched	slowly	at	0	°C	by	adding	dropwise	3	mL	of	water	followed	by	10	mL	of	1	N	HCl(aq).	The	crude	mixture	was	condensed	to	30	mL	of	solution	under	reduced	pressure,	and	the	solution	was	poured	into	200	mL	of	EtOAc.	The	organic	layer	was	washed	with	200	mL	of	brine	and	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	with	flash	column	chromatography	with	eluents	(EtOAc/CH2Cl2,	from	13	to	25%)	to	afford	4.3c	as	a	yellowish	solid:	yield	3.72	g	(91.4%);	silica	gel	TLC	(EtOAc/CH2Cl2,	1:4)	Rf	=	0.45;	1H	NMR	(400	MHz,	CDCl3)	δ	8.71	(s,	1H),	8.59	(s,	1H),	8.00	(d,	2H,	J	=	6.8	Hz),	7.65−7.04	(m,	18H),	6.37	(s,	2H),	4.58	(s,	1H),	4.13	(s,	1H),	3.94	(s,	1H),	1.07	(s,	9H);	 13C	NMR	(100.6	MHz,	CDCl3)	δ	165.0,	152.8,	151.8,	149.6,	141.9,	135.9,	135.7,	133.7,	132.7,	132.5,	131.7,	130.3,	128.8,	128.1,	128.0,	
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126.1,	 123.0,	 87.9,	 75.3,	 29.7,	 26.9,	 19.1;	 HRMS	 (ESI-TOF)	 C39H38N6O4SSiNa	 [M	 +	 Na]+	737.2343;	found	737.2358.		
N2-Acetyl-9-(2′-O-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-
threofuranosyl)guanine	(4.3d′).		To	a	solution	containing	1.32	g	(2.5	mmol)	of	4.2d′	and	0.27	g	(6.7	mmol)	of	NaH	in	20	mL	of	anhydrous	THF	was	added	dropwise	0.37	mL	(2.9	mmol)	of	phenyl	isothiocyanate,	and	the	mixture	 was	 stirred	 for	 1.5	 h	 at	 room	 temperature.	When	 TLC	 (MeOH/CHCl3,	 1:10)	showed	the	complete	consumption	of	starting	material,	the	reaction	was	quenched	with	the	addition	of	10	mL	of	water.	The	volatile	solution	was	evaporated	under	reduced	pressure,	and	the	residue	was	dissolved	in	100	mL	of	EtOAc.	The	organic	layer	was	washed	with	200	mL	 of	 brine	 and	 then	 200	mL	 of	H2O,	 dried	 over	MgSO4,	 and	 evaporated	 under	 reduced	pressure.	The	residue	was	purified	by	silica	gel	chromatography	with	eluents	(MeOH/DCM,	from	0	to	6%)	to	afford	the	product	4.3d′	as	a	pale-yellow	solid:	yield	920	mg	(57%);	silica	gel	TLC	(CH2Cl2/MeOH,	10:1)	Rf	=	0.65;	1H	NMR	(400	MHz,	CDCl3)	δ	12.33−11.91	(m,	1H),	9.74	(s,	1H),	8.23−8.16	(m,	1H),	7.57	(m,	5H),	7.41−7.25	(m,	7H),	7.20−7.17	(m,	2H),	7.06	(s,	1H),	6.50	(s,	1H),	3.79	(s,	1H),	3.75−3.72	(m,	2H),	2.16	(d,	3H,	J	=	12	Hz),	0.93	(d,	9H,	J	=	18	Hz);	 13C	NMR	(100.6	MHz,	CDCl3)	δ	156.1,	148.6,	147.9,	137.9,	135.9,	135.7,	132.5,	131.8,	130.2,	129.8,	129.0,	128.0,	127.8,	125.3,	122.8,	121.4,	115.2,	88.8,	87.5,	77.3,	75.5,	26.9,	26.8,	24.2,	19.0;	HRMS	(ESI-TOF)	C34H36N6O5SSiNa	[M	+	Na]+	691.2135;	found	691.2120.		
1-(2′-Deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)thymine	(4.4a).	
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1-(2′-O-Phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)	thymine	 (4.3a)	was	 coevaporated	 twice	with	 3	mL	 of	 anhydrous	 toluene	 under	 reduced	pressure	and	dried	overnight	under	vacuum.	To	a	solution	of	1.09	g	(2.1	mmol)	of	4.3a	in	15	mL	 of	 anhydrous	 toluene	 was	 added	 2.08	 mL	 (5.4	 mmol)	 of	 tris(trimethylsilyl)silane	followed	by	2.6	mL	of	triethylborane	(1	M	in	THF)	under	an	argon	atmosphere.	The	reaction	was	 flushed	 with	 dry	 air	 several	 times,	 and	 the	 resulting	 mixture	 was	 stirred	 at	 room	temperature	 for	 45	 min.	 When	 TLC	 (CH2Cl2/MeOH,	 10:1)	 showed	 the	 reaction	 to	 be	complete,	the	reaction	was	quenched	with	the	addition	of	7	mL	of	water.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	residue	was	then	purified	by	silica	gel	column	chromatography	eluent	(MeOH/CH2Cl2,	from	0	to	8%)	to	afford	the	product	4.4a:	yield	760	mg	(77.8%);	silica	gel	TLC	(CH2Cl2/MeOH,	20:1)	Rf	=	0.65;	1H	NMR	(400	MHz,	CDCl3)	δ	8.48	(s,	1H),	7.70	(d,	1H,	J	=	1.2	Hz),	7.63	(dd,	2H,	J	=	9.2,	6.8	Hz),	7.55	(dd,	2H,	J	=	9.6,	6.4	Hz),	7.46−7.36	(m,	6H),	6.12	(dd,	1H,	J_	_=	10,	5.6	Hz),	4.47−4.35	(m,	1H),	4.14	(m,	1H),	3.75	(dd,	1H,	J	=	13.6,	6.2	Hz),	2.43−2.36	(m,	1H),	2.12	(d,	1H,	J	=	16	Hz),	1.93	(d,	3H,	J	=	1.2	Hz),	1.61	(s,	1H),	1.05	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	164.0,	150.5,	136.7,	135.8,	133.0,	130.8,	128.1,	110.3,	86.1,	77.6,	72.3,	41.8,	27.0,	19.2,	12.8;	HRMS	(ESI-TOF)	C25H30N2O4SiNa	[M	+	Na]+	473.1873;	found	473.1868.		
N4-Benzoyl-1-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	
(4.4b).	
N4-Benzoyl-1-(2′-O-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L	threofuranosyl)cytosine	(3.3b)	was	coevaporated	with	10	mL	of	anhydrous	toluene	twice	under	 reduced	 pressure.	 To	 a	 solution	 containing	 2.0	 g	 (2.9	mmol)	 of	4.3b	 in	 58	mL	 of	
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anhydrous	toluene	was	added	2.18	mL	(7.3	mmol)	of	trimethylsilylsilane	followed	by	adding	dropwise	3.48	mL	(3.48	mmol)	of	triethylborane	(1	M	in	THF)	under	an	argon	atmosphere.	The	reaction	was	flushed	with	dry	air	several	times,	and	the	resulting	mixture	was	stirred	at	room	temperature	for	30	min.	When	TLC	showed	that	the	reaction	was	finished,	the	crude	solution	was	brought	to	150	mL	with	EtOAc,	washed	with	200	mL	of	brine	and	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	 by	 flash	 column	 chromatography	with	 eluents	 (MeOH/CH2Cl2,	 from	1	 to	 3%)	 to	afford	4.4b	as	a	white	solid:	yield	1.21	g	(77.4%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:40)	Rf	=	0.28;	1H	NMR	(400	MHz,	CDCl3)	δ	8.27	(d,	1H,	J	=	7.6	Hz),	7.94	(d,	2H,	J	=	7.2	Hz),	7.60−7.57	(m,	4H),	7.51−7.48	(m,	4H),	7.45−7.33	(m,	6H),	6.13	(d,	1H,	J	=	5.6	Hz),	4.47	(s,	1H),	4.23	(d,	1H,	J	=	10	Hz),	3.91	(dd,	1H,	J	=	10,	3.6	Hz),	2.39	(m,	2H)	0.99	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	162.3,	145.3,	135.7,	135.6,	133.1,	132.8,	132.6,	130.1,	130.1	129.0,	128.0,	127.9,	127.7,	 96.0,	 88.4,	 78.5,	 72.2,	 42.0,	 26.8,	 18.9;	HRMS	 (ESI-TOF)	C31H33N3O4SiNa	 [M	+	Na]+	562.2138;	found	562.2142.		
N6-Benzoyl-9-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	
(4.4c).	
N6-Benzoyl-9-(2′-O_-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	(4.3c)	was	coevaporated	with	10	mL	of	anhydrous	 toluene	 twice	under	 reduced	 pressure.	 To	 a	 solution	 containing	 1.8	 g	 (2.5	mmol)	 of	4.3c	 in	 25	mL	 of	anhydrous	toluene	was	added	1.95	mL	(6.3	mmol)	of	trimethylsilylsilane	followed	by	adding	dropwise	3.02	mL	(3.0	mmol)	of	triethylborane	(1	M	in	THF)	under	an	argon	atmosphere.	The	reaction	was	flushed	with	dry	air	several	times,	and	the	resulting	mixture	was	stirred	at	
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room	temperature	for	30	min.	When	TLC	showed	that	the	reaction	was	finished,	the	crude	solution	was	poured	into	150	mL	of	EtOAc,	washed	with	200	mL	of	brine	and	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	 by	 flash	 column	 chromatography	with	 eluents	 (MeOH/CH2Cl2,	 from	1	 to	 3%)	 to	afford	product	4.4c	as	a	white	solid:	yield	1.12g	(78.9%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:40)	Rf	=	0.3;	1H	NMR	(400	MHz,	CDCl3)	δ	9.65	(s,	1H),	8.74	(s,	1H),	8.57	(s,	1H),	8.00	(d,	2H,	J	=	7.2	Hz),	7.56	(d,	2H,	J	=	7.2	Hz),	7.51−7.27	(m,	11H),	6.41	(d,	1H,	J	=	6.8	Hz),	4.58	(s,	1H),	4.12	(d,	1H,	J	=	9.6	Hz),	3.90	(dd,	1H,	J	=	9.6,	3.6	Hz),	2.54	(m,	2H),	0.95	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	164.9,	152.3,	151.4,	149.4,	135.5,	135.4,	133.7,	132.6,	132.4,	130.0,	128.6,	127.8,	127.8,	123.3,	84.6,	77.1,	72.1,	41.3,	26.7,	18.7;	HRMS	(ESI-TOF)	C32H33N5O3SiNa	[M	+	Na]+	586.2250;	found	586.2251.		
N2-Acetyl-9-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)guanine	
(4.4d′).		
N2-Acetyl-9-(2′-O-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)guanine	(4.3d′)	was	co-evaporated	twice	with	3	mL	of	anhydrous	toluene	under	 reduced	pressure	 and	dried	 overnight	 under	 vacuum.	To	 a	 solution	 of	 0.82	 g	 (1.3	mmol)	 of	 4.3d′	 in	 15	 mL	 of	 anhydrous	 toluene	 was	 added	 1.3	 mL	 (3.1	 mmol)	 of	tris(trimethylsilyl)silane	followed	by	1.5	mL	of	triethylborane	(1	M	in	THF)	under	an	argon	atmosphere.	The	reaction	was	flushed	with	dry	air	several	times,	and	the	resulting	mixture	was	stirred	at	room	temperature	for	45	min,	at	which	time	TLC	(CH2Cl2/MeOH,	10:1)	showed	the	reaction	to	be	complete.	The	reaction	was	quenched	with	the	addition	of	3	mL	of	water.	The	volatile	solution	was	evaporated	under	reduced	pressure,	and	the	crude	product	was	
92		
purified	by	silica	gel	column	chromatography	with	eluents	(MeOH/CH2Cl2,	from	0	to	7%)	to	afford	the	product		4.4d’	as	a	white	solid:	yield	540	mg	(83.2%);	silica	gel	TLC	(CH2Cl2/MeOH,	20:1)	Rf	=	0.55;	1H	NMR	(400	MHz,	CDCl3)	δ	11.88	(s,	1H),	9.09	(s,	1H),	8.11	(s,	1H),	7.43−7.37	(m,	4H),	7.26−7.19	(m,	7	H),	7.17−7.07	(m,	1H),	5.91	(dd,	1H,	J	=	7.6,	3.2	Hz),	4.38	(s,	1H),	3.82	(d,	1H,	J	=	8	Hz),	3.66	(dd,	1H,	J	=	11.6,	4.0	Hz),	2.28−2.26	(m,	1H),	2.09	(s,	3H),	0.84	(s,	9H);	
13C	NMR(125.8	MHz)	δ	171.8,	148.2,	147.3,	138.2,	135.8,	132.9,	130.3,	128.1,	121.3,	84.1,	72.3,	 41.3,	 27.0,	 24.6,	 19.1;	 HRMS	 (ESI-TOF)	 C27H31N5O4SiNa	 [M	 +	 Na]+	 540.2064;	 found	540.2064.		
1-(2′-Deoxy-α-L-threofuranosyl)thymine	(4.5a).	To	 a	 cold	 solution	 (0−5	 °C)	 of	 750	 mg	 (1.6	 mmol)	 of	 1-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)thymine	(4.4a)	in	12	mL	of	THF	was	added	dropwise	1.9	mL	(1.9	mmol)	of	tetrabutylammonium	fluoride	(1	M	solution	in	THF),	and	the	mixture	was	stirred	for	2	h	at	0−5	°C.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	crude	 product	 was	 purified	 by	 silica	 gel	 column	 chromatography	 with	 eluents	(MeOH/CH2Cl2,	 from	 0	 to	 12%).	 1-(2′-Deoxy-α-L-threofuranosyl)thymine	 (4.5a)	 was	obtained	as	a	white	solid:	yield	305	mg	(86.3%);	silica	gel	TLC	(CH2Cl2/MeOH,	10:1)	Rf	=	0.35;	1H	NMR	(400	MHz,	DMSO-d6)	δ	6.89	(s,	1H),	5.18	(dd,	1	H,	J	=	8.4,	4.8	Hz),	3.50	(s,	1H),	3.13	(d,	1H,	J	=	7.6	Hz),	2.91	(dd,	1H,	J	=	10.4,	4.4	Hz),	1.64−1.60	(m,	2H),	1.02	(d,	1H,	J	=	11.6	Hz),	0.91	(s,	3H);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	163.9,	150.5,	137.1,	108.5,	84.6,	76.3,	68.8,	40.07,	12.3;	HRMS	(ESI-TOF)	C9H12N2O4Na	[M	+	Na]+	235.0797;	found	235.0791.		
N4-Benzoyl-1-(2′-deoxy-α-L-threofuranosyl)	cytosine	(4.5b).	
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To	a	cold	solution	(0−5	°C)	containing	1.2	g	(2.2	mmol)	of	N4-benzoyl-1-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	 (4.4b)	 in	 22	 mL	 of	 THF	 was	 added	dropwise	6.7	mL	(6.7	mmol)	of	 tetrabutylammonium	fluoride	(1	M	solution	 in	THF).	The	mixture	was	stirred	for	4	h	at	0	°C.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	 crude	 product	 was	 purified	 by	 flash	 column	 chromatography	 with	 eluents	(MeOH/CH2Cl2,	 from	2	to	5%).	Product	4.5b	was	obtained	as	a	white	solid:	yield	650	mg	(97.0%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:20)	Rf	=	0.31;	1H	NMR	(400	MHz,	CDCl3)	δ	8.08	(d,	1H,	J	=	7.6	Hz),	7.88	(d,	2H,	J	=	8.0	Hz),	7.58	(t,	1H,	J	=	7.2	Hz),	7.50−7.43	(m,	3H),	6.00	(d,	1H,	
J	=	6.8	Hz),	4.63	(m,	1H),	4.34	(d,	1H,	J	=	10	Hz),	4.11	(dd,	1H,	J	=	10,	3.6	Hz),	2.72	(d,	1H,	J	=	14.8	Hz),	2.47	(m,	1H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	168.9,	164.6,	157.9,	147.1,	134.7,	134.0,	129.8,	129.0,	97.5,	90.0,	79.4,	71.0,	42.3;	HRMS	(ESI-TOF)	C15H15N3O4Na	[M	+	Na]+	324.0960	;	found	324.0972.	
N6-Benzoyl-9-(2′-deoxy-α-L-threofuranosyl)	adenine	(4.5c).	To	a	cold	solution	(0−5	°C)	containing	1.3	g	(2.3	mmol)	of	N6-benzoyl-9-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	 (4.4b)	 in	 23	 mL	 of	 THF	 was	 added	dropwise	4.6	mL	(4.6	mmol)	of	 tetrabutylammonium	fluoride	(1	M	solution	 in	THF).	The	mixture	was	stirred	for	4	h	at	0	°C.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	 crude	 product	 was	 purified	 by	 flash	 column	 chromatography	 with	 eluents	(MeOH/CH2Cl2,	 from	2	 to	 4%)	 to	 afford	 the	product	4.5b	as	 a	white	 solid:	 yield	678	mg	(90.3%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:20)	Rf	=	0.28;	1H	NMR	(400	MHz,	CDCl3)	δ	8.72	(d,	2H,	J	=	3.6	Hz),	8.09	(d,	2H,	J	=	7.6	Hz),	7.66	(t,	1H,	J	=	7.6	Hz),	7.57	(t,	2H,	J	=	7.6	Hz),	6.53	(dd,	1H,	J	=	8.0,	1.6	Hz),	4.62	(t,	1H,	J	=	4.4	Hz),	4.20	(d,	1H,	J	=	9.6	Hz),	4.10	(dd,	1H,	J	=	9.6,	4.0	Hz),	2.78	(m,	1H),	2.49	(d,	1H,	 J	=	14.8	Hz);	 13C	NMR	(125.8	MHz,	CD3OD)	δ	168.1,	153.0,	
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151.0,	 145.0,	 135.0,	 133.9,	 129.8,	 129.4,	 125.1,	 86.2,	 78.6,	 71.3,	 41.8;	 HRMS	 (ESI-TOF)	C16H15N5O3Na	[M	+	Na]+	348.1073;	found	348.1076.	
	
N2-Acetyl-9-(2′-deoxy-α-L-threofuranosyl)guanine	(4.5d′).		To	 a	 cold	 solution	 (0−5	 °C)	 of	 530	mg	 (1.0	mmol)	 of	N2-acetyl-9-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)guanine	(4.4d’)	in	12	mL	of	THF	was	added	dropwise	1.3	mL	(1.3	mmol)	of	tetrabutylammonium	fluoride	(1	M	solution	in	THF),	and	the	mixture	was	stirred	for	1	h	at	0−5	°C.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	resulting	 crude	 product	 was	 purified	 by	 silica	 gel	 column	 chromatography	 with	 eluents	(MeOH/CH2Cl2,	from	0	to	10%)	to	afford	the	product	4.5d’	as	a	white	solid:	yield	220	mg	(77%);	silica	gel	TLC	(CH2Cl2/MeOH,	10:1)	Rf	=	0.35;	1H	NMR	(400	MHz,	DMSO-d6)	δ	11.14	(s,	 1H),	 10.83	 (s,	 1H),	 7.32	 (s,	 1H),	 5.24	 (dd,	 1H,	 J	=	10,	 6	Hz),	 4.52	 (s,	 1H),	 3.62	 (s,	 1H),	3.08−3.07	(m,	2H),	1.77−1.73	(m,	1H),	1.41−1.37	(m,	1H),	1.29	(s,	3H);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	173.5,	154.9,	148.2,	147.8,	138.2,	119.9,	83.3,	76.5,	69.0,	40.3,23.8;	HRMS	(ESI-TOF)	C11H13N5O4Na	[M	+	Na]+	302.0865;	found	302.0854.		
General	Procedure	A	for	the	Preparation	of	4.6a-d′.		To	a	suspension	of	4.5a−d’	 in	sublimed	tetrazole	in	anhydrous	acetonitrile	(1.8	equiv,	0.45	M)	was	added	(BnO)2PN(i-Pr)2	(1.3	equiv),	and	the	reaction	mixture	stirred	at	room	temperature	for	1	h.	The	reaction	mixture	was	cooled	to	0	°C,	treated	with	30%	H2O2	in	water	(3−10	 equiv),	 and	 stirred	 for	 an	 additional	 30	 min.	 The	 reaction	 mixture	 was	 then	evaporated	under	reduced	pressure	and	purified	by	silica	gel	chromatography.	
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1-(2′-Deoxy-α-L-threofuranosyl)thymine-3′-dibenzylmonophosphate	(4.6a).	General	procedure	A	was	used	with	the	following:	1.00	g	(4.7	mmol)	of	4.5a,	20	mL	(9	mmol)	 of	 tetrazole,	 1.80	 g	 (5.18	 mmol)	 of	 (BnO)2PN(i-Pr)2,	 and	 2	 mL	 of	 H2O2.	Characterization	 included	 the	 following:	 column	 chromatography	 with	 eluents	(EtOAc/MeOH,	100−98/2−95/5%);	yield	1.95	g	(87%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:20)	Rf	=	0.55;	1H	NMR	(400	MHz,	CDCl3)	δ	7.36−7.26	(m,	10	H),	6.09	(d,	1H,	J	=	8.6	Hz),	5.04−4.94	(m,	4H),	4.28	(m,	1H),	3.85	(d,	1H,	J	=	12.6	Hz),	2.48	(m,	1H),	2.16	(d,	1H,	J	=	15.6	Hz),	1.79	(s,	3H);	13CNMR	(125.8	MHz,	CDCl3)	δ	135.9,	129.1,	128.9,	128.2,	110.4,	85.5,	77.5	(d,	J	C,P	=	6.4	Hz),	76.9,	75.3	(d,	J	C,P	=	7.4	Hz),	70.0	(d,	J	C,P	=	5.9	Hz),	39.7,	12.7;	31P	NMR	(162	MHz,	CDCl3)	
δ	0.65;	HRMS	(ESI-TOF)	C23H25N2O7PNa	[M	+	Na]+	495.1297;	found	495.1299.		
N4-Benzoyl-1-(2′-deoxy-α-L-threofuranosyl)cytosine-3′-dibenzyl-monophosphate	
(4.6b).	General	procedure	A	was	used	with	the	following:	300	mg	(1.0	mmol)	of	4.5b,	4	mL	(1.8	mmol)	of	tetrazole	in	acetonitrile,	316	μL	(1.3	mmol)	of	(BnO)2PN(i-Pr)2,	and	2	mL	of	H2O2.	Characterization	 included	 the	 following:	 silica	 gel	 chromatography	 with	 eluents	(MeOH/CH2Cl2,	from	1.0	to	2.5%);	yield	410	mg	(73.3%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:40)	Rf	 =	0.33;	 1H	NMR	 (400	MHz,	CD3OD)	δ	8.07	 (d,	 1H,	 J	=	7.2	Hz),	 7.93	 (d,	 1H,	 J	=	6.8	Hz),	7.65−7.61	(m,	1H),	7.53	(m,	3H),	7.32−7.25	(m,	11H),	6.03	(d,	1H,	J	=	6.4	Hz),	5.05	(s,	1H),	4.96−4.88	(m,	4H),	4.42	(d,	1H,	J	=	10.8	Hz),	4.14	(d,	1H,	J	=	10.8	Hz),	2.63−2.49	(m,	2H);	13C	NMR	(125.8	MHz,	CD3OD)	δ	168.9,	164.7,	157.7,	146.0,	136.9	(d,	J	C,P	=	6.2	Hz),	136.7	(d,	J	C,P	=	5.9	Hz),	134.7,	134.0,	129.8,	129.8,	129.7,	129.7,	129.2,	129.1,	129.1,	97.8,	89.8,	78.8	(d,	J	C,P	=	5.4	Hz),	77.5	(d,	J	C,P	=	6.4	Hz),	71.1	(d,	J	C,P	=	6.0	Hz),	70.9	(d,	J	C,P	=	5.9	Hz),	40.8	(d,	J	C,P	=	3.8	
96		
Hz);	 31P	 NMR	 (162	 MHz,	 CD3OD)	 δ	 −1.48;	 HRMS	 (ESI-TOF)	 C29H28N3O7PNa	 [M	 +	 Na]+	584.1563;	found	584.1561.		
N6-Benzoyl-9-(2′-deoxy-α-L-threofuranosyl)adenine-3′-dibenzyl-monophosphate	
(4.6c).	General	procedure	A	was	used	with	the	following:	180	mg	(0.55	mmol)	of	4.5c,	2.2	mL	(1.0	mmol)	of	tetrazole	in	acetonitrile,	228	μL	(0.7	mmol)	of	(BnO)2PN(i-Pr)2,	and	2	mL	of	H2O2.	 Characterization	 included	 the	 following:	 silica	 gel	 chromatography	 with	 eluents	(MeOH/CH2Cl2,	from	1	to	2%);	yield	242	mg	(74.7%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:40)	Rf	=	0.35;	1H	NMR	(400	MHz,	CD3OD)	δ	8.61	(s,	1H),	8.34	(s,	1H),	8.00	(d,	2H,	J	=	7.2	Hz),	7.59	(t,	1H,	J	=	7.6	Hz),	7.51−7.48	(m,	2H),	7.28−7.20	(m,	8H),	7.15−7.13	(m,	2H),	6.41	(dd,	1H,	J	=	5.6,	2.8	Hz),	5.10	(s,	1H),	4.88−4.76	(m,	4H),	4.32	(d,	1H,	J	=	11.2	Hz),	4.09	(m,	1H),	2.70−2.68	(m,	2H);	13C	NMR	(125.8	MHz,	CD3OD)	δ	167.9,	153.0,	152.6,	150.9,	143.3,	136.8	(d,	J	C,P	=	6.0	Hz),	136.7	(d,	J	C,P	=	6.2	Hz),	135.0,	133.9,	129.8,	129.8,	129.7,	129.7,	129.6,	129.4,	129.2,	129.1,	124.9,	86.9,	78.9	(d,	J	C,P	=	5.4	Hz),	76.7	(d,	J	C,P	=	6.0	Hz),	71.0	(d,	J	C,P	=	6.0	Hz),	70.9	(d,	J	C,P	=5.8	Hz),	49.9,	40.5	(d,	J	C,P	=	4.2	Hz);	31P	NMR	(162	MHz,	CD3OD)	δ	−1.37;	HRMS	(ESI-TOF)	C29H28N3O7PNa	[M	+	Na]+	584.1563;	found	584.1561.		
N2-Acetyl-9-(2′-deoxy-α-L-threofuranosyl)guanine-3′-dibenzylmonophosphate	
(4.6d′).		General	procedure	A	was	used	with	the	following:	600	mg	(2.2	mmol)	of	4.5d’,	10	mL	(4.5	mmol)	of	tetrazole,	0.87	mL	(2.6	mmol)	of	(BnO)2PN(i_-Pr)2,	2	mL	of	H2O2.	Characterization	included	the	following:	column	chromatography	with	eluents	(MeOH/EtOAc,	2−5%);	yield	
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0.81	g	(76%);	silica	gel	TLC	(CH2Cl2/MeOH,	20:1)	Rf	=	0.65;	1H	NMR	(400	MHz,	CDCl3)	δ	12.14	(s,	1H),	10.75	(s,	1H),	7.85	(s,	1H),	7.36−7.25	(m,	10H),	6.02	(dd,	1H,	J	=	8.4,	4.4	Hz),	5.02−4.89	(m,	4H),	4.16−4.11	(m,	1H),	3.89−3.86	(m,	1H),	2.64	(d,	2H,	J	=	12	Hz),	2.27(s,	3H),	1.25	(s,	1H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	172.9,	155.9,	148.2,	147.7,	128.9,	128.8,	128.0,	121.7,	84.1,	77.1	(d,	J	C,P	=	6.0	Hz),	76.9,	69.9	(d,	J	C,P	=	6.0	Hz),	69.7,	38.8	(d,	J	C,P	=	4.2	Hz),	24.2;	31P	NMR	(162	MHz,	CDCl3)	δ	−1.20;	HRMS	(ESI-TOF)	C25H26N5O7PNa	[M	+	Na]+	562.1467;	found	562.1476.		
General	Procedure	B	for	the	Preparation	of	4.7a−d.	Trialkyl	monophosphates	4.6a−d	were	dissolved	in	methanol	and	purged	with	nitrogen	gas	three	times.	The	solution	was	added	to	0.1−0.2	mass	equivalent	of	10%	Pd/C	and	repurged	with	nitrogen	gas,	followed	by	hydrogen	gas.	The	mixture	was	stirred	at	room	temperature	for	1−2	h	under	hydrogen	gas,	at	which	time	TLC	showed	that	the	reaction	was	finished.	The	reaction	was	purged	with	nitrogen	gas	three	times	and	poured	on	a	pad	of	Celite	for	filtration.	The	 filtrate	was	 collected	and	evaporated	under	 reduced	pressure	 to	dryness.	The	 crude	product	was	added	to	15	mL	of	30%	NH4OH	for	deprotection	at	37	°C	for	18	h.	The	mixture	was	cooled	to	room	temperature,	and	the	solvent	was	evaporated	to	dryness.	The	residue	was	resuspended	 in	3	mL	of	methanol	at	40	°C	with	stirring,	and	the	solution	was	added	dropwise	 to	 40	 mL	 of	 acetone	 to	 precipitate	 the	 product	 as	 an	 ammonium	 salt.	 The	precipitate	was	collected	by	centrifugation	at	4400	rpm	at	room	temperature	for	15	min,	and	the	resulting	pellet	was	washed	twice	with	30	mL	of	acetone	and	dried	under	high	vacuum.	Products	3.7a−d	were	obtained	as	ammonium	salts.	
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1-(2′-Deoxy-α-L-threofuranosyl)thymine-3′-monophosphate	(4.7a).	General	procedure	B	was	used	with	 the	 following:	0.39	g	(0.8	mmol)	of	4.6a,	8	mL	of	MeOH,	and	130	mg	of	10%	Pd/C;	1H	NMR	(400	MHz,	CD3OD)	δ	7.57	(s,	1H),	6.12	(dd,	1H,	J	=	9.2,	6.0	Hz),	4.93	(s,	1H),	4.37	(d,	1H,	J	=	10.4	Hz),	3.96	(d,	1H,	J	=	8.4	Hz),	2.63	(m,	1H),	2.30	(d,	1H,	J	=	15.2	Hz),	1.88	(s,	3H);	13C	NMR	(125.8	MHz,	CD3OD)	δ	165.1,	151.0,	136.8,	109.5,	85.5,	75.5,	47.1,	39.1,	11.1;	 31P	NMR	δ	 :	−0.11;	HRMS	(ESI-TOF)	C9H13N2O7PNa	 [M	+	Na]+	315.0356;	found	315.0356.		
1-(2′-Deoxy-α-L-threofuranosyl)cytosine-3′-monophosphate	(4.7b).	General	procedure	B	was	used	with	the	following:	350	mg	(0.62	mmol)	of	4.6b,	10	mL	of	MeOH,	and	70	mg	of	10%	Pd/C;	yield	165	mg	(96.5%,	ε271:	13100);	1H	NMR	(400	MHz,	DMSO-d6)	δ	7.72	(d,	1H,	J	=	7.6	Hz),	5.91	(dd,	2H,	J	=	29.2,	7.6	Hz),	4.68	(s,	1H),	4.21	(d,	1H,	J	=	10.4	Hz),	3.87	(d,	1H,	J	=	10.4	Hz),	2.42	(m,	1H),	2.16	(d,	1H,	J	=	15.6	Hz);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	164.7,	154.4,	142.0,	93.7,	85.6,	75.3,	72.9,	40.4;	31P	NMR	(162	MHz,	DMSO-
d6)	δ	−0.51;	HRMS	(ESI)	C8H12N3O6PNa2	[M	−	H	+	2Na]+	322.0181;	found	322.0185.		
9-(2′-Deoxy-α-L-threofuranosyl)adenine-3′-monophosphate	(4.7c).	General	procedure	B	was	used	with	 the	 following:	1.3	g	 (2.2	mmol)	of	4.6c,	15	mL	of	MeOH,	and	200	mg	of	10%	Pd/C;	yield	650	mg	(97.8%,	ε259:	15200);	 1H	NMR	(400	MHz,	DMSO-d6)	δ	8.34	(s,	1H),	8.15	(s,	1H),	7.22	(s,	1H),	6.32	(d,	1H,	J	=	7.2	Hz),	4.91	(s,	1H),	4.17	(d,	1H,	J	=	9.6	Hz),	3.96	(dd,	1H,	J	=	9.2,	3.6	Hz),	2.75	(m,	1H),	2.52	(m,	1H);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	155.9,	152.6,	149.4,	139.4,	118.5,	82.5,	74.6	(d,	J	C,P	=	4.2	Hz),	73.2	(d,	J	C,P	=	
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3.7	Hz),	 38.8;	 31P	NMR	 (162	MHz,	DMSO-d6)	δ	−0.20;	HRMS	 (ESI)	C9H12N5O5PH	 [M	+	H]+	302.0654;	found	302.0668.		
9-(2′-Deoxy-α-L-threofuranosyl)guanine-3′-monophosphate	(4.7d).	In	the	first	step,	general	procedure	B	was	used	with	the	following:	0.73	g	(1.4	mmol,	1	equiv)	of	4.6a,	15	mL	of	MeOH,	and	180	mg	of	10%	Pd/C);	silica	gel	TLC	(CH2Cl2/MeOH	10:1)	Rf	=	0.35.	In	the	second	step,	the	conditions	of	general	procedure	B	and	5	mL	30%	NH4OH	in	37	°C	for	18	h	were	followed:	1H	NMR	(400	MHz,	D2O)	δ	8.17	(s,	1H),	6.31	(d,	1H,	J	=	9.6	Hz),	5.06	(s,	1H),	4.36	(d,	1H,	J	=	8.0	Hz),	4.19	(d,	1H,	J	=	8.4	Hz),	2.86	(s,	2H),	2.68	(d,	2H,	J	=	8.0	Hz),	2.27	(s,	3H);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	156.8,	153.6,	150.9,	136.1,	115.9,	81.8,	74.5,	72.1,	48.5,	40.0,	30.5;	31P	NMR	(162	MHz,	DMSO-d6)	δ	0.84;	HRMS	(ESI)	C9H11N5O6PNa2	[M	−	H	+	2Na]+	362.0242;	found	362.0250.	
General	Procedure	C	for	the	Preparation	of	4.8a−d.		To	 a	 solution	 containing	 1	 equiv	 of	 4.7a−d	 in	 anhydrous	 DMSO	 was	 added	 5	 equiv	 of	trimethylamine	 followed	 by	 2.5	 equiv	 of	 2-methylimidazole,	 2.5	 equiv	 of	triphenylphosphine,	and	2.5	equiv	of	2,	2′-dipyridyldisulfide	sequentially.	The	reaction	was	stirred	under	a	nitrogen	atmosphere	 for	6−8	h	at	 room	 temperature	with	monitoring	by	analytical	HPLC.	When	 the	HPLC	showed	 that	 the	reaction	was	 finished,	 the	product	was	precipitated	by	adding	dropwise	the	reaction	mixture	to	a	stirring	solution	containing	80	mL	of	acetone,	60	mL	of	diethyl	ether,	5	mL	of	triethylamine,	and	5	mL	of	saturated	NaClO4	in	acetone.	The	precipitate	was	collected	by	centrifugation	at	4400	rpm	for	15	min	at	room	temperature.	The	pellet	was	washed	twice	with	30	mL	of	washing	solution	(acetone/diethyl	
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ether	1:1)	and	dried	under	high	vacuum	to	afford	white	solid	products	4.8a−d	as	sodium	salts.		
1-(2′-Deoxy-α-L-threofuranosyl)thymine-3′-phosphor-2-methylimidazolide	(4.8a).	General	procedure	C	was	used	with	the	following:	100	mg	(0.36	mmol)	of	4.7a,	5	mL	of	anhydrous	 DMSO,	 250	 μL	 (1.8	 mmol)	 of	 trimethylamine,	 236	 mg	 (0.9	 mmol)	 of	triphenylphosphine,	and	198	mg	(0.9	mmol)	of	2,	2′-dipyridyldisulfide;	product	yield	115		mg	(97.4%,	ε267	=	9600);	31P	NMR	(162	MHz,	D2O)	δ	−7.81;	HRMS	(ESI-TOF)	C13H16N4O6P	[M	−	H]−	355.0787;	found	355.0800.		
1-(2′-Deoxy-α-L-threofuranosyl)cytosine-3′-phosphor-2-methylimidazolide	(4.8b).	General	procedure	C	was	used	with	the	following:	100	mg	(0.4	mmol)	of	4.7b,	2	mL	of	anhydrous	 DMSO,	 250	 μL	 (1.8	 mmol)	 of	 trimethylamine,	 236	 mg	 (0.9	 mmol)	 of	triphenylphosphine,	and	198	mg	(0.9	mmol)	of	2,	2′-dipyridyldisulfide;	product	yield	118	mg	(95.4%,	ε280:	13100),	HPLC	retention	time;	31P	NMR	(162	MHz,	D2O)	δ	−7.99;	HRMS	(ESI-TOF)	C12H15N5O5PNa2	[M	+	2Na]+	386.0606;	found	386.0617.		
9-(2′-Deoxy-α-L-threofuranosyl)adenine-3′-phosphor-2-methylimidazolide	(4.8c).	General	procedure	C	was	used	with	the	following:	40	mg	of	4.7c	(0.15	mmol),	1	mL	of	anhydrous	 DMSO,	 104	 μL	 (0.8	 mmol)	 of	 trimethylamine,	 79	 mg	 (0.3	 mmol)	 of	triphenylphosphine,	and	66	mg	(0.3	mmol)	of	2,	2′-dipyridyldisulfide;	product	yield	45	mg		(96.5%,	ε259:	15200),	HPLC	retention	time;	31P	NMR	(162	MHz,	D2O)	δ	−7.88;	HRMS	(ESI-TOF)	C13H15N7O4P	[M	−	H]−	364.0923;	found	364.0936.	
101		
	
9-(2′-Deoxy-α-L-threofuranosyl)guanine-3′-phosphor-2-methylimidazolide	(4.8d).	General	procedure	C	was	used	with	the	following:	50	mg	of	4.7d	(0.13	mmol),	1	mL	of	anhydrous	 DMSO,	 104	 μL	 (0.8	 mmol)	 of	 trimethylamine,	 79	 mg	 (0.3	 mmol)	 of	triphenylphosphine,	and	66	mg	(0.3	mmol)	of	2,	2′-dipyridyldisulfide;	product	yield	60	mg		(93.5%,	ε259:	13700);	31P	NMR	(162	MHz,	D2O)	δ	−8.15;	HRMS	(ESI-TOF)	C13H16N7O5PNa	[M	+	Na]+	404.0848;	found	404.0847.		
General	Procedure	C	for	the	Preparation	of	4.9a−d.		To	a	solution	of	4.8a−d	in	anhydrous	DMF	was	added	2	equiv	of	tributylamine	and	2	equiv	of	 tributylammonium	pyrophosphate.	The	 reaction	mixture	was	 stirred	under	 a	nitrogen	atmosphere	 for	 8−12	 h	 at	 room	 temperature	with	monitoring	 by	 analytical	HPLC.	When	HPLC	showed	that	the	reaction	was	finished,	the	reaction	mixture	was	added	dropwise	to	a	stirring	solution	containing	30	mL	of	acetone	and	5	mL	of	saturated	NaClO4	in	acetone.	The	precipitate	was	collected	by	centrifugation	at	4400	rpm	for	15	min	at	room	temperature	and	dried	 under	 vacuum	 for	 1	 h.	 The	 crude	 precipitate	 was	 dissolved	 in	 3	 mL	 of	 0.1	 M	triethylammonium	acetate	buffer	and	purified	by	a	semipreparative	HPLC	column.	Fractions	containing	triphosphates	were	collected,	concentrated	under	reduced	pressure,	pH	adjusted	with	triethylamine	to	7.0,	and	lyophilized	to	afford	the	product	as	a	triethylammonium	salt.	The	 solid	 product	was	 resuspended	 in	 3	mL	 of	methanol	 and	was	 added	 dropwise	 to	 a	solution	containing	40	mL	of	acetone	and	5	mL	of	saturated	NaClO4	in	acetone.	The	solution	was	 centrifuged	 at	 4400	 rpm	 for	 15	 min	 at	 room	 temperature.	 The	 supernatant	 was	discarded,	and	the	pellet	was	washed	with	30	mL	of	acetone	and	dried	under	vacuum	for	1	
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h.	The	resulting	white	solid	was	dissolved	in	RNase-free	water	containing	10	mM	Tris	pH	8.0	to	afford	the	4.9a−d	solution.		
1-(2′-Deoxy-α-L-threofuranosyl)thymine-3′-triphosphate	(4.9a).		Product	yield	after	HPLC	purification	was:	18.3	mg	(86%,	ε267:	9600);	1H	NMR	(600	MHz,	D2O)	δ	7.76	(s,	1H),	6.19	(d,	1H,	J	=	7.8	Hz),	5.09	(s,	1H),	4.45	(d,	1H,	J	=	12.6	Hz),	4.04	(d,	1H,	
J	=	10.8	Hz),	2.73	(m,	1H),	2.23	(d,	1H,	J	=	15.6	Hz);	13C	NMR	(150	MHz,	D2O):	δ	169.5,	154.6,	141.0,	113.7,	88.5,	78.3	(d,	J	=	3.5	Hz),	77.6	(d,	J	=	4.1	Hz),	41.3,	14.5;	31P	NMR	(162	MHz,	D2O):	δ	−5.80	(d,	J	=	19.4	Hz),	−10.86	(d,	J	=	19.4	Hz),	−20.59	(t,	J	=	19.4	Hz);	HRMS	(ESI-TOF)	C9H12N2O13P3Na2	[M	−	3H	+	2Na]−	494.9348;	found	494.9351.		
1-(2′-Deoxy-α-L-threofuranosyl)cytosine-3′-triphosphate	(4.9b).		Product	yield	after	HPLC	purification	was:	15.3	mg	 (78%,	 ε280:	13100);	 1H	NMR	(400	MHz,	D2O)	δ	7.99	(d,	1H,	J	=	7.6	Hz),	6.25	(d,	1H,	J	=	8.0	Hz),	6.13	(d,	1H,	J	=	7.2	Hz),	5.13	(s,	1H),	4.55	(d,	1H,	J	=	10.4	Hz),	4.12	(dd,	1H,	J	=	10.8,	2.8	Hz),	2.74	(m,	1H),	2.41	(d,	1H,	J	=	15.6	Hz);	13C	NMR	(150	MHz,	D2O)	δ	166.4,	157.9,	142.6,	96.0,	88.7,	75.9	(d,	J	=	5.6	Hz),	75.1	(d,	J	=	6.5	Hz),	39.2	(d,	J	=	5.9	Hz);	31P	NMR	(162	MHz,	D2O)	δ	−5.46	(d,	J	=	19.4	Hz),	−11.00	(d,	J	=	19.4	 Hz),	 −20.89	 (t,	 J	 =	 19.4	 Hz);	 HRMS	 (ESI-TOF)	 C8H11N3O12P3Na4	 [M	 −	 3H	 +	 4Na]+	525.9146;	found	525.9126.		
9-(2′-Deoxy-α-L-threofuranosyl)adenine-3′-triphosphate	(4.9c).		Product	yield	after	HPLC	purification	was:	7.4	mg	(56%,	ε259:	15200);	1H	NMR	(600	MHz,	D2O)	δ	8.48	(s,	1H),	8.21	(s,	1H),	6.43	(dd,	1H,	J	=	7.8,	1.2	Hz),	5.20	(d,	1H,	J	=	8.4	Hz),	4.38	(d,	
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1H,	J	=	10.2	Hz),	4.17	(dd,	1H,	J	=	10.2,	3.6	Hz),	2.89	(m,	1H),	2.77	(d,	1H,	J	=	15.6	Hz);	13C	NMR	(150	MHz,	D2O)	δ	155.6,	152.7,	148.8,	140.9,	118.6,	83.8,	75.7	(d,	J	=	4.7	Hz),	75.3	(d,	J	=	5.4	Hz),	38.7;	31P	NMR	(162	MHz,	D2O)	δ	−8.25	(d,	J	=	19.4	Hz),	−10.98	(d,	J	=	19.4	Hz),	−21.50	(t,	
J	=	19.4	Hz);	HRMS	(ESI-TOF)	C9H13N5O11P3	[M	−	H]−	459.9825;	found	459.9842.		
9-(2′-Deoxy-α-L-threofuranosyl)guanine-3′-triphosphate	(4.9d).		Product	yield	after	HPLC	purification	was:	9.3	mg	(62%,	ε259:	15400);	1H	NMR	(400	MHz,	D2O)	δ	8.17	(s,	1H),	6.27	(d,	1H,	J	=	7.2	Hz),	5.26	(m,	1H),	4.42	(d,	1H,	J	=	10.4	Hz),	4.20	(dd,	1H,	J	=	10.4,	2.8	Hz),	2.94	(m,	1H),	2.73	(m,	1H);	13C	NMR	(150	MHz,	D2O)	δ	161.4,	156.3,	151.4,	138.0,	116.5,	83.2,	75.3	(d,	J	=	4.8	Hz),	75.2	(d,	J	=	5.6	Hz),	38.4	(d,	J	=	4.8	Hz);	31P	NMR	(162	MHz,	D2O)	δ	−9.75	(d,	J	=	19.4	Hz),	−11.27	(d,	J	=	19.4	Hz),	−22.16	(t,	J	=	19.4	Hz);	HRMS	(ESI-TOF)	C9H11N5O12P3Na4	[M	−	3H	+	4Na]+	565.9208;	found	565.9213.	
	
Primer	Extension.		Primer	 extension	 reactions	were	performed	 in	 a	 final	 volume	of	 10	μL	using	10	pmol	 of	primer	 labeled	with	 a	 5′-IR680	 dye	 and	 15	 pmol	 of	 template.	 Each	 reaction	 contained	 a	primer−template	complex,	1×	ThermoPol	Buffer	[20	mM	Tris-HCl,	10	mM	(NH4)2SO4,	10	mM	KCl,	2	mM	MgSO4,	0.1%	Triton	X-100,	pH	8.8],	1	μL	of	Kod-RI	polymerase,	100	μL	of	each	TNA	triphosphate,	and	1	mM	MnCl2.	Reactions	were	incubated	for	1	h	at	55	°C,	quenched	with	stop	buffer	(8	M	urea,	45	mM	EDTA),	and	analyzed	by	20%	denaturing	urea	PAGE.	Gels	were	imaged	using	a	Li-Cor	imager.	
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Protein	Crystallization.		Kod-RI	for	X-ray	crystallography	was	expressed	and	purified	using	a	previously	published	protocol.15	An	initial	binary	complex	was	prepared	by	incubating	Kod-RI	(5	mg	mL−1)	with	1.5	molar	equivalents	of	the	primer−template	duplex	(primer,	5′-CGCGAACTGCG-3′	and	template,	5′-AAATTCGCAGTTCGCG-3′)	at	37	°C	for	30	min	in	a	buffer	supplemented	with	20	mM	MgCl2.	Five	molar	excess	of	the	2′-deoxy	tATP	monomer	was	added	to	the	binary	complex,	and	the	solution	was	incubated	at	37	°C	for	30	min.	The	resulting	binary	complex	was	further	incubated	with	5	M	excess	tTTP	at	37	°C	for	another	30	min.	The	ternary	complex	initially	cocrystallized	in	0.1	M	2-(N-morpholino)ethanesulfonic	acid	pH	6.0,	0.15	M	ammonium	sulfate,	and	15%	polyethylene	glycol	4000.	Crystals	were	further	optimized	in	24-well	trays	over	a	range	of	MES	pH	and	PEG	concentration.	Trays	were	stored	in	the	dark	at	room	temperature.	Crystals	typically	grew	between	1	and	4	weeks.												
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Figure	4-4.	ORTEP	representation	of	6-benzoyl-2′-deoxy-α-L-threofuranosyl	
adenosine	nucleoside	4.5c.	
(Figure	was	used	with	permission	from	.		J.	Org.	Chem.	2018,	83,	8840−8850.)	
	ORTEP	 representation	 of	 compound	4.5c	with	 thermal	 ellipsoids	 at	 the	 50%	probability	level.	The	saturated	compound	4.5c	was	dissolved	in	methanol	with	slow	crystallization	via	solvent	evaporation.	
	
Table	4.1.	Crystal	data	and	structure	refinement	for	jcc5.			Identification	code																																																																													jcc5		Empirical	formula																																																								C16	H15	N5	O3		Formula	weight																																																																													325.33		Temperature																																																																																	88(2)	K		Wavelength																																																																															0.71073	Å		Crystal	system																																																																								Monoclinic		Space	group																																																																																										P21		Unit	cell	dimensions																																																							a	=	6.817(4)	Å																							α	=	90°.																																																																																																b	=	7.077(4)	Å																							β	=	101.960(7)°.																																																																																														c	=	15.985(9)	Å																							γ	=	90°.				Volume																																																																																					754.4(8)	Å3		Z																																																																																																																				2		Density	(calculated)																																																									1.432	Mg/m3		Absorption	coefficient																																																									0.103	mm-1		F(000)																																																																																																			340		Crystal	color																																																																															colorless		Crystal	size																																															0.596	x	0.251	x	0.138	mm3		Theta	range	for	data	collection																															3.884	to	30.601°		Index	ranges																														-9	≤	h	≤	9,	-10	≤	k	≤	10,	-22	≤	l	≤	22		Reflections	collected																																																																					11727		
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Independent	reflections																															4580	[R(int)	=	0.0184]		Completeness	to																																											theta	=				25.500°	99.5	%		Absorption	correction															Semi-empirical	from	equivalents		Max.	and	min.	transmission																																1.0000	and	0.9635		Refinement	method																							Full-matrix	least-squares	on	F2		Data	/	restraints	/	parameters																																		4580	/	1	/	277		Goodness-of-fit	on	F2																																																																						1.048		Final	R	indices	[I>2sigma(I)	=	4425	data]	R1	=	0.0311,	wR2	=	0.0791		R	indices	(all	data,	0.70	Å)																			R1	=	0.0324,	wR2	=	0.0801		Largest	diff.	peak	and	hole																												0.428	and	-0.164	e.Å-3					
Table	4.2.	Atomic	coordinates	(	x	104)	and	equivalent	isotropic	displacement	
parameters	(Å2x	103)	for	jcc5.	U(eq)	is	defined	as	one	third	of	the	trace	of	the	
orthogonalized	Uij	tensor.		________________________________________________________________________________																																x																																			y																																		z																											U(eq)		________________________________________________________________________________		O(1")																3192(2)																					5573(2)																			2094(1)																		24(1)		O(3')																	9646(2)																					2828(2)																		7037(1)																		14(1)		O(4')																	11061(2)																			6955(2)																		7110(1)																		16(1)		N(1)																		4149(2)																					6607(2)																		3820(1)																			12(1)		N(3)																		5228(2)																					7171(2)																		5336(1)																			13(1)		N(6)																		6289(2)																						5304(2)																	2979(1)																			15(1)		N(7)																		9457(2)																						5259(2)																	4623(1)																			13(1)		N(9)																		8716(2)																						6318(2)																		5853(1)																		11(1)		C(1')																	8997(2)																						7014(2)																		6740(1)																			13(1)		C(1")																	4970(2)																					5214(2)																		2203(1)																				13(1)		C(2')																	7969(2)																						5773(2)																		7299(1)																			14(1)		C(2)																		3900(2)																						7159(2)																		4599(1)																			13(1)		C(2")																5904(2)																						4627(2)																		1474(1)																			12(1)		C(3')																	9567(2)																						4286(2)																		7637(1)																			14(1)		C(3")																7891(2)																							5036(2)																	1449(1)																				14(1)		
107		
C(4')																	11475(2)																				5444(2)																		7738(1)																			18(1)		C(4)																		7012(2)																						6535(2)																		5237(1)																				11(1)		C(4")																8619(2)																						4579(2)																		723(1)																					18(1)		C(5)																		7496(2)																						5883(2)																		4480(1)																			11(1)		C(5")																7379(3)																						3690(3)																		32(1)																								22(1)		C(6)																		5941(2)																						5937(2)																		3753(1)																			12(1)		C(6")																5405(3)																						3271(2)																		61(1)																								20(1)		C(7")																4666(2)																						3745(2)																		777(1)																						16(1)		C(8)																		10118(2)																			5563(2)																5448(1)																						13(1)		________________________________________________________________________________		
Table	4.3.	Bond	lengths	[Å]	and	angles	[°]	for	jcc5.		_____________________________________________________		O(1")-C(1")																																																	1.215(2)		O(3')-C(3')																																														1.4177(18)		O(3')-H(3')																																													0.86(3)		O(4')-C(1')																																														1.4093(19)		O(4')-C(4')																																														1.4537(19)		N(1)-C(6)																																																1.3349(19)		N(1)-C(2)																																																1.3481(19)		N(3)-C(2)																																																1.3294(19)		N(3)-C(4)																																																1.3371(19)		N(6)-C(1")																																														1.3739(18)		N(6)-C(6)																																																1.3827(19)		N(6)-H(6)																																																0.79(3)		N(7)-C(8)																																																1.3199(19)		N(7)-C(5)																																																1.3809(19)		N(9)-C(4)																																																1.3676(18)		N(9)-C(8)																																																1.3692(19)		N(9)-C(1')																																															1.4747(19)		C(1')-C(2')																																															1.523(2)		C(1')-H(1A)																																													1.00(2)		
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C(1")-C(2")																																														1.498(2)		C(2')-C(3')																																															1.531(2)		C(2')-H(2A)																																													0.96(2)		C(2')-H(2B)																																													0.97(3)		C(2)-H(2)																																																	0.93(2)		C(2")-C(3")																																														1.394(2)		C(2")-C(7")																																														1.398(2)		C(3')-C(4')																																																1.517(2)		C(3')-H(3A)																																														0.93(2)		C(3")-C(4")																																															1.391(2)		C(3")-H(3")																																														0.99(2)		C(4')-H(4A)																																														0.99(2)		C(4')-H(4B)																																														0.97(2)		C(4)-C(5)																																																		1.3971(19)		C(4")-C(5")																																														1.395(2)	C(4")-H(4")																																														1.00(2)		C(5)-C(6)																																																		1.4014(18)		C(5")-C(6")																																														1.388(3)		C(5")-H(5")																																													1.00(2)		C(6")-C(7")																																														1.385(2)		C(6")-H(6")																																														0.97(2)		C(7")-H(7")																																													0.95(2)		C(8)-H(8)																																																	0.97(2)		C(3')-O(3')-H(3')																																					108.1(17)		C(1')-O(4')-C(4')																																					110.22(11)		C(6)-N(1)-C(2)																																								117.99(12)		C(2)-N(3)-C(4)																																								111.18(12)		C(1")-N(6)-C(6)																																						128.38(13)		C(1")-N(6)-H(6)																																						115.2(17)		C(6)-N(6)-H(6)																																							116.3(17)		
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C(8)-N(7)-C(5)																																							103.43(12)		C(4)-N(9)-C(8)																																							105.96(12)		C(4)-N(9)-C(1')																																						125.21(12)		C(8)-N(9)-C(1')																																						128.35(12)		O(4')-C(1')-N(9)																																					108.25(11)		O(4')-C(1')-C(2')																																				106.11(12)		N(9)-C(1')-C(2')																																						112.77(12)		O(4')-C(1')-H(1A)																																		108.9(12)		N(9)-C(1')-H(1A)																																			106.6(12)		C(2')-C(1')-H(1A)																																			114.0(12)		O(1")-C(1")-N(6)																																		124.56(13)		O(1")-C(1")-C(2")																																	121.22(13)		N(6)-C(1")-C(2")																																			114.22(13)		C(1')-C(2')-C(3')																																				102.90(12)		C(1')-C(2')-H(2A)																																		114.7(14)		C(3')-C(2')-H(2A)																																		112.4(15)		C(1')-C(2')-H(2B)																																		109.5(16)		C(3')-C(2')-H(2B)																																		106.0(16)		H(2A)-C(2')-H(2B)																																111(2)		N(3)-C(2)-N(1)																																						128.89(14)	N(3)-C(2)-H(2)																																						117.3(12)		N(1)-C(2)-H(2)																																						113.8(12)		C(3")-C(2")-C(7")																																		119.94(13)		C(3")-C(2")-C(1")																																		122.53(12)		C(7")-C(2")-C(1")																																		117.40(14)		O(3')-C(3')-C(4')																																				108.25(13)		O(3')-C(3')-C(2')																																				112.65(12)		C(4')-C(3')-C(2')																																					101.42(13)		O(3')-C(3')-H(3A)																																		110.9(15)		C(4')-C(3')-H(3A)																																		111.5(14)		C(2')-C(3')-H(3A)																																		111.7(14)		
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C(4")-C(3")-C(2")																																			119.55(13)		C(4")-C(3")-H(3")																																		119.7(13)		C(2")-C(3")-H(3")																																		120.8(13)		O(4')-C(4')-C(3')																																				106.53(12)		O(4')-C(4')-H(4A)																																		107.8(15)		C(3')-C(4')-H(4A)																																		113.2(14)		O(4')-C(4')-H(4B)																																		108.9(13)		C(3')-C(4')-H(4B)																																		111.0(14)		H(4A)-C(4')-H(4B)																																109.2(19)		N(3)-C(4)-N(9)																																							127.60(13)		N(3)-C(4)-C(5)																																			126.75(12)		N(9)-C(4)-C(5)																																			105.61(12)		C(3")-C(4")-C(5")																														120.21(16)		C(3")-C(4")-H(4")																													118.3(13)		C(5")-C(4")-H(4")																														121.5(13)		N(7)-C(5)-C(4)																																			110.86(12)		N(7)-C(5)-C(6)																																			133.35(12)		C(4)-C(5)-C(6)																																			115.77(13)		C(6")-C(5")-C(4")																														120.17(15)		C(6")-C(5")-H(5")																													119.2(14)		C(4")-C(5")-H(5")																													120.6(14)		N(1)-C(6)-N(6)																																		121.12(12)		N(1)-C(6)-C(5)																																			119.40(12)		N(6)-C(6)-C(5)																																			119.48(13)		C(7")-C(6")-C(5")																													119.83(14)	C(7")-C(6")-H(6")																													120.4(14)		C(5")-C(6")-H(6")																													119.7(14)		C(6")-C(7")-C(2")																														120.29(15)		C(6")-C(7")-H(7")																													121.3(14)		C(2")-C(7")-H(7")																														118.4(14)		N(7)-C(8)-N(9)																																			114.13(13)		
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N(7)-C(8)-H(8)																																			125.6(12)		N(9)-C(8)-H(8)																																		120.3(12)			
	
	
	
	
	
	
Table	4.4.	Anisotropic	displacement	parameters	(Å2x	103)	for	jcc5.	The	anisotropic		
displacement	factor	exponent	takes	the	form:	-22[	h2	a*2U11	+	...	+	2	h	k	a*	b*	U12	]		______________________________________________________________________________																									U11											U22											U33														U23																U13															U12		______________________________________________________________________________		O(1")											13(1)								41(1)									18(1)										-8(1)														1(1)														4(1)		O(3')												13(1)								12(1)									15(1)										-2(1)													1(1)														-2(1)		O(4')												16(1)								17(1)									14(1)											2(1)												-2(1)														-5(1)		N(1)													12(1)								13(1)									13(1)												0(1)													3(1)														1(1)		N(3)														13(1)								12(1)									13(1)										-1(1)												3(1)															1(1)		N(6)													12(1)									24(1)									10(1)											0(1)												1(1)															6(1)		N(7)														11(1)								15(1)									14(1)											2(1)													3(1)																2(1)		N(9)														11(1)								11(1)									11(1)											0(1)													1(1)														-1(1)		C(1')													15(1)									12(1)									11(1)									-1(1)												1(1)															-1(1)		C(1")													14(1)								13(1)										11(1)								-1(1)												2(1)																	0(1)		C(2')												16(1)										15(1)										12(1)							-1(1)														4(1)															1(1)		C(2)														12(1)										12(1)								14(1)										0(1)														4(1)															2(1)		C(2")											14(1)											11(1)									11(1)									0(1)															2(1)															2(1)		C(3')													16(1)									14(1)											10(1)							1(1)															2(1)														-2(1)		C(3")											15(1)										14(1)											12(1)							0(1)															1(1)																1(1)		C(4')													18(1)									15(1)											16(1)							1(1)													-4(1)														-3(1)		
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C(4)													13(1)											9(1)												10(1)								1(1)												2(1)															-1(1)		C(4")												17(1)										22(1)										17(1)									0(1)										6(1)																		2(1)		C(5)												11(1)												12(1)										10(1)								1(1)											3(1)																	1(1)		C(5")											28(1)											25(1)											15(1)							-3(1)											8(1)																3(1)		C(6)												13(1)											13(1)												10(1)								1(1)										2(1)																	1(1)		C(6")											25(1)											20(1)											14(1)								-6(1)										2(1)																0(1)		C(7")											16(1)												16(1)											15(1)							-3(1)										1(1)														-1(1)		C(8)													12(1)												14(1)											13(1)									2(1)										2(1)															0(1)		______________________________________________________________________________		
Table	4.5.	Hydrogen	coordinates	(	x	104)	and	isotropic	displacement	parameters	
(Å2x	10	3)	for	jcc5.		________________________________________________________________________________																															x																															y																															z																													U(eq)		________________________________________________________________________________		H(3')													8480(40)														2320(40)																6903(15)																25(6)		H(6)														7370(40)														4880(40)																2985(15)																23(6)		H(1A)											8540(30)														8350(30)																6704(13)																13(5)		H(2A)											6720(30)														5220(40)																7007(14)																23(5)		H(2B)											7780(40)														6490(40)																7793(16)																	32(6)		H(2)														2610(30)														7560(30)																4608(12)																	9(4)		H(3A)											9410(30)														3790(30)																8160(14)																	17(5)		H(3")												8770(40)														5690(40)																1931(15)																	25(6)		H(4A)										11880(40)													6030(40)															8309(15)																	24(6)		H(4B)										12580(30)													4680(30)															7623(14)																	20(5)		H(4")											10030(40)												4950(40)																704(14)																				23(5)		H(5")											7890(30)															3350(40)															-488(15)																		24(6)		H(6")											4580(40)															2590(40)															-407(14)																		25(6)		H(7")											3310(40)															3510(40)																	804(15)																		21(5)		H(8)													11460(30)													5310(30)															5763(13)																	12(5)		
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Table	4.6.	Torsion	angles	[°]	for	jcc5.		________________________________________________________________		C(4')-O(4')-C(1')-N(9)																																										-108.16(13)		C(4')-O(4')-C(1')-C(2')																																													13.14(15)		C(4)-N(9)-C(1')-O(4')																																											-165.27(12)		C(8)-N(9)-C(1')-O(4')																																																		5.70(19)		C(4)-N(9)-C(1')-C(2')																																																77.65(17)		C(8)-N(9)-C(1')-C(2')																																												-111.39(16)		C(6)-N(6)-C(1")-O(1")																																																				-5.5(3)		C(6)-N(6)-C(1")-C(2")																																													174.32(14)		O(4')-C(1')-C(2')-C(3')																																													-30.58(14)		N(9)-C(1')-C(2')-C(3')																																																87.76(14)		C(4)-N(3)-C(2)-N(1)																																																										0.2(2)		C(6)-N(1)-C(2)-N(3)																																																										1.4(2)		O(1")-C(1")-C(2")-C(3")																																									149.34(16)		N(6)-C(1")-C(2")-C(3")																																												-30.53(19)		O(1")-C(1")-C(2")-C(7")																																														-26.5(2)		N(6)-C(1")-C(2")-C(7")																																											153.64(14)		C(1')-C(2')-C(3')-O(3')																																													-80.41(14)		C(1')-C(2')-C(3')-C(4')																																															35.10(14)		C(7")-C(2")-C(3")-C(4")																																																			0.7(2)		C(1")-C(2")-C(3")-C(4")																																								-175.05(14)		C(1')-O(4')-C(4')-C(3')																																																	9.93(16)		O(3')-C(3')-C(4')-O(4')																																														90.50(14)		C(2')-C(3')-C(4')-O(4')																																												-28.21(15)		C(2)-N(3)-C(4)-N(9)																																														-178.76(13)		C(2)-N(3)-C(4)-C(5)																																																								-1.5(2)		C(8)-N(9)-C(4)-N(3)																																																177.83(14)		C(1')-N(9)-C(4)-N(3)																																																							-9.5(2)		C(8)-N(9)-C(4)-C(5)																																																				0.07(14)		C(1')-N(9)-C(4)-C(5)																																															172.71(12)		
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C(2")-C(3")-C(4")-C(5")																																																	-1.0(2)		C(8)-N(7)-C(5)-C(4)																																																			-0.75(15)		C(8)-N(7)-C(5)-C(6)																																														-178.72(15)		N(3)-C(4)-C(5)-N(7)																																														-177.36(13)		N(9)-C(4)-C(5)-N(7)																																																				0.43(15)	N(3)-C(4)-C(5)-C(6)																																																									1.0(2)		N(9)-C(4)-C(5)-C(6)																																																178.79(12)		C(3")-C(4")-C(5")-C(6")																																																			0.5(3)		C(2)-N(1)-C(6)-N(6)																																															178.47(13)		C(2)-N(1)-C(6)-C(5)																																																			-1.84(19)		C(1")-N(6)-C(6)-N(1)																																																					-1.4(2)		C(1")-N(6)-C(6)-C(5)																																													178.95(14)		N(7)-C(5)-C(6)-N(1)																																															178.67(14)		C(4)-C(5)-C(6)-N(1)																																																				0.77(19)		N(7)-C(5)-C(6)-N(6)																																																							-1.6(2)		C(4)-C(5)-C(6)-N(6)																																														-179.54(13)		C(4")-C(5")-C(6")-C(7")																																																		0.3(3)		C(5")-C(6")-C(7")-C(2")																																																	-0.6(2)		C(3")-C(2")-C(7")-C(6")																																																			0.1(2)		C(1")-C(2")-C(7")-C(6")																																										176.08(14)		C(5)-N(7)-C(8)-N(9)																																																					0.81(16)		C(4)-N(9)-C(8)-N(7)																																																			-0.58(16)		C(1')-N(9)-C(8)-N(7)																																														-172.91(13)				
Table	4.7.	Hydrogen	bonds	for	jcc5	[Å	and	°].		____________________________________________________________________________		D-H...A																													d(D-H)															d(H...A)													d(D...A)																<(DHA)		____________________________________________________________________________		O(3')-H(3')...O(1")#					1	0.86(3)											2.48(3)										3.0553(19)												125(2)		
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O(3')-H(3')...N(1)#1								0.86(3)											1.99(3)											2.802(2)																158(2)		N(6)-H(6)...O(4')#2									0.79(3)												2.35(3)											3.001(2)															140(2)		____________________________________________________________________________		Symmetry	transformations	used	to	generate	equivalent	atoms:		#1	-x+1,y-1/2,-z+1	#2	-x+2,y-1/2,-z+1		
	
Table	4-1.	Crystal	data	and	structure	refinement	for	3.5c.			
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Chapter	5	
P(V)	Reagents	for	the	Scalable	Synthesis	of	Natural	and	Modified	Nucleoside	
Triphosphates	
	
Publication	Note	This	paper	was	originally	published	in	the	Journal	Of	The	American	Chemical	Society.	Jen-Yu	Liao†,	Saikat	Bala †,	Arlene	K.	Ngor,	Eric	J.	Yik	and	John	C.	Chaput*		P(V)	Reagents	for	the	Scalable	Synthesis	of	Natural	and	Modified	Nucleoside	Triphosphates	
	Journal	of	the	American	Chemical	Society,	2019.	141,34,13286-13289 (	†	Equal	Contribution) Copyright	©	2019	American	Chemical	Society		
5.1	Contribution	Statement		Chaput,	J.	C.,	Bala,	S.	and	Liao.	J.	Y.	designed	the	synthetic	strategy.	All	authors	contributed	to	the	synthesis,	optimization,	and	characterization	of	the	synthetic	compounds.	Bala,	S.	and	Liao,	 J.-Y.	 involved	 in	 the	 experimental	 section	 writing	 and	 supporting	 information	compiling.	Liao,	J.-Y.,	Bala,	S.	and	Chaput,	J.	C.	wrote	the	manuscript.	
	
5.2	Abstract	of	the	Chapter	Natural	 and	 chemically	modified	nucleoside	 triphosphates	 impact	nearly	 every	major	aspect	of	healthcare	research	from	DNA	sequencing	to	drug	discovery.	However,	a	scalable	synthetic	route	to	these	molecules	has	long	been	hindered	by	the	need	for	purification	by	high	performance	 liquid	 chromatography	 (HPLC).	We	describe	 a	 fundamentally	 different	
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approach	that	uses	a	novel	P(V)	pyrene	pyrophosphate	reagent	to	generate	derivatives	that	are	purified	by	silica	gel	chromatography	and	converted	to	the	desired	compounds	on	scales	vastly	 exceeding	 those	achievable	by	HPLC.	The	power	of	 this	 approach	 is	demonstrated	through	the	synthesis	of	a	broad	range	of	natural	and	unnatural	nucleoside	triphosphates	using	efficient,	inexpensive,	and	operationally	straightforward	protocols.		
5.3	Introduction	Polymerases	are	among	the	most	powerful	tools	in	the	molecular	biology	arsenal,	permitting	researchers	to	precisely	synthesize	the	DNA	sequences	of	genes,	gene	clusters,	and	entire	genomes	for	diverse	applications	ranging	from	basic	research	to	biotechnology	and	 medicine.	 1,2	 Polymerase-mediated	 DNA	 synthesis	 has	 reduced	 the	 cost	 of	 DNA	sequencing	 by	 allowing	 next-generation	 sequencing	 (NGS)	 platforms	 to	 read	 massive	numbers	of	amplicons	and	has	enabled	digital	archiving	by	compressing	 information	into	strands	of	DNA	sequences	that	can	be	read	by	NGS	analysis	and	decoded	by	bioinformatic	assembly.	3,4	Engineered	polymerases,	developed	by	directed	evolution,	have	also	grown	in	demand	by	enabling	the	synthesis	of	artificial	genetic	polymers	with	backbone	structures	that	are	distinct	from	those	found	in	nature.	5,6	Such	enzymes	are	now	used	to	support	the	evolution	of	affinity	reagents	(aptamers)	and	catalysts	with	molecular	compositions	that	are	better	equipped	to	function	in	harsh	biological	environments.	7-10	Today,	no	single	strategy	has	been	developed	that	can	be	applied	universally	to	the	synthesis	 of	 all	 nucleoside	 triphosphates.	 Natural	 DNA	 triphosphates	 (dNTPs)	 used	 to	support	traditional	DNA	synthesis	applications	are	manufactured	using	enzymatic	methods,	while	 modified	 nucleoside	 triphosphates	 developed	 for	 biotechnology	 and	 medicinal	
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purposes	are	produced	by	chemical	synthesis.	 11-13	 In	general,	enzymatic	strategies	suffer	from	high	substrate	specificity	(low	tolerance	for	analogs),	while	synthetic	routes	struggle	with	 functional	 group	 compatibility,	 difficult	 reaction	 conditions,	 and	 yield.	 For	 example,	attempts	 to	 synthesize	 α-L-threofuranosyl	 adenosine	 triphosphates	 using	 the	 classic	Yoshikawa	 or	 Ludwig-Eckstein	 methods	 (Fig.	 5.1)	 produced	 complex	 mixtures	 of	phosphorylated	compounds	with	the	desired	compound	present	as	a	minor	product.	 14,	15	Even	 more	 problematic	 is	 the	 requirement	 for	 both	 strategies	 to	 separate	 highly	 polar	nucleoside	 triphosphates	 from	 polar	 side	 products	 using	 high	 performance	 liquid	chromatography	(HPLC).	In	academic	environments,	HPLC	purification	is	a	tedious	process	that	 limits	 the	 scale	 of	 nucleoside	 triphosphate	 synthesis	 to	 a	 few	 tens	 of	milligrams	 of	compound	per	week	and	requires	subsequent	freeze-drying	steps	that	can	lead	to	compound	degradation.		 	
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Figure	5.1.	HPLC	analysis	of	a-L-threofuranosyl	adenosine	triphosphate	using	the	traditional	Yoshikawa	or	Ludwig-Eckstein	methods.	Red	arrow	indicates	the	location	of	the	desired	peak	in	the	crude	reaction	mixture.		(Figure	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019.	141,	34,	13286-13289)			 Efforts	to	synthesize	nucleoside	triphosphates	independent	of	HPLC	purification	first	appeared	in	2014	with	a	phosphorylation	strategy	that	involves	iterative	cycles	of	coupling,	oxidation,	and	deprotection.16-18	This	is	a	P(III)-based	reagent	method	that	relies	on	derivatized	phosphoramidite	reagents	to	facilitate	P-O	bond	formation.	Free	nucleosides	are	converted	to	nucleoside	triphosphates	through	the	production	of	P(III)-P(V)	anhydride	intermediates	that	are	oxidized	and	deprotected	during	each	cycle	of	P(V)	phosphate	generation.	16	The	iterative	strategy	benefits	from	high	yields,	rapid	coupling	rates,	and	convenient	 (non-dry)	 reaction	 conditions	 but	 is	 marked	 by	 several	 disadvantages	 that	include:	(1)	the	need	for	quantitative	functional	group	transformations,	which	are	necessary	to	avoid	the	accumulation	of	unwanted	side	products;	(2)	prolonged	deprotection	conditions	due	to	slow	removal	of	the	second	P-O	protecting	group	on	the	phosphorylating	reagent;	(3)	incompatibility	with	certain	chemical	reagents	and	nucleoside	protecting	groups;	and	(4)	a	lengthy	 pathway	 that	 involves	 9	 functional	 group	 transformations	 to	 convert	 each	nucleoside	to	its	corresponding	triphosphate.16-18	In	attempt	to	address	these	concerns,	we	conceived	a	fundamentally	different	approach	for	the	synthesis	of	natural	and	modified	nucleoside	triphosphates	that	required	invention	of	 a	 novel	 P(V)-based	 organic	 pyrophosphate	 reagent	 to	 mediate	 P-O	 bond	 formation	between	 the	 a-	 and	b-phosphate	positions.	Our	 vision	was	 to	 establish	 an	Hoard-Ott-like	
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procedure	 (Fig.	 5.2)	 using	 nucleoside	 and	 pyrophosphate	 reagents	 that	 were	 suitably	hydrophobic	so	as	to	generate	nucleoside	triphosphate	derivatives	that	were	amenable	to	purification	 by	 silica	 gel	 chromatography	 but	 could	 be	 readily	 converted	 to	 the	 desired	compound	using	standard	deprotection	and	precipitation	conditions.19	We	felt	that	this	type	of	convergent	synthesis	strategy	would	provide	a	direct	and	scalable	route	to	natural	and	chemically	 modified	 nucleoside	 triphosphates	 using	 operationally	 simple	 protocols	 that	process	and	discovery	chemists	would	find	appealing.	Critical	to	this	effort	was	the	need	to	establish	a	new	class	of	organic	pyrophosphate	reagents	that	contain	a	large	hydrophobic	moiety	attached	to	the	pyrophosphate	group	via	a	cleavable	linker	and	to	demonstrate	that	these	 reagents	 could	 mediate	 the	 synthesis	 of	 nucleoside	 triphosphates.	 Reducing	 this	concept	 to	 practice	 involved	 a	 systematic	 evaluation	 of	 three	 key	 components:	 (1)	hydrophobic	groups	necessary	to	construct	a	stable	organic	pyrophosphate	reagent	that	is	a	solid	compound	at	room	temperature	and	exhibits	minimal	hygroscopic	properties;	 (2)	a	strong	leaving	group	to	activate	the	nucleoside	monophosphate	for	nucleophilic	attack	by	the	pyrophosphate	reagent;	and	(3)	a	suitable	Lewis	acid	to	accelerate	phosphodiester	bond	formation	(Fig.	5.2).	
125		
	
	
Figure	5.2.	Strategy	and	methodology	development.	Vision	for	the	scalable	synthesis	of	natural	and	modified	nucleoside	triphosphates	using	a	new	class	of	organopyrophosphate	reagents.	R,	the	aromatic	substitution	attached	to	a	cleavable	sulfonylethyl	linker.	LG,	leavinggroup	moiety.	B,	nucleobase	moieties:	adenine	(A),	guanine	(G),	cytosine	(C),	thymine	(T).			 (Figure	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019.	141,	34,	13286-13289)		 The	 goals	 of	 our	 study	 were	 ultimately	 met	 through	 a	 systematic	 exploration	 and	subsequent	 optimization	 of	 reaction	 conditions	 which	 revealed	 that	 pyrene,	 2-methylimidazole,	and	zinc	chloride	provided	the	optimal	hydrophobic	moiety,	leaving	group,	
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and	 Lewis	 acid	 catalyst,	 respectively,	 necessary	 to	mediate	 the	 synthesis	 of	 nucleoside	 5	triphosphates	 in	 their	 fully	 protected	 form.	 The	 crystal	 structure	 of	 the	 pyrene	pyrophosphate	reagent	verified	correct	synthesis	of	the	organic	pyrophosphate	reagent	(Fig	
5.3).												
	
	
	
	
Figure	 5.3.	 ORTEP	 representation	 of	 2-(pyrenesulfonylethyl)	 pyrophosphate	 (7)	 with	thermal	 ellipsoids	 at	 the	 50%	 probability	 level.	 Crystals	 were	 prepared	 using	 the	 vapor	diffusion	method.	The	compound	was	dissolved	in	a	minimal	amount	of	methanol	in	a	2	mL	open	vial,	which	was	placed	in	a	20	mL	sealed	vial	containing	4	mL	of	anhydrous	toluene.	The	 crystal	 grew	 over	 a	 1-month	 period	 under	 vapor	 equilibrium	 conditions	 at	 room	temperature.		 (Figure	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)			
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5.5	Results	and	Discussions	To	test	the	feasibility	of	this	approach,	we	applied	the	pyrene	pyrophosphate	method	to	the	 synthesis	 of	 natural	 thymidine-5’-triphosphate	 (dTTP).	 As	 shown	 in	 Figure	 5.4,	activated	thymidine-5’-monophosphate	is	readily	converted	to	a	fully	protected	thymidine-5’-triphosphate	derivative,	which	was	purified	by	silica	gel	chromatography,	deprotected,	and	precipitated	to	obtain	the	desired	product	as	a	highly	pure	compound	in	sodium	form.	In	this	reaction,	10	molar	equivalents	of	ZnCl2	enabled	a	near	quantitative	coupling	(>95%)	of	 the	pyrene	pyrophosphate	 reagent	 to	 the	activated	nucleoside	monophosphate	after	3	hours	of	stirring	in	DMF	at	24	oC.	The	phosphorylation	reaction	also	generated	trace	amounts	(1-2%)	of	unwanted	side	products,	including	dinucleotide	diphosphate,	that	were	removed	by	silica	gel	purification	using	a	10%	H2O/isopropanol	mobile	phase	containing	1%	Hünig’s	base	[diisopropylethylamine,	DIPEA]	as	an	organic	counterion.	Following	purification,	the	triphosphate	intermediate	was	deprotected	with	concentrated	ammonium	hydroxide	(33%	aq.)	and	precipitated	as	the	sodium	salt	using	standard	conditions.	Analytical	HPLC	analysis	reveals	that	chemically	synthesized	dTTP	was	equivalent	in	purity	to	a	commercial	standard	(Fig.	 5.4c),	 demonstrating	 that	 the	 process	 of	 the	 nucleotide	 triphosphate	 synthesis	 is	capable	of	generating	material	that	is	identical	in	purity	to	commercial	compounds	obtained	by	conventional	enzymatic	synthesis.						
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Figure	5.4.	Synthesis	and	purity	comparison	of	thymidine	triphosphate.	(a)	Application	of	the	organopyrophosphate	reagent	to	the	synthesis	of	natural	thymidine-5’-triphosphate.	(b)	HPLC	 traces	 provided	 for	 the	 activated	monophosphate,	 fully	 protected	 triphosphate	
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intermediate	after	silica	gel	purification,	and	thymidine	triphosphate	after	precipitation	as	the	sodium	salt.	(c)	Comparison	of	chemically	synthesized	thymidine	3’-triphosphate	(dTTP)	with	a	commercial	standard.	thymidine-5’-triphosphate	(the	mirror	image	form	of	natural	D-dTTP).		
(Figure	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)		 	Because	enzymatic	approaches	are	not	compatible	with	most	nucleic	acid	analogs,	we	decided	to	broaden	the	scope	of	the	reaction	by	applying	the	pyrene	pyrophosphate	method	to	 a	 select	 panel	 of	 thymidine	 analogs	 (Fig.	 5.5).	 The	 list	 of	 target	 molecules	 included	thymidine-3’-	triphosphate	(a	regioisomer	of	natural	dTTP),	α	-L-threofuranosyl	thymidine	3’-triphosphate	 (tTTP,	 a	 building	 block	 for	 threose	 nucleic	 acid,	 TNA),	 20	 and	 L-DNA-	thymidine-5’-	triphosphate		The	 last	 two	examples	have	become	valuable	compounds	for	biomedical	research	due	 to	 recent	 advances	 in	 polymerase	 engineering	 that	 have	 enabled	 the	 synthesis	 of	artificial	genetic	polymers	with	non-natural	sugar-phosphate	backbones,	21,22	some	of	which	have	 been	 used	 to	 evolve	 biologically	 stable	 aptamers	 and	 catalysts.	 7-10	 As	with	 natural	dTTP,	each	unnatural	thymidine	triphosphate	was	obtained	in	highly	pure	form	(>95%)	as	the	 desired	 sodium	 salt.	 Occasionally,	 we	 did	 observe	 a	 small	 amount	 of	 nucleoside	diphosphate	(dNDP)	(~1-2%)	after	deprotection	of	the	protected	nucleoside	triphosphates.	dNDPs	are	common	contaminants	of	commercial	nucleotide	triphosphates	due	to	the	slow	
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hydrolysis	of	ATP	to	ADP.	23	However,	these	molecules	do	not	interfere	with	normal	DNA	synthesis	as	natural	DNA	polymerases	are	highly	specific	for	dNTP	substrates.	24										
	
	
	
	
Figure	5.5.	Synthesis	of	thymidine	triphosphate	analogs.	The	organopyrophosphate	reagent	was	applied	to	the	synthesis	of	thymidine	3’-triphosphate,	a-L-threofuranosyl	thymidine	3’-	triphosphate,	and	L-thymidine	5’-triphosphate.	HPLC	traces	provided	after	precipitation	as	the	sodium	salt.		 (Figure	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)		 Next,	we	prepared	a	complete	set	of	DNA	nucleoside	triphosphates	(dNTPs)	using	the	pyrene	pyrophosphate	method.	Each	activated	nucleoside	monophosphate	was	converted	to	the	 desired	 nucleoside	 triphosphate	 following	 the	 standard	 procedure	 of	 pyrene	pyrophosphate	 coupling,	 purification	 by	 silica	 gel	 chromatography,	 deprotection	 with	concentrated	 ammonium	 hydroxide,	 and	 precipitation	 as	 the	 sodium	 salt	 (Fig.	 5.6a).	Concurrently,	we	also	synthesized	all	four	TNA	nucleoside	triphosphates	(tNTPs),	which	are	
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the	 substrates	 for	 engineered	 TNA	 polymerases	 developed	 by	 directed	 evolution	 (Fig.	
5.6b)21.	 In	 all	 cases,	 analytical	 HPLC	 chromatograms	 reveal	 high	 conversion	 (>95%)	 of	activated	 nucleoside	 triphosphate	 into	 the	 fully	 protected	 nucleoside	 triphosphate.	Following	 deprotection	 and	 precipitation,	 the	 desired	 DNA	 and	 TNA	 nucleoside	triphosphates	 were	 produced	 in	 highly	 pure	 form	 on	 scales	 (>500	 milligrams)	 and	timeframes	(2-3	days)	vastly	exceeding	those	of	traditional	protocols.	Since	 nucleoside	 triphosphates	 would	 ultimately	 be	 used	 as	 substrates	 for	oligonucleotide	synthesis,	we	chose	to	investigate	the	use	of	these	reagents	in	a	conventional	DNA	 synthesis	 assay.	 One	 critical	 question	 that	 our	 study	 aimed	 to	 address	 is	 whether	chemically	 synthesized	 DNA	 triphosphates	 function	 with	 same	 level	 of	 efficiency	 as	enzymatically	 produced	 dNTPs	 obtained	 from	 commercial	 venders.	 To	 address	 this	question,	the	polymerase	chain	reaction	(PCR)	was	used	to	amplify	an	arbitrary	DNA	sample	in	reaction	mixtures	that	contained	either	chemically	synthesized	or	commercial	dNTPs.	We	chose	to	amplify	a	200	base	pair	segment	that	defines	the	finger	subdomain	of	an	archaeal	DNA	polymerase	isolated	from	the	thermophilic	species	Thermococcus	kodakarensis	(Kod).	
25	Analysis	of	 the	 resulting	PCR	amplicons	by	agarose	gel	 electrophoresis	 confirmed	 that	chemically	synthesized	dNTP	substrates	function	identically	to	commercial	dNTPs,	as	both	reactions	produce	equivalent	amounts	of	DNA	at	each	cycle	of	PCR	amplification	(Fig.	5.6a).	Moreover,	 DNA	 sequencing	 of	 the	 amplified	 product	 failed	 to	 identify	 any	 instances	 of	insertions,	deletions,	or	mutations,	indicating	that	the	reactions	proceed	with	high	template-sequence	fidelity.			
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Figure	 5.6.	 	 Polymerase	 activity	 assay	 of	 chemically	 synthesized	 DNA	 and	 TNA	
nucleoside	 triphosphates.	 All	 four	 DNA	 and	 TNA	 nucleoside	 triphosphates	 were	constructed	using	 the	organic	 pyrophosphate	method.	 (a)	 Chemically	 synthesized	dNTPs	were	 evaluated	 against	 commercial	 reagents	 in	 a	 standard	 PCR	 reaction.	 (b)	 Chemically	synthesized	tNTPs	purified	by	silica	gel	chromatography	(SG)	were	evaluated	against	HPLC	purified	tNTPs	(HPLC)	 in	a	polymerase-mediated	primer-extension	reaction	using	Kod-RI	TNA	polymerase.	(Figure	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)	
	Next,	we	evaluated	the	set	of	chemically	synthesized	TNA	triphosphates	as	substrates	for	TNA	synthesis	using	an	engineered	TNA	polymerase.	25	In	this	assay,	a	DNA	primer-template	complex	was	extended	with	TNA	using	either	newly	synthesized	tNTPs	or	tNTPs	obtained	by	a	traditional	Hoard-Ott-like	approach	that	requires	HPLC	purification.	26	Analysis	of	the	resulting	 primer-extension	 reactions	 by	 denaturing	 polyacrylamide	 gel	 electrophoresis	
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reveals	that	the	two	sets	of	TNA	substrates	generate	equivalent	amounts	of	full-length	TNA	product	after	3	hours	of	incubation	at	55	oC	(Fig.	5.6b).	This	result,	along	with	the	PCR	assay,	confirms	 that	 the	 pyrene	 pyrophosphate	 method	 produces	 high	 quality	 nucleoside	triphosphates	that	function	as	substrates	for	natural	and	engineered	polymerases.	Historically,	 the	 synthesis	 of	 chemically	 modified	 nucleoside	 triphosphates	 has	 been	limited	by	such	 factors	as	scalability,	 low	yields,	difficult	reaction	conditions,	and	tedious	purifications	 protocols.	 11-13	 Efforts	 to	 overcome	 these	 problems	 have	 resulted	 in	 an	astonishing	number	of	publications,	nearly	all	of	which	require	HPLC	purification.	11-13	Here,	we	describe	a	synthetic	route	to	nucleic	acid	building	blocks	that	(1)	is	not	constrained	to	natural	 substrates;	 (2)	 is	 scalable	 to	 gram	 quantities	 of	 material;	 (3)	 eliminates	 the	requirement	 for	 HPLC	 purification;	 and	 (4)	 avoids	 the	 need	 for	 freeze	 drying.	 The	pyrophosphate	reagent	and	activated	nucleoside	monophosphates	described	in	this	study	are	 readily	 produced	 on	 scales	 of	 5-10	 grams	 using	 synthetic	 methodology	 that	 is	inexpensive,	straightforward	and	high	yielding.	The	availability	of	these	reagents	makes	it	possible	 to	 generate	 1.0	 gram	 of	 nucleoside	 triphosphate,	 which	 is	 enough	 material	 to	perform	5	 liters	 of	 PCR	or	 100,000	PCR	 reactions	with	 a	 standard	50	μL	 volume.	Unlike	conventional	tributyl	ammonium	pyrophosphate,	pyrene	pyrophosphate	is	a	solid	at	room	temperature	and	stable	to	atmospheric	conditions,	allowing	it	to	be	used	without	specialized	equipment	and	stored	for	long	periods	of	time	without	loss	of	activity.	Last,	the	pyrene	 pyrophosphate	 method	 was	 found	 to	 be	 superior	 for	 synthesizing	 chemically	modified	 nucleotides	 that	were	 challenging	 to	 synthesize	 using	 the	 classic	 Yoshikawa	 or	Ludwig-Eckstein	methods.	14,	15	Based	on	these	considerations,	we	believe	that	the	current	
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approach	provides	an	alternative	paradigm	for	synthesizing	large	quantities	of	nucleoside	triphosphates	for	emerging	applications	in	biotechnology	and	molecular	medicine.	
	
5.5	Experimental	Details	
General	Information	All	moisture	sensitive	reactions	were	carried	out	in	anhydrous	solvents	under	an	argon	or	nitrogen	atmosphere.	All	commercial	reagents,	solvents	and	anhydrous	solvents	were	used	without	further	purification.	Solvents	used	for	triphosphate	purification	by	silica	column	 chromatography	 were	 purchased	 as	 HPLC	 grade.	 Reaction	 progresses	 were	monitored	by	 thin	 layer	chromatography	using	glass-backed	analytical	SiliaPlate	with	UV	active	F254	indicator.	Flash	column	chromatography	was	performed	with	SiliaFlash.	P60	silica	gel	(40-63	um	particle	size).		
1H,	 13C,	 or	 31P	 Nuclear	 Magnetic	 Resonance	 (NMR)	 spectra	 were	 recorded	 at	 room	temperature	 either	 on	 a	 Bruker	DRX	 400	 or	 500	MHz	 spectrometer	 at	 the	University	 of	California,	Irvine	NMR	Facility.	The	1H	and	13C	NMR	chemical	shifts	(δ)	are	reported	in	parts	per	million	(ppm)	with	tetramethylsilane	or	deuterium	solvent	as	an	internal	reference.	The	31P	NMR	chemical	shifts	are	proton	decoupled	and	reported	in	parts	per	million	referenced	to	the	deuterium	solvent	calibrated	in	1H	NMR.	Peaks	multiplicity	are	designated	with	the	following	 abbreviations:	 s,	 singlet;	 d,	 doublet;	 dd,	 doublet	 of	 doublets;	 ddd,	 doublet	 of	doublet	of	doublets;	 t,	 triplet;	m,	multiplet;	br,	broad.	X-ray	crystal	data	was	collected	by	Bruker	 SMART	 APEX	 II	 diffractometer	 at	 University	 of	 California,	 Irvine	 X-ray	Crystallography	Facility.	
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HPLC	analysis	was	performed	on	a	reverse-phase	C18	150	Å~	4.6	mm2	column	with	5	μm	particle	size	(Agilent,	USA)	using	a	mobile	phase	of	100	mM	triethylammonium	acetate	buffer	(pH	7.0)/acetonitrile.	High	resolution	mass	spectrometry	(HRMS)	data	were	acquired	using	the	electrospray	ionization	time-of-flight	(ESI-TOF)	method	at	the	University	 of	 California,	 Irvine	 Mass	 Spectrometry	 Core	 Facility.	 The	 nucleoside	monophosphates,	phosphorimidazolides	and	triphosphates	were	dissolved	in	RNase-free	water	with	10	mM	Tris	pH	8.0	and	quantified	by	Nanodrop	2000	(Thermo	Scientific,	USA)	using	Beer’s	law.	(T,	ε267:	9600	M−1cm−1.	C,	ε280:	13100	M−1cm−1.	G,	ε253:	13700	M−1cm−1.	A,	ε259:	15200	M−1cm−1.)		
SYNTHESIS	OF	PYRENE	PYROPHOSPHATE	
2-(Pyrenethio)ethanol	(5.2).	To	 a	 solution	 containing	 9.98	 g	 (177.8	mmol)	 of	 potassium	 hydroxide	 in	 250	mL	 of	anhydrous	 DMF	 was	 added	 12.5	 mL	 (177.8	 mmol)	 of	 2-mercaptoethanol.	 The	 reaction	mixture	was	heated	to	80	oC	with	stirring	until	potassium	hydroxide	dissolved.	A	premade	solution	containing	25	g	(88.9	mmol)	of	1-bromopyrene	(5.1)	in	200	mL	of	anhydrous	DMF	was	dropwise	added	to	the	reaction	and	stirred	at	110	oC	for	3	hours.	Then,	the	reaction	was	cooled	to	room	temperature,	condensed	to	100	mL	of	solution	under	diminished	pressure	and	diluted	into	500	mL	of	CH2Cl2.	The	organic	layer	was	washed	with	200	mL	of	H2O	four	times.	And	the	combined	aqueous	layer	was	back	extracted	with	200	mL	of	CH2Cl2	two	times.	The	 organic	 layers	 were	 combined	 and	 evaporated	 to	 the	 dryness	 under	 diminished	pressure.	The	 crude	product	was	purified	by	 silica	 column	chromatography	with	 eluents	(CH2Cl2/Hexane,	25%	to	50%,	then	EtOAc/CH2Cl2,	from	0%	to	2%)	to	afford	the	compound	
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2	as	a	yellowish	solid;	yield:	21.3	g	(85.8%);	silica	gel	TLC	(EtOAc/Hexane,	1:2)	Rf	=	0.35;	1H	NMR	(400	MHz,	CDCl3)	δ	8.61	(d,	1H,	J	=	9.2	Hz),	8.07-8.00	(m,	4H),	7.93-7.81	(m,	4H),	3.71	(t,	2H,	J	=	6.0	Hz),	3.18	(t,	2H,	J	=	6.0	Hz);	HRMS	(ESI-TOF)	calcd.	for	C18H14OSNa	[M+Na]+	301.0663;	found	301.0658.	This	is	a	known	compound	previously	reported	in	the	literature.1	
	
Scheme	5.1:	Synthesis	of	1-(2-(pyrenesulfonyl)ethyl)pyrophosphate										
	
(Scheme	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,34,13286-13289)	
	
2-(Pyrenesulfonyl)ethanol	(5.3).	To	a	solution	containing	71	g	(114.9	mmol,	80%	technical	grade)	of	magnesium	bis(monoperoxyphthalate)	hexahydrate	in	450	mL	of	anhydrous	DMF	was	slowly	added	a	pre-made	solution	of	21.3	g	(76.6	mmol)	of	compound	(5.2)	in	150	mL	of	anhydrous	DMF	at	0	oC.	The	reaction	was	stirring	at	room	temperature	for	12	h.	At	which	the	TLC	showed	
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the	reaction	was	finished,	the	reaction	was	dropwise	added	to	a	solution	containing	2	L	of	satd.	NaHCO3(aq)	while	stirring.	The	precipitate	was	washed	with	300	mL	of	H2O	twice,	and	dried	under	high	vacuum	to	afford	the	compound	5.3	as	a	yellowish	solid;	yield:	22.8	g	(96%);	silica	gel	TLC	(EtOAc/CH2Cl2,	1:20)	Rf	=	0.22;	1H	NMR	(400	MHz,	CDCl3)	δ	9.00	(d,	1H,	J	=	9.2	Hz),	8.71	(d,	1H,	J	=	8.4	Hz),	8.34-8.31	(m,	3H),	8.27-8.23	(m,	2H),	8.14-	8.09	(m,	2H),	4.00	(t,	2H,	J	=	5.2	Hz),	3.64	(t,	2H,	J	=	5.2	Hz);	13C	NMR	(125.8	MHz,	CDCl3-10%	DMSO-d6)	δ	135.5,	130.8,	130.7,	130.6,	130.3,	129.9,	128.9,	127.5,	127.2,	127.1,	127.0,	126.9,	125.0,	124.1,	123.9,	122.4,	58.6,	56.1;	HRMS	(ESI-TOF)	calcd.	for	C18H14O3SNa	[M+Na]+	333.0561;	found	333.0571.		
Dibenzyl-1-(2-(pyrenesulfonyl)ethyl)	monophosphate	(5.4).	To	a	mixture	containing	5	g	(16.1	mmol)	of	2-(pyrenesulfonyl)ethanol	(5.3),	2.03	g	(29.0	mmol)	of	tetrazole	in	106	mL	of	anhydrous	solution	(MeCN/CH2Cl2,	1:1)	was	slowly	added	6.64	mL	(20.9	mmol)	of	(BnO)2PN(i-Pr)2	at	room	temperature.	The	reaction	was	sonicated	until	the	solid	disappeared	(otherwise	add	additional	20	mL	of	anhydrous	DMF)	and	the	mixture	was	stirring	at	room	temperature	for	3	h.	Then	reaction	was	cooled	to	-	40	oC	followed	by	adding	15	mL	of	H2O2	(33%	in	H2O)	for	additional	1	h	stirring	at	room	temperature.	The	solution	was	condensed	to	20	mL	under	diminished	pressure	and	poured	to	150	mL	EtOAc.	The	organic	layer	was	washed	with	100	mL	brine,	200	mL	satd.	NaHCO3,	200	mL	H2O,	dried	over	MgSO4	and	evaporated	under	diminished	pressure.	The	crude	product	was	purified	by	silica	column	chromatography	with	eluent	(CH2Cl2/Hexane,	from	25%	to	100%,	then	MeOH/CH2Cl2,	from	1%	to	3%)	to	afford	the	yellowish	solid	product	5.4;	yield:	6.73	g	(73.2	%);	TLC	(EtOAc/CH2Cl2,	1:20)	Rf	=	0.34;	1H	
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NMR	(400	MHz,	CDCl3)	δ	8.89	(d,	1H,	J	=	9.2	Hz),	8.60	(d,	1H,	J	=	8.0	Hz),	8.15-8.11	(m,	3H),	8.01-7.94	(m,	3H),	7.82	(d,	1H,	J	=	8.8	Hz),	7.20-7.16	(m,	6H),	7.06-7.04	(m,	4H),	4.67	(d,	4H,	J	=	8.4	Hz),	4.36	(dd,	2H,	J	=	14,	6.0	Hz),	3.70	(t,	2H,	J	=	6.0	Hz);	13C	NMR	(125.8	MHz,	CDCl3)	δ	135.2,	135.2,	135.1,	130.5,	130.4,	129.9,	129.5,	128.7,	128.3,	128.3,	127.6,	127.4,	127.1,	127.0,	126.7,	126.6,	124.5,	123.9,	123.4,	122.0,	69.2	(d,	J	C,P	=	5.8	Hz),	60.7	(d,	J	C,P	=	5.0	Hz),	56.3	(d,	J	C,P	=	7.2	Hz);	31P	NMR	(162	MHz,	CDCl3)	δ	-0.41;	HRMS	(ESI-TOF)	calcd.	for	C32H27O6PSNa	[M+Na]+	593.1164;	found	593.1158.		
1-(2-(Pyrenesulfonyl)ethyl)	monophosphate	(5.5).	To	a	solution	containing	6.73	g	(11.8	mmol)	of	dibenzyl-1-(2-(pyrenesulfonyl)ethyl)	monophosphate	(5.4)	in	50	mL	of	MeOH	was	purged	with	nitrogen	gas.	The	solution	was	added	to	0.1-0.2	mass	equivalent	of	10%	Pd/C,	and	repurged	with	nitrogen	gas	followed	by	adding	hydrogen	gas.	The	mixture	was	stirred	at	room	temperature	for	3	h	with	monitoring	by	TLC	(MeOH/CH2Cl2,	1:10	with	1%	Et3N).	The	resulting	suspension	was	filtered	over	a	pad	of	celite,	washed	with	100	mL	of	MeOH	four	times,	evaporated,	and	then	coevaporated	with	dry	C2H4Cl2	under	reduced	pressure	to	afford	the	product	5.5	as	a	yellowish	solid;	yield	4.42	g	(96%);	TLC	(MeOH/CH2Cl2,	1:10	with	1%	triethylamine)	Rf	=	0;	1H	NMR	(400	MHz,	CD3OD)	δ	8.72	(d,	1H,	J	=	9.6	Hz),	8.44	(d,	1H,	J	=	8.4	Hz),	8.00-	7.90	(m,	4H),	7.79-7.75	(m,	2H),	7.66	(d,	1H,	J	=	8.8	Hz),	4.34	(dd,	2H,	J	=	12.4,	6.0	Hz),	3.82	(t,	2H,	J	=	6.0	Hz);	13C	NMR	(125.8	MHz,	CD3OD+10%	DMSO-d6)	δ	136.6,	131.7,	131.5,	131.5,	131.4,	130.8,	129.8,	128.4,	128.2,	128.0,	127.8,	127.7,	125.5,	125.2,	124.4,	123.2,	60.9	(d,	J	C,P	=	4.2	Hz),	57.6	(d,	J	C,P	=	7.2	Hz);	31P	NMR	(162	MHz,	CD3OD)	δ	-	0.56.	HRMS	(ESI-TOF)	calcd.	for	C18H14O6PS	[M-H]-	389.0249;	found	389.0234.	
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1-(2-(Pyrenesulfonyl)ethyl)-(β-dibenzyl)pyrophosphate	(5.6).	To	the	4.42	g	(11.3	mmol)	of	1-(2-(pyrenesulfonyl)ethyl)	monophosphate	(5.5)	in	39.3	mL	of	anhydrous	dichloromethane	was	added	5.33	mL	(15.8	mmol)	of	(BnO)2PN(i-Pr)2	at	room	temperature	under	a	nitrogen	atomosphore.	After	two	hours	stirring,	the	reaction	was	slowly	added	to	6.16	mL	(33.9	mmol)	of	tert-butyl	hydrogen	peroxide	(5.5	M	in	decane)	at	-40	 oC	 and	 stirred	 for	 an	 additional	 30	 minutes	 at	 room	 temperature.	 The	 reaction	 was	evaporated	under	diminished	pressure	and	the	crude	product	was	purified	by	silica	column	chromatography	with	the	eluents	(MeCN	then	MeOH/CH2Cl2	from	1%	to	3%	containing	 1%	 triethylamine)	 to	 afford	 the	 solid	 product	5.6;	 	 yield:	 6.5	 g	 (76.6%);	 TLC	(2:100	MeOH-CH2Cl2	with	1%	triethylamine)	Rf	=	0.26;	1H	NMR	(400	MHz,	CD3OD)	δ	8.90	(d,	1H,	J	=	9.6	Hz),	8.56	(d,	1H,	J	=	8.0	Hz),	8.15-8.11	(m,	3H),	8.06-8.00	(m,	2H),	7.94	(t,	1H,	J	=	8.0	Hz),	7.87	(d,	1H,	J	=	8.8	Hz),	7.19	(m,	10H),	4.94	(d,	4H,	J	=	7.6	Hz),	4.32	(dd,	2H,	J	=	15.2,	6.8	Hz),	3.75	(t,	2H,	 J	=	6.8	Hz);	13C	NMR	(125.8	MHz,	CDCl3)	δ	136.0,	135.9,	135.6,	130.9,	130.7,	130.7,	130.6,	130.0,	129.1,	128.5,	128.3,	127.8,	127.7,	127.3,	127.2,	127.1,	127.0,	125.1,	124.3,	124.0,	122.6,	69.3	(d,	J	C,P	=	5.5	Hz),	59.7	(d,	J	C,P	=	5.5	Hz),	57.0	(d,	J	C,P	=	6.9	Hz);	31P	NMR	(162	MHz,	CDCl3)	δ	-11.2	(d,	J	=	18.5	Hz),	-	11.6	(d,	J	=	18.5	Hz);	HRMS	(ESI-TOF)	calcd.	for	C32H27O9P2SNa2	[M-H+2Na]+	695.0646;	found	695.0660.		
1-2-(Pyrenesulfonyl)ethyl)pyrophosphate	(5.7).	To	a	solution	containing	6.5	g	of	1-(2-(pyrenesulfonyl)ethyl)-(β-dibenzyl)pyrophosphate	
(4.6)	 in	30	mL	of	MeOH	was	purged	with	nitrogen	gas.	The	solution	was	added	to	0.1-0.2	mass	equivalent	of	10%	Pd/C	and	purged	with	nitrogen	gas	followed	by	adding	hydrogen	gas.	 The	 mixture	 was	 stirred	 at	 room	 temperature	 for	 3	 h	 with	 monitoring	 by	 TLC	
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(MeOH/CH2Cl2,	 1:10	with	 1%	Et3N).	 The	 resulting	 suspension	was	 filtered	 over	 a	 pad	 of	celite,	washed	with	100	mL	of	MeOH	three	times,	evaporated,	and	coevaporated	with	dry	C2H4Cl2	under	reduced	pressure	to	afford	the	product	as	a	yellowish	solid	5.7;	yield:	4.27	g	(90.9%);	TLC	(MeOH/CH2Cl2,	1:10	with	1%	triethylamine)	Rf	=	0;	1H	NMR	(400	MHz,	CD3OD)	δ	8.93	(d,	1H,	J	=	9.2	Hz),	8.61	(d,	1H,	J	=	8.0	Hz),	8.29-8.22	(m,	4H),	8.13	(d,	1H,	J	=	8.8	Hz),	8.05-8.00	(m,	2H),	4.35	(m,	2H),	3.91	(t,	2H,	J	=	10.4	Hz);	13C	NMR	(125.8	MHz,	D2O)	δ	135.0,	130.7,	130.1,	129.7,	129.2,	129.0,	128.3,	127.3,	127.1,	127.0,	126.6,	126.3,	124.4,	123.6,	122.4,	121.8,	60.6,	57.3	(d,	J	C,P	=	6.0	Hz);	31P	NMR	(162	MHz,	D2O)	δ	-10.0	(d,	J	=	16.8	Hz),	-11.5	(d,	
J	 =	 16.8	 Hz);	 HRMS	 (ESI-TOF)	 calcd.	 For	 C18H14O9P2SNa3	 [M-2H+3Na]+	 536.9527;	 found	536.9521.		
SYNTHESIS	OF	NUCLEOSIDE	TRIPHOSPHATES	
General	procedure	A:	synthesis	of	protected	nucleoside	monophosphates.	To	a	mixture	containing	suitably	protected	free	nucleoside	(compounds:	5.8a-d,	5.14,	5.20a-d,	and	5.26)	and	1.8	equivalents	of	tetrazole	in	an	anhydrous	solvent	(MeCN/CH2Cl2,	1:1)	was	added	to	1.3	equivalents	of	(BnO)2PN(i-Pr)2	under	a	nitrogen	atmosphere.	The	mixture	was	stirred	at	room	 temperature	 for	 1-3	 hours	 and	 the	 reaction	 was	monitored	 by	 TLC.	 At	 which	 the	starting	material	was	consumed,	the	reaction	was	slowly	added	excess	H2O2	(33%	in	H2O)	at	-40	oC	and	the	resulting	mixture	was	stirred	at	room	temperature	for	1	hour.	The	solution	was	then	diluted	with	15-20	times	volume	of	CH2Cl2	and	the	organic	layer	was	sequentially	washed	with	saturated	NaHCO3(aq),	brine,	and	water.	The	organic	extracts	were	combined,	dried	 with	 MgSO4,	 and	 evaporated	 under	 diminished	 pressure.	 The	 crude	 residue	 was	
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purified	 by	 silica	 gel	 chromatography	 and	 the	 fractions	 containing	 the	 product	 were	collected	and	evaporated	to	afford	the	product	5.9a-d,	5.15,	5.21a-d,	or	5.27.	
General	 procedure	 B:	 synthesis	 of	 nucleoside	 monophosphates.	 To	 a	 solution	containing	the	protected	nucleoside	monophosphate	(compounds	5.9a-d,	5.15,	5.21a-d,	and	5.27)	 in	 MeOH	 was	 purged	 with	 nitrogen	 gas.	 The	 solution	 was	 added	 0.1-0.2	 mass	equivalent	of	10%	Pd/C,	and	re-purged	with	nitrogen	gas	followed	by	adding	hydrogen	gas.	The	 mixture	 was	 stirred	 at	 room	 temperature	 for	 3-5	 hours	 with	 monitoring	 by	 TLC	(MeOH/CH2Cl2,	1:10	with	1%	triethylamine).	Then	the	solution	was	purged	with	nitrogen,	filtered	over	a	pad	of	celite,	and	washed	with	MeOH	or	MeOH	containing	2%	triethylamine.	The	filtrate	was	collected,	evaporated	and	coevaporated	with	dry	1,	2-dichloroethane	under	reduced	pressure	to	afford	the	product	5.10a-d,	5.16,	5.22a-d,	or	5.28.	
General	procedure	C	:	synthesis	of	activated	nucleoside	monophosphates.	To	a	solution	containing	 the	 nucleoside	monophosphate	 (compounds	 5.a-d,	 5.16,	 5.22a-d	 and	 5.28)	 in	anhydrous	DMF	under	a	nitrogen	atmosphere	was	slowly	added	5	equivalents	of	anhydrous	triethylamine	at	0	oC.	After	5	minutes	with	stirring,	2	equivalents	of	2-	methylimidazole	was	added	followed	by	2	equivalents	of	triphenylphosphine.	After	10	minutes	of	stirring	at	room	temperature,	2	equivalents	of	2,	2’-dipyridyl	disulfide	was	added	and	stirring	was	continued	for	an	additional	3	hours	at	room	temperature	with	monitoring	by	analytical	HPLC	(mobile	phase:	MeCN/0.1	M	TEAA	buffer,	from	0%	to	50%	over	40	minutes).	After	consumption	of	the	starting	material,	 the	product	was	precipitated	by	adding	 the	reaction	dropwise	with	stirring	to	300	mL	of	diethyl	ether.	The	precipitate	was	collected	by	centrifuging	at	4400	rpm	for	15	minutes	at	 room	 temperature.	The	 supernatant	was	discarded,	 and	 the	pellet	was	resuspended	with	minimal	 amount	 of	 CH2Cl2	 or	 anhydrous	DMF	 (DMF	 is	 used	when	 the	
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nucleoside	monophosphate	is	not	soluble	in	CH2Cl2).	The	solution	was	added	dropwise	to	a	premade	solution	of	ether/ethyl	acetate/triethylamine	(5:10:1)	containing	8	equivalents	of	sodium	perchlorate	for	a	second	precipitation.	The	suspended	solid	was	centrifuged	at	4400	rpm	for	15	minutes	at	room	temperature,	the	supernatant	was	discarded,	and	the	pellet	was	washed	twice	with	40	mL	of	mixed	solvent	(ether/ethyl	acetate,	1:2),	and	dried	under	high	vacuum	to	afford	the	product	5.11a-d,	5.17,	5.23a-d	or	5.29.	
General	procedure	D	:	synthesis	of	fully	protected	nucleoside	triphosphates.	To	a	mixture	 containing	 the	 activated	 nucleoside	 monophosphate	 (compounds	 5.11a-d,	 5.17,	5.23a-d	and	5..29)	and	1.2	equivalents	of	1-(2-(pyrenesulfonyl)ethyl)pyrophosphate	(5.7)	was	added	along	with	8-10	equivalents	of	a	premade	solution	of	ZnCl2	(1.0	M	in	anhydrous	DMF)	under	a	nitrogen	atmosphere.	The	mixture	was	stirred	at	room	temperature	for	3-5	hours	and	the	reaction	progress	was	monitored	by	HPLC	(MeCN/0.1	M	TEAA	buffer,	from	0%	to	50%	over	40	minutes).	At	which	the	starting	material	was	consumed,	the	reaction	was	dropwise	added	to	ethyl	acetate	or	ether	for	precipitation.	The	precipitate	was	centrifuged	and	collected	at	4400	rpm	for	10	minutes	at	room	temperature,	and	the	supernatant	was	discarded.	The	pellet	was	resuspended	by	20%	H2O	in	MeCN	with	2%	Hunig’s	base	and	the	solid	was	filtered	by	pyrex	glass	funnel	with	filter	paper.	The	filtrate	was	collected	and	evaporated	under	diminished	pressure	and	dry-packing	loaded	to	silica	gel	 for	normal	phase	silica	column	chromatography.	The	fractions	containing	the	product	were	 collected	 and	 evaporated	under	diminished	pressure	 at	 30-40	 oC.	 The	product	was	resuspended	with	CH2Cl2	and	insoluble	silica	gel	was	removed	by	filtration.	The	filtrate	was	collected	and	evaporated	to	dryness	to	afford	the	product	5.12a-d,	5.18,	5.24a-d,	or	5.30.	
General	procedure	E:	synthesis	of	free	nucleoside	triphosphates.	To	a	solution	of	
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fully	protected	nucleoside	triphosphate	(compounds:	5.12a,	5.18,	5.24a,	and	5.30)	in	50	mL	of	33%	NH4OH(aq)	was	stirred	for	18	hours	at	room	temperature	or	(compounds:	5..12b-d,	and	5.24b-d)	was	stirred	for	3	hours	at	37	oC	and	15	hours	at	room	temperature	in	a	sealed	tube.	After	the	reaction,	the	solvent	was	evaporated	under	diminished	pressure.	The	solid	was	resuspended	with	Milli-Q	water	and	the	aqueous	solution	was	washed	with	CH2Cl2	and	ethyl	acetate.	The	organic	portion	was	discarded	and	the	aqueous	extract	was	collected,	and	evaporated	under	diminished	pressure.	The	crude	solid	was	resuspended	with	minimal	amount	of	RNAse	free	water,	filtrated	by	0.22	um	syringe	filter	and	dropwise	added	to	the	forty	times	volume	of	acetone	at	room	temperature	containing	15	equivalents	of	sodium	perchlorate.	The	resulting	suspension	was	centrifuged	at	4400	rpm	for	15	minutes	at	room	temperature.	The	supernatant	was	discarded	and	the	pellet	was	washed	with	organic	solution	(acetone/CH2Cl2,	10:1)	twice	to	afford	the	product	5.13a-d,	5.19,	5.25a-d,or	5.31.	
	
Scheme	5.2:	Synthesis	of	thymidine-5’-triphosphate	(dTTP,	5.13a)	
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(Scheme	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)	
	
3’-O-Benzoyl-2’-deoxythymidine-5’-dibenzylmonophosphate	(5.9a).	General	procedure	A	with	1g	(2.9	mmol)	of	3’-O-benzoyl-2’-deoxythymidine	5.8a,2	364.4	mg	(5.2	mmol)	of	tetrazole,	28.9	mL	of	anhydrous	solution	(MeCN/CH2Cl2,	1:1),	1.3	mL	(3.8	mmol)	of	dibenzyl-N,	N-diisopropylphosphoramidite	for	3	hours	reaction	at	room	temperature.	 Then,	 6	 mL	 of	 30%	 H2O2(aq)	 for	 1	 hour	 oxidation	 reaction	 at	 room	temperature.	 Column	 chromatography	with	 eluents	 (MeOH/CH2Cl2,	 from	1%	 to	1.4%)	 to	afford	the	product	5.9a	as	a	white	solid;	yield:	1.2	g	(68.5%);	TLC	(MeOH/CH2Cl2,	1:40)	Rf	=	0.23;	1H	NMR	(400	MHz,	CD3OD)	δ	8.03-8.00	(m,	2H),	7.62-7.58	(m,	1H),	7.48-7.45	(m,	3H),	
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7.36-	7.29	(m,	10H),	6.32	(dd,	1H,	J	=	8.4,	6.0	Hz),	5.42-5.40	(m,	1H),	5.12-5.07	(m,	4H),	4.34-4.28	(m,	3H),	2.47	(ddd,	1H,	J	=	14.4,	6.0,	2.0	Hz),	2.26-2.18	(m,	1H),	1.77	(d,	3H,	J	=	1.2	Hz);	HRMS	(ESI-TOF)	calcd.	for	C31H31N2O9PNa	[M+Na]+	629.1665;	found	629.1664.	This	is	a	known	compound	previously	reported	in	the	literature.2	
	
3’-O-Benzoyl-2’-deoxythymidine-5’-monophosphate	(5.10a).	General	procedure	B	with	1.2	g	(1.9	mmol)	of	5.9a,	50	mL	of	MeOH,	and	200	mg	of	10%	Pd/C	for	3	hours	stirring	at	room	temperature.	The	suspension	was	filtered	over	a	pad	of	celite,	and	washed	with	100	mL	of	MeOH	containing	2%	triethylamine	four	times	to	afford	the	product	5.10a	 as	 a	white	 foam	of	 triethylammonium	salt;	 yield:	1.11	g	 (88.7%);	TLC	(MeOH/CH2Cl2,	1:10	with	1%	triethylamine)	Rf	=	0;	1H	NMR	(400	MHz,	DMSO-d6)	δ	11.41	(s,	1H),	8.09	(d,	2H,	J	=	8.0	Hz),	7.77-7.74	(m,	2H),	7.62	(t,	2H,	J	=	7.6	Hz),	6.41	(dd,	1H,	J	=	8.0,	6.8	Hz),	5.57	(s,	1H),	4.41	(s,	1H),	4.18	(m,	2H),	2.58-2.57	(m,	2H),	1.88	(s,	3H);	 13C	NMR	(125.8	MHz,	DMSO-d6)	δ	168.6,	167.3,	152.7,	138.6,	135.6,	131.0,	130.4,	130.3,	113.0,	86.2,	85.1	(d,	J	C,P	=	8.7	Hz),	78.0,	66.2,	37.9,	31.9,	13.2;	31P	NMR	(162	MHz,	DMSO-d6)	δ	0.24;	HRMS	(ESI-TOF)	calcd.	for	C17H18N2O9PNa2	[M-H+2Na]+	471.0545;	found	471.0539.	
	
3’-O-Benzoyl-2’-deoxythymidine-5’-phosphor-2-methylimidazolide	(5.11a).	General	procedure	C	with	1.11	g	(1.8	mmol)	of	4.10a,	7.8	mL	of	anhydrous	DMF,	1.63	mL	(11.7	mmol)	of	triethylamine,	385	mg	(4.7	mmol)	of	2-methylimidazole,	1.23	g	(4.7	mmol)	of	triphenylphosphine,	1.04	g	(4.72	mmol)	of	dipyridyl	disulfide	for	2	hours	reaction	at	room	temperature.	First	precipitation	was	achieved	with	250	mL	of	diethyl	ether.	The	product	was	resuspended	with	10	mL	of	DMF	and	dropwise	added	to	the	solution	containing	2.01	g	of	
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sodium	 perchlorate,	 15	 mL	 of	 triethylamine	 in	 300	 mL	 of	 ethyl	 acetate	 for	 second	precipitation.	The	product	was	afforded	as	a	white	solid	5.11a;	yield:	0.89	g	(98.9%);	31P	NMR	(162	MHz,	D2O)	δ	-6.83;	HRMS	(ESI-TOF)	calcd.	for	C21H23N4O8PNa	[M+Na]+	513.1151;	found	513.1141.	
	
3’-O-Benzoyl-2’-deoxythymidine-5’-(γ-(2-(pyrenesulfonyl)ethyl))triphosphate	
(5.12a).	General	procedure	D	with	0.89	g	(1.7	mmol)	of	4.11a,	1.09	g	(1.91	mmol)	of	1-2-	(pyrenesulfonyl)ethyl)	pyrophosphate	(5.7)	and	13.92	mL	(13.92	mmol)	of	ZnCl2	solution	(1.0	M	in	anhydrous	DMF)	for	3	hours	stirring	at	room	temperature.	Then	crude	was	precipitated	by	dropwise	adding	the	solution	to	the	300	mL	of	ethyl	acetate	with	stirring.	After	centrifugation,	the	pellet	was	resuspended	by	20%	H2O/MeCN	containing	2%	Hunig’s	base	and	filtered	by	pyrex	glass	funnel.	The	filtrate	was	evaporated	and	the	crude	material	was	purified	by	silica	column	chromatography	with	eluents	(H2O/(isopropanol-	MeCN	1:1)	from	2%	to	7%	containing	1%	diisopropylethylamine	(DIPEA)	to	obtain	pure	5.12a;	yield:	1.43	g	(64.9%);	TLC	(H2O/acetone	1:10	with	2%	diisopropylethylamine)	Rf	=	0.29;	1H	NMR	(400	MHz,	D2O)	δ	8.25	(d,	1H,	J	=	8.8	Hz),	8.10	(d,	1H,	J	=	7.6	Hz),	7.41	(d,	1H,	J	=	9.2	Hz),	7.33-7.27	(m,	3H),	7.19-7.13	(m,	4H),	6.94-6.89	(m,	3H),	6.68	(t,	2H,	J	=	6.4	Hz),	5.61	(s,	1H),	5.16	(s,	1H),	4.49	(s,	2H),	4.15-4.07	(m,	2H),	3.78	(m,	3H)	2.04-	1.94	(m,	2H),	1.70	(s,	3H);	
31P	NMR	(162	MHz,	D2O)	δ	-10.22	(brs,	2P),	-20.50	(brs,	1P);	HRMS	(ESI-TOF)	calcd.	For	C35H31N2O17P3SNa3	[M-2H+3Na]+	945.0250;	found	945.0261.		
2’-deoxythymidine-5’-triphosphate	(5.13a).	
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General	procedure	E	with	1.43	g	(1.1	mmol)	of	5.12a,	50	mL	of	33%	NH4OH(aq)	for	18	h	stirring	at	room	temperature.	The	product	4.13a	was	afforded	as	a	white	solid;	yield:	453	mg	(83.2%,	T,	ε267:	9600	M−1cm−1);	1H	NMR	(400	MHz,	D2O)	δ	7.74	(s,	1H),	6.37	(t,	1H,	,	J	=	6.0	Hz),	4.69	(s,	1H),	4.28-4.24	(m,	3H),	2.42	(s,	2H),	1.96	(s,	3H);	31P	NMR	(162	MHz,	D2O)	δ	-4.06	(d,	J	=	16.2	Hz),	-9.30	(d,	J	=	16.2	Hz),	-17.95	(brs).		
Scheme	5.3:	Synthesis	of	2’-deoxycytidine-5’-triphosphate	(dCTP,	5.13b)	
													
	
(Scheme	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019.	141,	34,	13286-13289)	
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3’-O,	N4-Dibenzoyl-2’-deoxycytidine-5’-dibenzylmonophosphate	(5.9b).	General	 procedure	A	with	1.04	 g	 (2.4	mmol)	 of	 3’-O,	N4-dibenzoyl-2’-deoxythymidine	
5.8b,2	306	mg	(4.3	mmol)	of	tetrazole,	16	mL	of	anhydrous	solution	(MeCN/CH2Cl2,	1:1),	0.99	mL	 (3.1	mmol)	 of	 dibenzyl-N,	N-diisopropylphosphoramidite	 for	 1	 hour	 stirring	 at	 room	temperature	 followed	 by	 6	 mL	 of	 H2O2	 for	 1	 hour	 oxidation	 reaction.	 Column	chromatography	with	eluents	(MeOH/CH2Cl2,	from	0%	to	12.5%)	to	afford	the	product	5.9b	as	a	white	solid;	yield:	1.26	g	(75.5	%);	TLC	(MeOH/CH2Cl2,	1:60)	Rf	=	0.32;	1H	NMR	(400	MHz,	CDCl3)	δ	8.12	(d,	1H,	J	=	7.6	Hz),	8.02	(d,	2H,	J	=	7.6	Hz),	7.96	(d,	2H,	J	=	7.6	Hz),	7.59-7.52	(m,	2H),	7.48-7.41	(m,	5H),	7.36-7.28	(m,	10H),	6.37	(dd,	1H,	J	=	8.4,	5.6	Hz),	5.41	(d,	1H,	
J	=	6.4	Hz),	5.14-5.02	(m,	4H),	4.42-4.32	(m,	3H),	2.82	(dd,	1H,	J	=	14.0,	5.2	Hz),	2.05-1.97	(m,	1H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	165.7,	162.4,	154.6,	143.8,	135.4,	135.3,	133.4,	133.1,	132.9,	129.6,	128.9,	128.7,	128.6,	128.6,	128.4,	127.9,	127.9,	127.7	96.9,	87.0,	83.6	(d,	J	C,P	=	7.8	Hz),	75.0,	69.7	(d,	J	C,P	=	5.3	Hz),	66.8	(d,	J	C,P	=	5.2	Hz),	38.7;	31P	NMR	(162	MHz,	CDCl3)	δ	0.76;	HRMS	(ESI-TOF)	calcd.	for	C37H34N3O9PNa	[M+Na]+	718.1931;	found	718.1949.		
3’-O,	N4-Dibenzoyl-2’-deoxycytidine-5’-monophosphate	(5.10b).	General	procedure	B	with	1.26	g	(1.8	mmol)	of	5.9b,	100	mL	of	MeOH,	and	250	mg	of	10%	Pd/C	for	3	h	stirring.	The	suspension	was	filtered	over	a	pad	of	celite,	washed	with	100	mL	of	MeOH	containing	2%	triethylamine	four	times	to	afford	the	product	5.10a	as	a	white	foam	of	triethylammonium	salt;	yield:	1.05	g	(84.1%);	TLC	(MeOH/CH2Cl2,	1:10)	Rf	=	0;	1H	NMR	(400	MHz,	CD3OD)	δ	8.68	(d,	1H,	J	=	6.8	Hz),	8.08	(d,	2H,	J	=	7.6	Hz),	7.98	(d,	2H,	J	=	7.6	Hz),	7.71	(d,	1H,	J	=	7.2	Hz),	7.65-7.62	(m,	2H),	7.55-7.49	(m,	4H),	6.45	(t,	1H,	J	=	6.0	Hz),	5.69	(d,	1H,	J	=	4.0	Hz),	4.51	(s,	1H),	4.22	(s,	1H),	2.78	(dd,	1H,	J	=	13.6,	4.0	Hz),	2.59	-2.52	(m,	1H);	
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13CNMR	(125.8	MHz,	CD3OD)	δ	168.9,	167.2,	164.9,	157.9,	146.9,	134.8,	134.5,	134.0,	131.0,	130.6,	129.8,	129.7,	129.1,	99.1,	88.7,	86.5	(d,	J	C,P	=	8.4	Hz),	77.8,	65.8,	40.1;	31P	NMR	(162	MHz,	CD3OD)	δ	1.22;	HRMS	(ESI-TOF)	calcd.	 for	C23H22N3O9PNa	[M+Na]+	538.0991;	 found	538.0984.		
3’-O,	N4-Dibenzoyl-2’-deoxycytidine-5’-phosphor-2-methylimidazolide	(5.11b).	General	procedure	C	with	1.05	g	(1.5	mmol)	of	5.10b,	7.3	mL	of	anhydrous	DMF,	1.02	mL	(7.3	mmol)	of	triethylamine,	252	mg	(3.0	mmol)	of	2-methylimidazole,	918	mg	(3.5	mmol)	of	triphenylphosphine,	804	mg	(3.7	mmol)	of	dipyridyl	disulfide	for	2	hours	reaction	at	room	temperature.	First	precipitation	was	achieved	with	250	mL	of	diethyl	ether.	The	product	was	resuspended	with	10	mL	of	DMF	and	dropwise	added	to	the	solution	containing	1.79	g	of	sodium	 perchlorate,	 15	 mL	 of	 triethylamine	 in	 300	 mL	 of	 mixing	 solution	 (ethyl	acetate/ether	 1.5:1)	 for	 second	 precipitation.	 The	 product	was	 afforded	 as	 a	white	 solid	
5.11b;	yield:	0.82	g	(93.4%);	31P	NMR	(162	MHz,	D2O)	δ	-6.63;	HRMS	(ESI-TOF)	calcd.	for	C27H25N5O8PNa2	[M-H+2Na]+	624.1236;	found	624.1256.		
3’-O,N4-Dibenzoyl-2’-deoxycytidine-5’-(γ-(2-(pyrenesulfonyl)ethyl))triphosphate	
(5.12b).	General	 procedure	 D	 with	 0.82	 g	 (1.4	 mmol)	 of	 5.11b,	 0.77	 g	 (1.6	 mmol)	 of	 1-(2-	(pyrenesulfonyl)ethyl)	pyrophosphate	(5.7)	and	13.6	mL	(13.6	mmol)	of	ZnCl2	solution	(1.0	M	in	anhydrous	DMF)	for	3	hours	with	stirring.	Then	crude	was	precipitated	by	dropwise	adding	 the	 solution	 to	 the	 300	mL	 of	 ethyl	 acetate	 with	 stirring	 for	 precipitation.	 After	centrifugation,	the	pellet	was	resuspended	by	20%	H2O/MeCN	containing	2%	Hunig’s	base	
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and	 filtered	 by	 pyrex	 glass	 funnel.	 The	 filtrate	 was	 evaporated	 and	 crude	 product	 was	purified	by	silica	column	chromatography	with	eluents	7%	H2O/isopropanol	containing	1%	diisopropylethylamine	(DIPEA)	and	then	H2O	in	(isopropanol/MeCN	1:1)	from	5%	to	8	%	containing	1%	diisopropylethylamine	(DIPEA)	to	afford	the	white	solid	5.12b;	yield:	1.07	g	(58.1	%);	 TLC	 (H2O/acetone	 1:10	 containing	 2%	DIPEA):	 Rf	 =	 0.32;	 1H	NMR	 (500	MHz,	D2O/DMSO-d6	1:1)	δ	11.15	(s,	1H),	8.91	(s,	1H),	8.60-7.95	(m,	7H),	7.62-	7.33	(m,	4H),	6.25	(s,	1H),	5.47	(s,	1H),	4.33-3.90	(m,	4H),	2.34	(s,	1H);	31P	NMR	(162	MHz,	D2O/DMSO-d6	1:1)	δ	-12.13	(d,	1P,	J	=	17.2	Hz),	-12.38	(d,	1P,	J	=	14.9	Hz),	-22.59	(brs,	1P);	HRMS	(ESI-TOF)	calcd.	for	C41H34N3O17P3SNa3	[M-2H+3Na]+	1034.0515;	found	1034.0485.		
2’-deoxythymidine-5’-triphosphate	(5.13b).	General	procedure	E	with	1.04	g	(0.8	mmol)	of	5.12b	in	55	mL	of	33%	NH4OH(aq)	for	3	hours	 deprotection	 at	 37	 oC	 and	 then	 15	 hours	 deprotection	 at	 room	 temperature.	 The	product	5.13b	was	afforded	as	a	white	solid;	yield:	302	mg	(82.5%,	C,	ε280:	13100	M−1cm−1);	
1H	NMR	(400	MHz,	D2O)	δ	7.96	(d,	1H,	J	=	7.2	Hz),	6.36	(t,	1H,	J	=	6.4	Hz),	6.18	(t,	1H,	J	=	6.8	Hz),	4.64	(s,	1H),	4.26	(s,	3H),	2.47-2.32	(m,	2H);	31P	NMR	(162	MHz,	D2O)	δ	5.04	(brs),	-9.23	(brs),	-18.71	(brs).		
Scheme	5.4:	Synthesis	of	2’-deoxyadenosine-5’-triphosphate	(dATP,	5.13c)		 			
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(Scheme	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)	
	
3’-O,	N6,	N6-Tribenzoyl-2’-deoxyadenosine-5’-dibenzylmonophosphate	(5.9c).	General	procedure	A	with	1.03	g	(1.8	mmol)	of	3’-O,	N6,	N6-tribenzoyl-2’-deoxyadenosine	
5.8c,2	233	mg	(3.3	mmol)	of	tetrazole,	12	mL	of	anhydrous	solution	(MeCN/CH2Cl2,	1:1),	0.75	mL	 (2.4	mmol)	 of	 dibenzyl-N,	N-diisopropylphosphoramidite	 for	 1	 hour	 stirring	 at	 room	temperature.	Then,	the	reaction	was	added	to	6	mL	of	H2O2	for	1	hour	oxidation	reaction.	Column	 chromatography	 with	 eluents	 (EtOAc/hexane,	 from	 33%	 to	 66%)	 to	 afford	 the	product	5.9c	as	a	white	foam;	yield:	1.33	g	(88.3	%);	TLC	(EtOAc/hexane,	1:60)	Rf	=	0.32;	1H	NMR	(400	MHz,	CDCl3)	δ	8.63	(s,	1H),	8.38	(s,	1H),	8.06	(d,	2H,	J	=	8.0	Hz),	7.87	(d,	3H,	J	=	8.0	Hz),	7.64-7.61	(m,	1H),	7.50-7.46	(m,	4H),	7.37-7.28	(m,	15H),	6.60-6.56	(m,	1H),	5.55	(d,	1H,	
J	=	5.6	Hz),	5.07-5.01	(m,	4H),	4.40	(s,	1H),	4.34-4.24	(m,	2H),	2.72-2.67	(m,	2H);	13CNMR	
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(125.8	MHz,	CDCl3)	δ	172.7,	166.2,	153.2,	152.6,	152.3,	143.5,	134.5,	134.1,	133.4,	129.9,	129.5,	129.1,	129.1,	129.1,	129.1,	129.1,	129.0,	129.0,	128.6,	128.6,	128.1,	84.9,	83.9	(d,	J	C,P	=	10.4	Hz),	75.0,	69.7	(d,	J	C,P	=	5.3	Hz),	66.8	(d,	J	C,P	=	5.2	Hz),	38.7;	31P	NMR	(162	MHz,	CDCl3)	δ	0.70;	HRMS	(ESI-TOF)	calcd.	for	C45H38N5O9PNa	[M+Na]+	846.2305;	found	846.2291.		
3’-O,	N6,	N6-Tribenzoyl-2’-deoxyadenosine-5’-monophosphate	(5.10c).	General	procedure	B	with	1.33	g	(1.6	mmol)	of	5.9c,	100	mL	of	MeOH,	and	230	mg	of	10%	Pd/C	for	3	hours	stirring.	The	suspension	was	filtered	over	a	pad	of	celite,	washed	with	100	mL	of	MeOH	containing	2%	triethylamine	four	times	to	afford	the	product	5.10c	as	a	white	foam	of	 triethylammonium	salt;	yield:	0.88	g	 (84.5	%);	TLC	(MeOH/CH2Cl2	1:10	with	1%	triethylamine)	Rf	=	0;	1H	NMR	(400	MHz,	CD3OD)	δ	8.93	(s,	1H),	8.69	(s,	1H),	8.06	(d,	2H,	J	=	7.6	Hz),	7.80-7.78	(m,	3H),	7.62-7.58	(m,	1H),	7.49-7.47	(m,	4H),	7.37-	7.34	(m,	3H),	6.71	(t,	1H,	J	=	1.6	Hz),	5.77	(d,	1H,	J	=	5.6	Hz),	4.47	(s,	1H),	4.17-4.13	(m,	2H),	3.14-3.12	(m,	1H),	2.74	(dd,	1H,	J	=	13.6,	5.6	Hz);	13C	NMR	(125.8	MHz,	CD3OD)	δ	173.7,	167.2,	154.4,	153.1,	152.6,	146.3,	135.4,	134.5,	134.5,	134.2,	131.0,	130.6,	130.4,	129.8,	129.7,	129.6,	129.4,	128.9,	86.0	(d,	J	C,P	=	10.4	Hz),	77.9,	66.2,	55.6,	47.5,	39.1;	31P	NMR	(162	MHz,	CD3OD)	δ	2.30;	HRMS	(ESI-TOF)	calcd.	for	C31H25N5O9PNa2	[M-H+	2Na]+	688.1185;	found	688.1204.		
3’-O,	N6,	N6-Tribenzoyl-2’-deoxyadenosine-5’-phosphor-2-methylimidazolide	(5.11c).		General	procedure	C	with	0.88	g	(1.4	mmol)	of	5.10c,	7.15	mL	of	anhydrous	DMF,	1.0	mL	(7.1	mmol)	of	triethylamine,	239	mg	(2.9	mmol)	of	2-methylimidazole,	760	mg	(2.9	mmol)	of	triphenylphosphine,	642	mg	(2.9	mmol)	of	dipyridyl	disulfide	for	2	hours	reaction	at	room	temperature.	The	crude	was	dropwise	added	to	300	mL	of	ether	for	precipitation	and	the	
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solid	was	collected	by	centrifugation	at	4400	rpm	for	10	minutes	at	room	temperature.	The	crude	product	was	resuspended	with	minimal	volume	of	CH2Cl2	and	dropwise	added	to	300	mL	of	ether	containing	1.4	g	of	LiClO4.	The	precipitate	was	collected	by	centrifugation	at	4400	rpm	 for	 10	 minutes	 at	 room	 temperature	 to	 afford	 the	 white	 solid	 5.11c;	 yield:	 1.08	 g	(97.5%);	 31P	 NMR	 (162	 MHz,	 D2O)	 δ	 -7.59;	 HRMS	 (ESI-TOF)	 calcd.	 for	 C35H30N7O8PNa	[M+Na]+	730.1791;	found	730.1799.		
3’-O,	N6,	N6-Tribenzoyl-2’-deoxyadenosine	-5’-γ-(2-(pyrenesulfonyl)ethyl]-	
triphosphate	(5.12c).	General	 procedure	 D	 with	 1.08	 g	 (1.3	 mmol)	 of	 5.11c,	 0.77	 g	 (1.6	 mmol)	 of	 1-(2-	(pyrenesulfonyl)ethyl)-pyrophosphate	(5.7)	and	13.6	mL	(13.6	mmol)	of	ZnCl2	solution	(1.0	M	 in	 anhydrous	 DMF)	 for	 3	 hours	 with	 stirring.	 After	 the	 reaction,	 the	 solution	 was	precipitated	by	300	mL	of	ether.	After	centrifugation,	the	pellet	was	resuspended	by	20%	H2O/MeCN	containing	2%	Hunig’s	base	and	filtered	by	pyrex	glass	funnel.	The	filtrate	was	evaporated	 and	 the	 crude	 product	 was	 purified	 by	 silica	 column	 chromatography	 with	eluents	[(8%	H2O/isopropanol+1%	diisopropylethylamine),	then	(H2O/(isopropanol	MeCN	1:1)	from	2%	to	7%	containing	1%	diisopropylethylamine	(DIPEA)]	to	afford	the	white	solid	
5.12c;	yield:	928	mg	(46.7%);	TLC	(H2O/acetone	1:10	containing	2%	DIPEA):	Rf	=	0.28;	1H	NMR	(600	MHz,	D2O/DMSO-d6	1:1)	δ	8.58-8.57	(m,	1H),	8.45	(s,	1H),	8.37-8.33	(m,	2H),	8.06-7.70	(m,	11H),	7.57-7.32	(m,	7H),	5.94	(t,	1H,	J	=	7.2	Hz),	5.31	(s,	1H),	4.20	(d,	2H,	J	=	6.6	Hz),	3.99-3.97	(m,	2H),	3.86-3.84	(m,	1H),	3.75-3.74	(m,	1H),	2.55	(s,	1H),	2.10	(dd,	1H,	J	=	13.8,	4.8	Hz);	31P	NMR	(162	MHz,	D2O/	DMSO-d6	1:1)	δ	-10.24	(d,	J	=	14.9	Hz),	-10.45	(d,	J	=	14.7	Hz),	-20.67	(brs,	1P);	HRMS	(ESI-TOF)	calcd.	For	C42H34N5O16P3SNa	[M-2H+Na]+	1012.0832;	
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found	1012.0827.	During	HRMS,	analysis	one	of	the	two	benzoyl	group	is	removed	from	the	exocyclic	amino	group.		
2’-deoxyadenosine-5’-triphosphate	(5.13c).	General	procedure	E	with	928	mg	(0.6	mmol)	of	5.12c	in	45	mL	of	33%	NH4OH(aq)	in	deprotection	step	for	3	hours	at	37	oC	and	then	15	hours	at	room	temperature.	The	product	
5.13c	was	afforded	as	a	white	solid;	yield:	284	mg	(92.6%,	A,	ε259:	15200	M−1cm−1);	1H	NMR	(400	MHz,	D2O)	δ	8.37	(s,	1H),	8.08	(s,	1H),	6.39	(t,	1H,	J	=	6.4	Hz),	4.33	(s,	1H),	4.26	(s,	2H),	2.81-2.74	(m,	1H),	2.66-2.60	(m,	1H);	31P	NMR	(162	MHz,	D2O)	δ	-3.97	(d,	J	=	15.7	Hz),	-9.22	(d,	J	=	16.0	Hz),	-17.85	(t,	J	=	13.3	Hz).		
Scheme	5.5:	Synthesis	of	2’-deoxyguanosine-5’-triphosphate	(dGTP,	5.13d)	
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(Scheme	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)	
	
3’-O,	N2-Dibenzoyl-2’-deoxyguanosine-5’-dibenzylmonophosphate	(5.9d).	General	procedure	A	with	1.0	g	(2.1	mmol)	of	3’-O,	N2-dibenzoyl-2’-deoxyguanosine.	0.29	g	(4.2	mmol)	of	tetrazole,	15	mL	of	anhydrous	solution	(MeCN/CH2Cl2,	1:1),	0.85	mL	(2.5	mmol)	 of	 dibenzyl-N,	 N-diisopropylphosphoramidite	 for	 1	 hour	 stirring	 at	 room	temperature.	Then,	the	reaction	was	added	to	6	mL	of	H2O2	for	1	hour	oxidation	reaction.	Column	 chromatography	 with	 eluents	 (EtOAc/hexane,	 from	 33%	 to	 66%)	 to	 afford	 the	product	5.9d	as	a	white	foam;	yield:	1.35	g	(85.9	%);	TLC	(EtOAc/hexane,	1:60)	Rf	=	0.32;	1H	NMR	(400	MHz,	CDCl3)	δ	12.51	(s,	1H),	11.03	(s,	1H),	8.14	(d,	2H,	J	=	6.0	Hz),	8.06	(d,	2H,	J	=	16.0	Hz),	7.73	(s,	1H),	7.62-7.60	(m,	2H),	7.50-7.45	(m,	4	H),	7.33	(m,	5H),	7.26-7.22	(m,	1H),	7.19-7.16	(m,	1H),	7.00	(d,	2H,	J	=	16.0	Hz),	6.25	(dd,	1H,	J	=	12.0,	2.8	Hz),	5.70	(d,	1H,	J	=	4.4	Hz),	5.08	(d,	2H,	J	=	4.4	Hz),	4.80	(m,	2H),	4.56	(m,	1H),	4.43	(s,	1H),	4.35	(m,	1H),	3.60	(m,	1H),	2.51	(s,	1H);	 13C	NMR	(125.8	MHz,	CDCl3)	δ	169.2,	166.0,	155.7,	148.2,	148.1,	139.5,	135.4,	135.1,	135.0,	133.8,	133.2,	132.1,	129.8,	129.3,	128.9,	128.8,	128.7,	128.6,	128.5,	128.3,	128.2,	128.2,	127.3,	127.3,	123.5,	86.8,	83.2,	75.8,	69.9	(d,	J	C,P	=	5.3	Hz),	69.4	(d,	J	C,P	=	5.2	Hz),	66.8,	35.5;	31P	NMR	(162	MHz,	CDCl3)	δ	-0.55;	HRMS	(ESI-TOF)	calcd.	for	C38H34N5O9PNa	[M+Na]+	758.1992;	found	758.2000.	
	
3’-O,	N2-Dibenzoyl-2’-deoxyguanosine-5’-monophosphate	(5.10d)	General	procedure	B	with	0.88	g	(1.2	mmol)	of	5.9d,	10	mL	of	MeOH,	and	250	mg	of	10%	Pd/C	for	3	hours	with	stirring.	The	suspension	was	filtered	over	a	pad	of	celite,	washed	with	100	mL	of	MeOH	containing	2%	triethylamine	four	times	to	afford	the	product	5.10d	as	a	
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white	foam	of	triethylammonium	salt;	yield:	0.72	g	(84.5	%);	TLC	(MeOH/CH2Cl2	1:10	with	1%	triethylamine);	1H	NMR	(400	MHz,	DMSO-d6)	δ	8.28	(s,	1H),	8.18	(d,	2H,	J	=	6.4	Hz),	8.03	(m,	2H),	7.70-7.62	(m,	1H),	7.61-7.59	(m,	1H),	7.57-7.54	(m,	2H),	7.51	(m,	2H),	6.44	(m,	1H),	5.71	(d,	1H,	J	=	3.6	Hz),	4.38	(s,	1H),	4.12	(m,	1H),	4.02	(m,	1H),	3.35	(m,	1H),	2.56	(dd,	1H,	J	=	15.6,	6.8	Hz).	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	169.8,	165.1,	155.2,	148.8,	139.2,	133.6,	132.8,	132.7,	129.4,	129.3,	128.8,	128.7,	128.2,	128.0,	126.8,	121.1,	84.6,	83.7,	76.8,	63.9,	30.5;	
31P	NMR	(162	MHz,	CD3OD)	δ	-0.34;	HRMS	(ESI-TOF)	calcd.	for	C24H21N5O9PNa2	[M-H+2Na]+	600.0872;	found	600.0865.		
3’-O,	N2-Dibenzoyl-2’-deoxyguanosine-5’-phosphor-2-methylimidazolide	(5.11d).	General	procedure	C	with	0.65	g	(1.2	mmol)	of	5.10d,	10	mL	of	anhydrous	DMF,	0.82	mL	(7.2	mmol)	of	triethylamine,	240	mg	(5.6	mmol)	of	2-methylimidazole,	768.3	mg	(2.9	mmol)	of	triphenylphosphine,	645.5	mg	(2.93	mmol)	of	dipyridyl	disulfide	for	2	hours	reaction	at	room	 temperature.	 First	 precipitation	 was	 achieved	 with	 300	 mL	 of	 diethyl	 ether.	 The	product	 was	 resuspended	 with	 15	 mL	 of	 CH2Cl2	 and	 dropwise	 added	 to	 the	 solution	containing	1.17	g	of	sodium	perchlorate,	15	mL	of	triethylamine	in	300	mL	of	ethyl	acetate	for	 second	 precipitation.	 The	 product	was	 afforded	 as	 a	white	 solid	5.11d;	 yield:	 0.68	 g	(93.4%);	31P	NMR	(162	MHz,	D2O)	δ	-8.70;	HRMS	(ESI-TOF)	calcd.	For	C28H25N7O8PNa2	[M-H+2Na]+	664.1298;	found	664.1276.		
3’-O,-N2-Dibenzoyl-2’-deoxyadenosine-5’-(γ-(2-(pyrenesulfonyl)ethyl))-	triphosphate	
(5.12d).	
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General	 procedure	 D	 with	 0.5	 g	 (0.81	 mmol)	 of	 5.11d,	 0.495	 g	 (1.0	 mmol)	 of	 1-(2-	(pyrenesulfonyl)ethyl)-pyrophosphate	(5.7)	and	5.38	mL	(8.0	mmol)	of	ZnCl2	solution	(1.5	M	in	anhydrous	DMF)	for	3	h	with	stirring.	After	the	reaction,	the	solution	was	precipitated	by	300	mL	of	ether.	Silica	column	chromatography	with	eluents	[(H2O	in	isopropanol/MeCN)	1:1	from	3%	to	8	%	containing	1%	diisopropylethylamine	(DIPEA)]	to	afford	the	white	solid	
5.12d;	yield:	1.07	g	(58.1	%);	TLC	(H2O/acetonitrile	1:10	containing	2%	DIPEA)	Rf	=	0.34;	
1H	NMR	(400	MHz,	DMSO-d6)	δ	7.90-7.60	(m,	1H),	7.31	(s,	6H),	7.03-6.98	(m,	5H),	6.72	(m,	3H),	6.52	(s,	4H),	5.32	(s,	1H),	4.62	(s,	1H),	3.36	(brs,	2H),	3.16	(brs,	2H),	2.87	(s,	1H),	2.09	(s,	2H);	 31P	 NMR	 (162	 MHz,	 DMSO-d6)	 δ	 -11.34,	 -12.12,	 -20.44;	 HRMS	 (ESI-TOF)	 calcd.	 for	C42H34N5O17P3SNa	[M-2H+Na]-	1028.0781;	found	1028.0796.		
2’-deoxyguanosine-5’-triphosphate	(5.13d).	General	procedure	E	with	800	mg	(0.	81	mmol)	of	5.12d	in	45	mL	of	33%	NH4OH(aq)	for	3	hours	at	37	oC	and	then	15	hours	deprotection	reaction	at	room	temperature.	The	product	
5.13d	was	afforded	as	a	white	solid;	yield:	372	mg	(91.1	%,	G,	ε253:	13700	M−1cm−1);	1H	NMR	(400	MHz,	D2O)	δ	8.15	(m,	1H),	6.32	(s,	1H),	4.27	(s,	1H),	4.19	(m,	2H),	4.15	(s,	1H),	2.79	(brs,	1H),	2.52	(s,	1H);	31P	NMR	(162	MHz,	D2O)	δ	-5.80	(d,	J	=	15.7	Hz),	-	10.86	(d,	J	=	16.0	Hz),	-20.59	(t,	J	=	13.3	Hz).		
Scheme	5.6:	Synthesis	of	2’-deoxythymidine-3’-triphosphate	(3’-TTP,	5.19)				
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(Scheme	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)		
5’-Benzoyl-2’-deoxythymidine-3’-dibenzylmonophosphate	(5.15).	General	procedure	A	with	1.04	g	(3.0	mmol)	of	5’-benzoyl-2’-deoxythymidine	5.14,	383	mg	(5.4	mmol)	of	tetrazole,	30	mL	of	anhydrous	solution	(MeCN/CH2Cl2,	1:1),	1.23	mL	(3.91	mmol)	 of	 dibenzyl-N,	 N-diisopropylphosphoramidite	 for	 3	 hours	 reaction	 at	 room	temperature.	Then	8	mL	of	30%	H2O2(aq)	for	1	hour	reaction	at	room	temperature.	Column	chromatography	with	eluents	(MeOH/CH2Cl2,	from	1%	to	1.4	%)	to	afford	the	product	5.15	as	a	white	solid;	yield:	1.28	g	(70.3	%);	TLC	(MeOH/CH2Cl2,	1:40)	Rf	=	0.22;	1H	NMR	(400	MHz,	CDCl3)	δ	9.46	(s,	1H),	7.97	(d,	2H,	J	=	8.0	Hz),	7.61-7.57	(m,	1H),	7.45	(t,	2H,	J	=	7.2	Hz),	
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7.35-7.31	(m,	10H),	7.08	(s,	1H),	6.25	(dd,	1H,	J	=	7.6,	6.4	Hz),	5.11-4.97	(m,	5H),	4.56	(dd,	1H,	
J	=	13.2,	3.6	Hz),	4.33-4.29	(m,	2H),	2.48	(dd,	1H,	J	=	14.4,	5.6	Hz),	2.11-2.06	(m,	1H),	1.57	(s,	3H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	165.7,	163.8,	150.4,	135.3,	135.2,	134.3,	133.5,	129.3,	129.2,	128.7,	128.7,	128.6,	128.6,	128.1,	128.1,	111.4,	84.5,	82.6	(d,	J	C,P	=	5.4	Hz),	69.8,	69.8,	69.8,	63.6,	38.6	(d,	J	C,P	=	4,7	Hz),	12.0;	31P	NMR	(162	MHz,	CDCl3)	δ	-0.31;	HRMS	(ESI-TOF)	calcd.	for	C31H31N2O9PNa	[M+Na]+	629.1665;	found	629.1666.		
5’-Benzoyl-2’-deoxythymidine-3’-monophosphate	(5.16).	General	procedure	B	with	1.28	g	(2.1	mmol)	of	5.15,	50	mL	of	MeOH,	and	200	mg	of	10%	Pd/C	for	3	hours	with	stirring	at	room	temperature.	The	suspension	was	filtered	over	a	pad	of	celite,	washed	with	100	mL	of	MeOH	four	times	to	afford	the	product	5.16	as	a	white	foam;	yield:	0.86	g	(96.2%);	TLC	(MeOH/CH2Cl2,	1:10)	Rf	=	0;	1H	NMR	(400	MHz,	CD3OD)	δ	8.06	(d,	2H,	J	=	7.2	Hz),	7.64	(t,	1H,	J	=	7.6	Hz),	7.51	(t,	2H,	J	=	7.6	Hz),	7.39	(s,	1H),	6.29	(m,	1H),	5.10	(t,	1H,	J	=	6.8	Hz),	4.70	(dd,	1H,	J	=	12.0,	3.2	Hz),	4.57-4.47	(m,	2H),	2.63	(ddd,	1H,	J	=	14.0,	6.0,	2.4	Hz),	2.43	(m,	1H),	1.62	(s,	3H);	13C	NMR	(125.8	MHz,	CD3OD)	δ	167.4,	166.1,	152.1,	137.0,	134.6,	130.8,	130.5,	129.8,	111.8,	86.4,	84.6,	77.2,	65.1,	39.5,	12.2;	31P	NMR	(162	MHz,	CD3OD)	δ	0.42;	HRMS	(ESI-TOF)	calcd.	For	C17H18N2O9PNa2	 [M-H+2Na]+	471.0545;	 found	471.0551.		
5’-Benzoyl-2’-deoxythymidine-3’-phosphor-2-methylimidazolide	(5.17).	General	procedure	C	with	0.86	g	(2.0	mmol)	of	5.16,	10	mL	of	anhydrous	DMF,	1.39	mL	(10.0	mmol)	of	triethylamine,	328	mg	(4.1	mmol)	of	2-methylimidazole,	1.05	g	(4.0	mmol)	of	 triphenylphosphine,	 903	 g	 (4.0	 mmol)	 of	 dipyridyl	 disulfide.	 First	 precipitation	 was	
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achieved	in	250	mL	of	diethyl	ether.	The	product	was	resuspended	with	10	mL	of	DMF	and	dropwise	 added	 to	 the	 solution	 containing	 2.0	 g	 of	 sodium	 perchlorate,	 20	 mL	 of	triethylamine	 in	 400	mL	 of	 ethyl	 acetate	 for	 the	 second	 precipitation.	 The	 product	 was	afforded	as	a	white	solid	5.17;	yield:	0.89	g	(86.9%);	31P	NMR	(162	MHz,	D2O)	δ	-7.57;	HRMS	(ESI-TOF)	calcd.	for	C21H23N4O8PNa	[M+Na]+	513.1151;	found	513.1158.		
	
5’-Benzoyl-2’-deoxythymidine-3’-γ-(2-(pyrenesulfonyl)ethyl)triphosphate	 (5.18).	General	 procedure	 D	 with	 0.89	 g	 (1.7	 mmol)	 of	 5.16,	 0.89	 g	 (1.9	 mmol)	 of	 1-(2-	(pyrenesulfonyl)ethyl))	pyrophosphate	(7)	and	11.5	mL	(17.30	mmol)	of	ZnCl2	solution	(1.5	M	 in	 anhydrous	 DMF)	 for	 3	 hours	 with	 stirring	 at	 room	 temperature.	 The	 product	 was	purified	by	2.5	cm	silica	gel	flash	column	with	eluents	[H2O-isopropanol	from	5%	to	10	%	containing	1%	diisopropylethylamine	(DIPEA)]	to	afford	the	yellowish	solid	5.18;	yield:	1.23	g	(55.8%);	TLC	(1:10	H2O-acetone/2%-DIPEA):	Rf	=30.8;	1H	NMR	(400	MHz,	D2O)	δ	8.25	(d,	1H,	J	=	8.8	Hz),	8.11	(d,	1H,	J	=	6.4	Hz),	7.47	(d,	1H,	J	=	8.0	Hz),	7.36-7.34	(m,	4H),	7.15-7.07	(m,	2H),	6.94-6.79	(m,	5H),	6.26	(s,	1H),	5.12	(s,	1H),	4.85	(s,	1H),	4.48-4.25	(m,	5H),	3.80	(s,	2H),	2.35	(s,	1H),	1.84	(s,	1H),	0.66	(s,	3H);	31P	NMR	(162	MHz,	D2O)	δ	-10.56	(d,	1P,	J	=	12.5	Hz),	 -11.07	 (d,	 1P,	 J	 =	 14,1	 Hz),	 -20.85	 (brs,	 1P);	 HRMS	 (ESI-TOF)	 calcd.	 for	C35H30N2O17P3SNa4	[M-3H+4Na]+	967.0069;	found	967.0080.		
2’-deoxythymidine-3’-triphosphate	(5.19).	General	procedure	E	with	1.23	g	of	5.18,	5mL	of	CH2Cl2	and	50	mL	of	33%	NH4OH(aq)	for	18	hours	deprotection	at	room	temperature.	The	product	5.19	was	afforded	as	a	white	solid;	yield:	404	mg	(86%,	ε267	=	9600	M-1cm-1);	1H	NMR	(400	MHz,	D2O)	δ	7.74	(s,	1H),	6.40	
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(t,	1H,	J	=	7.6	Hz),	5.05	(s,	1H),	4.34	(d,	1H,	J	=	2.8	Hz),	3.92	(d,	2H,	J	=	3.6	Hz),	2.70-	2.65	(m,	1H),	2.54-2.47	(m,	1H),	1.96	(s,	3H);	31P	NMR	(162	MHz,	D2O)	δ	-4.03	(d,	1P,	J	=	17.0	Hz),	-9.99	(d,	1P,	J	=	16.7	Hz),	-18.47	(brs,	1P).	
	
Scheme	 5.7:	 Synthesis	 of	 1-(α-L-threofuranosyl)thymidine-3’-triphosphate	 (tTTP,	
5.25a)	
	 												
(Scheme	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,		141,	34,	13286-13289)	
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1-(2’-O-benzoyl-α-L-threofuranosyl)thymidine-3’-dibenzylmonophosphate	(5.21a).	General	 procedure	 A	 with	 1g	 (3.0	 mmol)	 of	 1-(2’-O-benzoyl-α-L-threofuranosyl)	thymine,4	379.7	mg	(5.4	mmol)	of	tetrazole,	24	mL	of	anhydrous	solution	(MeCN/CH2Cl2,	1:1),	1.24	mL	(3.9	mmol)	of	dibenzyl-N,	N-diisopropylphosphoramidite	for	3	hours	stirring	at	 room	 temperature	 and	 6	mL	 of	 H2O2	 for	 1	 hour	 oxidation	 reaction.	 Silica	 gel	 column	chromatography	 with	 eluents	 (MeOH/CH2Cl2,	 from	 0	 to	 2%).	 The	 product	 5.21a	 was	acquired	 as	 a	white	 solid;	 yield:	 1.25	 g	 (70.1	%).	 This	 is	 a	 known	 compound	 previously	reported	in	the	literature.5	
1-(2’-O-benzoyl-α-L-threofuranosyl)thymidine-3’-monophosphate	(5.22a)	General	procedure	B	with	1.25	g	(2.1	mmol)	of	5.21a,	50	mL	of	MeOH,	and	200	mg	of	10%	Pd/C	for	3	hours	stirring.	The	suspension	was	filtered	over	a	pad	of	celite,	washed	with	100	mL	of	MeOH	four	times.	The	product	5.22a	was	afforded	as	a	white	foam;	yield:	0.83	g	(92.4%);	TLC	(MeOH/CH2Cl2,	1:10)	Rf	=	0;	1H	NMR	(400	MHz,	CD3OD)	δ	8.05	(d,	1H,	J	=	7.6	Hz),	7.64	(t,	1H,	J	=	7.2	Hz),	7.57	(s,	1H),	7.50	(t,	2H,	J	=	7.2	Hz),	6.05	(s,	1H),	5.60	(s,	1H),	5.01	(s,	1H),	4.52	(d,	1H,	J	=	10.4	Hz),	4.29	(d,	1H,	J	=	9.2	Hz),	1.92	(s,	3H);	13C	NMR	(125.8	MHz,	CD3OD)	δ	166.3,	152.2,	138.0,	134.9,	130.9,	130.1,	129.7,	111.7,	91.2,	82.1	(d,	J	C,P	=	5.9	Hz),	79.0,	 74.7,	 12.5;	 31P	 NMR	 (162	 MHz,	 CDCl3)	 δ	 -0.23;	 HRMS	 (ESI-TOF)	 calcd.	 for	C16H17N2O9PNa	[M+Na]+	435.0569;	found	435.0557.		
1-(2’-O-benzoyl-α-L-threofuranosyl)thymidine-3’-monophosphor-2-	
methylimidazolide	(5.23a)	General	procedure	C	with	0.83	g	(2	mmol)	of	5.22a,	7.0	mL	of	anhydrous	DMF,	1.40	mL	(10.1	mmol)	of	triethylamine,	328	mg	(4	mmol)	of	2-methylimidazole,	1.05	g	(4	mmol)	of	
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triphenylphosphine,	0.88	g	(4	mmol)	of	dipyridyl	disulfide.	First	precipitation	was	achieved	with	 250	mL	 of	 diethyl	 ether.	 The	 product	 was	 resuspended	with	 15	mL	 of	 CH2Cl2	 and	dropwise	 added	 to	 the	 solution	 containing	 2.01	 g	 of	 sodium	 perchlorate,	 10	 mL	 of	triethylamine	in	300	mL	of	ethyl	acetate	for	the	second	precipitation.	The	product	5.23a	was	afforded	as	a	white	solid;	yield:	0.98	g	(98.3%);	31P	NMR	(162	MHz,	D2O)	δ	-8.17;	HRMS	(ESI-TOF)	calcd.	for	C20H21N4O8PNa	[M+Na]+	499.0995;	found	499.0992.			
1-(2’-O-benzoyl-α-L-threofuranosyl)thymidine-3’-(γ-(2-(pyrenesulfonyl)ethyl))	
triphosphate	(5.24a)	General	procedure	D	with	0.98	g	(1.9	mmol)	of	5.23a,	1.11	g	(2.4	mmol)	of	7	and	13.13	mL	 (19.7	mmol,	 1.5	M	 in	 anhydrous	DMF)	of	 ZnCl2	 solution	 for	3	hours	 stirring	 at	 room	temperature.	 The	 product	 was	 purified	 by	 2	 cm	 silica	 gel	 column	 chromatography	with	eluents	[H2O-isopropanol	from	5%	to	12.5	%	containing	1%	diisopropylethylamine	(DIPEA)]	to	 afford	 the	white	 solid	5.24a;	 yield:	 1.53	 g	 (62.1%);	 TLC	 (1:10	H2O-acetone	with	 2%-DIPEA):	Rf	=	0.25;	1H	NMR	(400	MHz,	D2O)	δ	8.22	(d,	1H,	J	=	9.2	Hz),	8.09	(d,	1H,	J	=	8.0	Hz),	7.48-7.30	(m,	7H),	7.09-6.98	(m,	4H),	6.84	(t,	2H,	J	=	6.8	Hz),	5.32	(s,	1H),	5.20	(s,	1H),	4.89	(s,	1H),	4.48-4.40	(m,	3H),	3.97	(d,	1H,	J	=	8.0	Hz),	3.76	(m,	2H),	1.50	(s,	3H);	31P	NMR	(162	MHz,	D2O)	δ	-10.23	(d,	J	=	13.0	Hz),	-11.65	(d,	J	=	13.9	Hz),	-	20.59	(brs);	HRMS	(ESI-TOF)	calcd.	for	C34H29N2O17P3SNa3	[M-2H+3Na]+	931.0093;	found	931.0049.		
1-(α-L-threofuranosyl)thymidine-3’-triphosphate	(5.25a)	
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General	procedure	E	with	1.53	g	(1.2	mmol)	of	5.24a	in	50	mL	of	33%	NH4OH(aq)	for	18	hours	deprotection	at	room	temperature.	The	product	5.25a	was	afforded	as	a	white	solid;	yield:	445	mg	(78.9%,	ε267	=	9600	M-1cm-1);	1H	NMR	(400	MHz,	D2O)	δ	7.62	(s,	1H),	5.85	(s,	1H),	4.90	(s,	1H),	4.61	(s,	1H),	4.51	(d,	1H,	J	=	10.4	Hz),	4.40	(d,	1H,	J	=	9.2	Hz),	1.95	(s,	1H);	
31P	NMR	(162	MHz,	D2O)	δ	-4.89	(d,	J	=	14.7	Hz),	-11.02	(d,	J	=	18.63	Hz),	-	19.80	(brs).		
Scheme	 5.8:	 Synthesis	 of	 1-(α-L-threofuranosyl)cytidine-3’-triphosphate	 (tCTP,	
5.25b)	
	 												
(Scheme	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)	
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N4-Benzoyl-1-(2’-O-benzoyl-α-L-threofuranosyl)cytidine-3’-dibenzylmonophosphate	
(5.21b)	Modified	general	procedure	A5	with	1g	(2.4	mmol)	of	N4-benzoyl-1-(2’-O-benzoyl-α-L-threofuranosyl)	cytosine	(5.20b),4	300	mg	(4.3	mmol)	of	tetrazole,	15.8	mL	of	anhydrous	solution	 (MeCN/CH2Cl2,	 1:1),	 0.98	 mL	 (3.1	 mmol)	 of	 dibenzyl-N,	 N-diisopropylphosphoramidite	for	1	hour	reaction	at	room	temperature	and	5	mL	of	H2O2	for	1	hour	oxidation	 reaction.	After	 the	 reaction,	 the	product	5.21b	was	afforded	as	 a	white	solid;	yield:	1.29	g	(79.3	%).	Additional	compound	characterization.5	
	
N4-Benzoyl-1-(2’-O-benzoyl-α-L-threofuranosyl)cytidine-3’-monophosphate	(5.22b).	General	procedure	B	with	1.29	g	(1.9	mmol)	of	5.21b,	50	mL	of	MeOH,	and	250	mg	of	10%	Pd/C	for	5	hours	stirring.	The	suspension	was	filtered	over	a	pad	of	celite,	washed	with	100	mL	of	MeOH	containing	2%	triethylamine	four	times.	The	product	5.22b	was	afforded	as	a	white	foam	of	a	triethylammonium	salt;	yield	1.23	g	(92.8%);1H	NMR	(400	MHz,	CDCl3)	δ	8.26	(d,	1H,	J	=	7.6	Hz),	7.99	(d,	2H,	J	=	7.2	Hz),	7.90	(d,	2H,	J	=	7.6	Hz),	7.57-7.53	(m,	2H),	7.47-7.39	(m,	5H),	6.18	(s,	1H),	5.66	(s,	1H),	4.91-4.85	(m,	2H),	4.28	(dd,	1H,	J	=	10.4,	3.2	Hz);	
13C	NMR	(125.8	MHz,CDCl3)	δ	164.6,	162.7,	154.9,	146.2,	133.5,	132.9,	129.9,	129.3,	128.9,	128.9,	128.5,	128.0,	128.0,	96.6,	91.4,	80.9	(d,	J	C,P	=	6.5	Hz),	76.4	(d,	J	C,P	=	4.7	Hz),	57.9;	31P	NMR	 (162	MHz,	 CDCl3)	 δ	 -1.15;	HRMS	 (ESITOF)	 calcd.	 for	 C20H20N3O9PNa3	 [M-2H+3Na]+	546.0630;	found	546.0640.		
N4-Benzoyl-1-(2’-O-benzoyl-α-L-threofuranosyl)cytidine-3’-monophosphor-2-	
methylimidazolide	(5.23b)	
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General	procedure	C	with	1.02	g	(1.8	mmol)	of	5.22b,	4.3	mL	of	anhydrous	DMF,	0.87	mL	(6.4	mmol)	of	triethylamine,	287	mg	(3.5	mmol)	of	2-methylimidazole,	0.94	g	(3.6	mmol)	of	triphenylphosphine,	0.79	g	 (3.6	mmol)	of	dipyridyl	disulfide	 for	2	hours	 stirring	at	 room	temperature.	First	precipitation	was	achieved	with	200	mL	of	diethyl	ether.	The	product	was	resuspended	with	15	mL	of	CH2Cl2	and	dropwise	added	to	the	solution	containing	2.04	g	of	sodium	 perchlorate,	 10	 mL	 of	 triethylamine	 in	 300	 mL	 of	 ethyl	 acetate	 for	 the	 second	precipitation.	The	product	5.23b	was	afforded	as	a	white	solid;	yield:	0.94	g	(91.5%);	31P	NMR	(162	MHz,	D2O)	δ	-7.56;	HRMS	(ESI-TOF)	calcd.	for	C26H24N5O8PNa	[M+Na]+	588.1260;	found	588.1246.	
N4-Benzoyl-1-(2’-O-benzoyl-α-L-threofuranosyl)cytidine-3’-(γ-(2-
(pyrenesulfonyl)ethyl)	triphosphate	(5.24b)	General	procedure	D	with	0.94	g	(1.6	mmol)	of	5.23b,	0.9	g	(1.9	mmol)	of	7	and	10.67	mL	(16	 mmol,	 1.5	 M	 in	 anhydrous	 DMF)	 of	 ZnCl2	 solution	 for	 5	 hours	 stirring	 at	 room	temperature.	 The	 product	 was	 purified	 by	 silica	 gel	 chromatography	 with	 eluents	 [(6%	H2O/isopropanol	containing	1%	DIPEA)	and	then	(5%	to	10%	of	H2O/(isopropanol-MeCN	1:1))	containing	1%	diisopropylethylamine	(DIPEA)	to	afford	the	white	solid	5.24b;	yield:	1.43	g	(66.7%);	TLC	(1:10	H2O-acetone	with	2%-DIPEA)	Rf	=	0.25;	1H	NMR	(400	MHz,	D2O)	δ	8.18	(s,	1H),	8.04	(s,	1H),	7.63-7.25	(m,	13H),	7.14	(s,	3H),	6.95-6.91	(m,	4H),	6.64	(s,	1H),	5.57	(s,	1H),	5.41	(s,	1H),	4.94	(s,	1H),	4.63	(s,	1H),	4.44	(s,	2H),	4.23	(s,	1H),	3.74-3.63	(m,	2H);	31P	NMR	(162	MHz,	D2O)	δ	-10.23	(d,	J	=	13.0	Hz),	-11.65	(d,	J	=	13.9	Hz),	-20.59	(brs);	HRMS	(ESI-TOF)	calcd.	for	C40H32N3O17P3SNa	[M+Na]+	974.0563;	found	974.0620.		
1-(α-L-threofuranosyl)cytidine-3’-triphosphate	(5.25b)	
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General	procedure	E	with	1.43	g	(1.0	mmol)	of	5.24b	in	50	mL	of	33%	NH4OH(aq)	for	3	hours	at	37	oC	and	then	15	hours	deprotection	reaction	at	room	temperature.	The	product	
5.25b	was	afforded	as	a	white	solid;	yield:	412	mg	(85.8%,	ε280	=	13100	M-1cm-1);	1H	NMR	(400	MHz,	D2O)	δ	7.82	(d,	1H,	J	=	7.6	Hz),	6.09	(d,	1H,	J	=	7.6	Hz),	5.90	(s,	1H),	4.91	(d,	1H,	J	=	4.8	Hz),	4.58-4.53	(m,	2H),	4.42	(d,	1H,	J	=	6.8	Hz);	31P	NMR	(162	MHz,	D2O)	δ	-4.26	(brs),	-10.93	(d,	J	=	17.3	Hz),	-19.15	(brs).		
Scheme	 5.9:	 Synthesis	 of	 9-(α-L-threofuranosyl)adenosine-3’-triphosphate	 (tATP,	
5.25c)	
	
	
	
	
	
	
	
	
	
	
	
	
	
(Scheme	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)	
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N6-Benzoyl-9-(2’-O-benzoyl-α-L-threofuranosyl)adenosine-3’-dibenzyl	
monophosphate	(5.21c)	General	 procedure	 A	 with	 1.0	 g	 (2.3	 mmol)	 of	 N6-benzoyl-9-(2’-O-benzoyl-α-L-threofuranosyl)	 adenine	 (5.20c),	 4	 3	 mg	 (4.5	 mmol)	 of	 tetrazole,	 15	 mL	 of	 anhydrous	solution	 (MeCN/CH2Cl2,	 1:1),	 0.91	 mL	 (2.7	 mmol)	 of	 dibenzyl-N,	 N-diisopropylphosphoramidite	for	3	hours	reaction	at	room	temperature	and	5	mL	of	H2O2	for	1	hour	oxidation	reaction.	The	product	5.21c	afford	as	a	white	solid;	yield:	1.41	g	(88.4	%).	Additional	compound	characterization.5	
N6-Benzoyl-9-(2’-O-benzoyl-α-L-threofuranosyl)adenosine-3’-monophosphate	
(5.22c)	General	procedure	B	with	1.3	g	(1.8	mmol)	of	5.21c,	10	mL	of	MeOH,	and	400	mg	of	10%	Pd/C	for	12	hours	with	stirring.	The	suspension	was	filtered	over	a	pad	of	celite,	washed	with	100	mL	of	MeOH	four	times.	The	product	5.22c	was	afford	as	a	white	solid;	yield:	943	mg	(97.4%);1H	NMR	(400	MHz,	CD3OD):	δ	8.98	(s,	1H),	8.91	(s,	1H),	8.26-8.17	(m,	4H),	7.83-7.80	(m,	2H),	7.74-7.65	(m,	4	H),	6.68	(s,	1H),	6.18	(s,	1H),	5.33	(s,	1H),	4.88-4.85	(m,	1H),	4.66	(dd,	1H,	J	=	14,	6.4	Hz).	13C	NMR	(125.8	MHz,	DMSO-d6):	δ	164.7,	151.9,	150.4,	142.8,	133.9,	133.3,	132.4,	129.6,	129.0,	128.7,	128.4,	128.4,	125.3,	109.4,	87.0,	80.3,	76.2,	72.6;	31P	NMR	(162	MHz,	DMSO-d6)	δ:	0.30;	HRMS	(ESI-TOF)	calcd.	For	C23H21N5O8P	[M	+	H]+	526.1128;	found	526.1118.		
N6-Benzoyl-9-(2’-O-benzoyl-α-L-threofuranosyl)adenosine-3’-monophosphor-2-	
methylimidazolide	(5.23c)	
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General	procedure	C	with	0.93	g	(1.6	mmol)	of	5.22c,	12	mL	of	anhydrous	DMF,	1.1	mL	(7.9	mmol)	of	triethylamine,	284	mg	(3.9	mmol)	of	2-methylimidazole,	1.03	g	(3.9	mmol)	of	triphenylphosphine,	0.87	g	(3.9	mmol)	of	dipyridyl	disulfide.	First	precipitation	was	achieved	with	150	mL	of	diethyl	ether.	The	product	was	resuspended	with	5	mL	of	CH2Cl2	and	dropwise	added	to	the	solution	containing	1.5	g	of	sodium	perchlorate,	6	mL	of	triethylamine	in	150	mL	of	ethyl	acetate	for	the	second	precipitation.	The	product	afford	as	a	white	solid	5.23c;	yield:	0.89	g	(93.0	%);	31P	NMR	(162	MHz,	DMSO-d6)	δ:	-9.80;	HRMS	(ESI-TOF)	calcd.	for	C27H24N7O7PNa	[M	+	Na]+	612.1373;	found	612.1345.		
N6-Benzoyl-9-(2’-O-benzoyl-α-L-threofuranosyl)adenosine-3’-γ-[2-	
(pyrenesulphonyl)ethyl]	triphosphate	(5.24c)	General	procedure	D	with	0.6	g	(1.02	mmol)	of	5.23c,	0.52	g	(1.1mmol)	of	7	and	7	mL	(10.1	 mmol,	 1.5	 M	 in	 anhydrous	 DMF)	 of	 ZnCl2	 solution	 for	 3	 hours	 stirring	 at	 room	temperature.	The	product	was	purified	by	silica	gel	chromatography	with	eluents	[MeOH-CHCl3	from	5%	to	12	%	containing	1%	diisopropylethylamine	(DIPEA)]	to	afford	the	white	solid	5.24c;	yield	0.64	g	(63.1	%);	TLC	(1:10	H2O-acetone	with	2%-DIPEA)	Rf	=	0.31;	1H	NMR	(400	MHz,	D2O)	δ	9.50	(s,	1H),	9.18-7.56	(m,	7H),	7.51-7.46	(m,	6H),	7.35-7.09	(m,	9H),	6.19	(m,	1H),	5.72	(m,	1H),	4.72-4.52	(m,	1H),	3.48	(s,	2H),	2.99	(d,	2H,	J=12	Hz);	31P	NMR	(162	MHz,	D2O)	δ	-9.21	(d,	J	=	12.9	Hz),	-10.51	(d,	J	=	13.0	Hz),	-19.24	(brs);	HRMS	(ESI-TOF)	calcd.	for	C41H32N5O16P3SNa	[M-2H+Na]-	998.0676;	found	998.0667.		
9-(α-L-threofuranosyl)adenosine-3’-triphosphate	(5.25c)	
170		
General	procedure	E	with	0.5	g	(0.5	mmol)	of	5.24c,	35	mL	of	33%	NH4OH(aq)	for	3	hours	deprotection	at	37	oC,	and	then	15	hours	deprotection	reaction	at	room	temperature.	The	product	was	afforded	as	a	white	solid;	yield:	0.21	g	(86.2	%,	ε280	=	15200	M-1cm-1);	1H	NMR	(400	MHz,	D2O)	δ	8.36	(s,	1H),	8.27	(s,	1H),	6.16	(s,	1	H),	5.09	(d,	1	H,	J	=	8.0	Hz),	4.96	(s,	1H),	4.50	(s,	2H);	31P	NMR	(162	MHz,	D2O)	δ	-4.02	(d,	J	=	16.6	Hz),	-10.51	(d,	J	=	16.2	Hz)	,	-17.77	(brs).	
Scheme	 5.10:	 Synthesis	 of	 9-(α-L-threofuranosyl)guanosine-3’-triphosphate	 (tGTP,	
5.25d)	
	
	
	
	
	
	
	
	
	
	
	
	
(Scheme	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)	
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N2-Acetyl-9-(2’-O-benzoyl-α-L-threofuranosyl)guanosine-3’-dibenzylmonophosphate	
(5.21d)	General	 procedure	 A	 with	 1	 g	 (1.7	 mmol)	 of	 N2-acetyl-9-(2’-O-benzoyl-α-L-threofuranosyl)	 guanine	 (5.20d),4	 212	mg	 (3.0	mmol)	 of	 tetrazole,	 12	mL	 of	 anhydrous	solution	 (MeCN/CH2Cl2,	 1:1),	 735	 mL	 (2.2	 mmol)	 of	 dibenzyl-N,	 N-diisopropylphosphoramidite	for	3	hours	reaction	at	room	temperature	and	6	mL	of	H2O2	for	1	 hour	 oxidation.	 Column	 chromatography	 with	 eluents	 (EtOAc/Hexane,	 50%;	 then	EtOAc/CH2Cl2,	from	16%	to	25%)	to	afford	the	product	5.21d	as	a	white	solid;	yield:	1.14	g	(79.4	%).	TLC	(EtOAc/CH2Cl2,	1:4)	Rf	=	0.44;	This	is	a	known	compound	previously	reported	in	the	literature.5	
	
N2-Acetyl-9-(2’-O-benzoyl-α-L-threofuranosyl)guanosine-3’-monophosphate	(5.22d)	General	procedure	B	with	1.63	g	(2.5	mmol)	of	5.21d,	15	mL	of	MeOH,	and	600	mg	of	10%	Pd/C	for	3	hours	stirring.	The	suspension	was	filtered	over	a	pad	of	celite,	washed	with	100	mL	of	MeOH	four	times.	The	product	5.22d	was	afford	as	a	white	solid;	yield;	1.04	g	(87.7	%).1H	NMR	(400	MHz,	DMSO-d6):	δ	12.1	(s,	1H),	11.68	(s,	1H),	8.13	(s,	1H),	8.04-	8.02	(m,	2H),	7.74-7.70	(m,	1H),	7.59-7.55	(m,	2H),	6.11	(d,	1H,	J	=	4	Hz),	5.86	(s,	1H),	5.09	(d,	1H,	
J	=	2.4	Hz)	4.47-4.45	(m,	1H),	4.38-4.34	(m,	1H),	2.15	(s,	3H);	13C	NMR	(125.8	MHz,	DMSO-	
d6):	δ	173.5,	164.5,	154.8,	148.4,	148.1,	137.7,	134.1,	129.6,	128.9,	128.3,	119.9,	86.9,	80.6,	76.5,	72.8,	48.6,	23.8;	 31P	NMR	(162	MHz,	DMSO-d6):	δ	 	 -0.89;	HRMS	(ESI-TOF)	calcd.	 for	C18H18N5O9PNa	[M	+	Na]+	502.0740;	found	502.0727.		
N2-Acetyl-9-(2’-O-benzoyl-α-L-threofuranosyl)guanosine-3’-monophosphor-2-	
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methylimidazolide	(5.23d)	General	procedure	C	with	0.94	g	(1.9	mmol)	of	5.22d,	12	mL	of	anhydrous	DMF,	1.3	mL	(9.9	mmol)	of	triethylamine,	355	mg	(4.9	mmol)	of	2-methylimidazole,	1.29	g	(4.9	mmol)	of	triphenylphosphine,	 1.086	 g	 (4.9	 mmol)	 of	 dipyridyl	 disulfide.	 First	 precipitation	 was	achieved	with	150	mL	of	diethyl	ether.	The	product	was	resuspended	with	5	mL	of	CH2Cl2	and	 dropwise	 added	 to	 the	 solution	 containing	 1.5	 g	 of	 sodium	 perchlorate,	 6	 mL	 of	trimethylamine	in	150	mL	of	ethyl	acetate	for	the	second	precipitation.	The	product	afford	as	a	white	solid	5.23d;	yield:	0.88	g	(82.1	%);	31P	NMR	(162	MHz,	DMSO-d6):	δ		-9.77;	HRMS	(ESI-TOF)	calcd.	for	C22H22N7O8PNa	[M	+	Na]+	566.1165;	found	566.1163.		
N2-Acetyl-9-(2’-O-benzoyl-α-L-threofuranosyl)guanosine-3’-(γ-(2-
(pyrenesulfonyl)ethyl))	triphosphate	(5.24d)	General	procedure	D	with	0.5	g	(0.92	mmol)	of	5.23d,	0.56	g	(1.2	mmol)	of	7	and	10	mL	(9.2	 mmol,	 1.5	 M	 in	 anhydrous	 DMF)	 of	 ZnCl2	 solution	 for	 3	 hours	 stirring	 at	 room	temperature.	 The	 product	 was	 purified	 by	 silica	 gel	 chromatography	 with	 eluents	[(H2O/isopropanol	 from	 5%	 to	 10%	 then	 H2O/(isopropanol-MeCN	 1:1)	 containing	 1%	diisopropylethylamine	(DIPEA)]	to	afford	the	white	solid	5.24d;	yield:	0.74	g	(80.9	%);	TLC	(1:10	H2O-acetonitrile	with	2%	DIPEA)	Rf	=	0.31;	1H	NMR	(400	MHz,	D2O)	d	12.00	(m,	1H),	8.96	(d,	1H,	J	=	8.4	Hz),	8.65	(d,	1H,	J	=	8.2	Hz),	8.48-8.42	(m,	3H),	8.39-8.30	(m,	1H),	8.28	(s,	1H),	8.19-8.11	(m,	2H),	7.99-7.97	(m,	1H),	7.51	(brs,	2H),	7.25	(s,	2H),	7.13	(s,	2H),	7.01	(s,	1H),	6.01	(s,	1H),	5.85	(s,	1H),	5.09	(s,	1H),	4.63	(s,	1H),	4.19	(s,	2H),	3.90	(d,	2H,	J	=	5.6	Hz),	3.07	(s,	2H),	1.93	(s,	3H);	31P	NMR	(162	MHz,	D2O)	δ	-12.87(brs,	2P),	-20.71	(brs,1P);	HRMS	(ESI-TOF)	calcd.	for	C36H30N5O17P3SNa	[M-2H+Na]-952.0473;	found	952.0466	
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9-(α-L-threofuranosyl)guanosine-3’-triphosphate	(5.25d)	General	procedure	E	with	0.55	g	of	5.24c,	50mL	of	33%	NH4OH(aq)	for	3	hours	deprotection	at	37	oC	and	then	15	hours	at	room	temperature.	The	product	was	afforded	as	a	white	solid;	yield:	0.24	g	(87.2	%,	ε253	=	13700	M-1cm-1);	1H	NMR	(400	MHz,	D2O)	δ	7.84	(m,	1H),	6.06	(d,	1H,	J	=	7.2	Hz),	5.84	(1	H),	4.53	(d,	1	H,	J	=	8	Hz),	4.41	(m,	1H),	4.31	(s,	2H),3.35	(m,	2H),	2.96	(m,	1H);	31P	NMR	(162	MHz,	D2O)	δ	-9.75	(d,	J	=	20.4	Hz),	-	11.27	(d,	J	=	20.4	Hz),	-22.16	(d,	J	=	16.2	Hz).		
Scheme	5.11:	Synthesis	of	L-2’-deoxythymidine-5’-triphosphate	(L-dTTP,	5.31)	
	
	
	
	
	
	
	
	
	
	
	
	
(Scheme	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)	
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3’-Benzoyl-2’-deoxy-L-thymidine-5’-dibenzylmonophosphate	(5.27)	General	procedure	A	with	200	mg	(0.6	mmol)	of	26,	72.9	mg	(1.18	mmol)	of	tetrazole,	12	mL	 of	 anhydrous	 solution	 (MeCN/CH2Cl2,	 1:1),	 260	 μL	 (0.75	 mmol)	 of	 dibenzyl-N,	 N	diisopropylphosphoramidite	for	3	hours	reaction	at	room	temperature.	Then	2	mL	of	30%	H2O2(aq)	for	1	hour	oxidation	reaction	at	room	temperature.	Column	chromatography	with	eluents	(MeOH/CH2Cl2,	from	1%	to	1.4	%)	to	afford	the	product	5.27	as	a	white	solid;	yield:	0.32	g	(68.2%);	TLC	(MeOH/CH2Cl2,	1:40)	Rf	=	0.23;	1H	NMR	(400	MHz,	CD3OD)	δ	7.96	(d,	2H,	J	=	7.6	Hz),	7.55-7.52	(m,	1H),	7.41-7.38	(m,	3H),	7.31-7.25	(m,	10H),	6.30	(dd,	1H,	J	=	14.4,	2.4	Hz),	5.35	(d,	1H,	J	=	6.8	Hz),	5.06-5.03	(m,	4H),	4.31-4.28	(m,	2H),	4.24	(brs,	1H),	2.42	(dd,	J	=	19.2,	8.4	Hz),	2.21-2.14	(m,	1H),	1.72	(s,	3H);	13CNMR	(125.8	MHz,	CD3OD)	δ	167.9,	166.7,	152.9,	137.8,	137.7,	137.7,	137.7,	137.6,	135.4,	131.5,	131.3,	130.6,	130.5,	130.5,	130.0,	130.0,	112.9,	87.0,	84.7	(d,	JC,P	=	6.5	Hz),	76.9,	71.8	(t,	J	C,P	=	4.5	Hz),	69.4	(d,	J	C,P	=	4.6	Hz),	38.6,	13.4	(d,	J	C,P	=	2.7	Hz);	31P	NMR	(162	MHz,	CD3OD)	δ	0.19;	HRMS	(ESI-TOF)	calcd.	for	C31H31N2O9PNa	[M+Na]+	629.1665;	found	629.1685.	
	
3’-Benzoyl-2’-deoxy-L-thymidine-5’-monophosphate	(5.28)	General	procedure	B	with	300	mg	(0.49	mmol)	of	5.27,	15	mL	of	MeOH,	and	80	mg	of	10%	Pd/C	for	3	hours	stirring	at	room	temperature.	The	suspension	was	filtered	over	a	pad	of	celite,	and	washed	with	60	mL	of	MeOH	containing	2%	triethylamine	four	times	to	afford	the	product	5.28	as	a	white	foam	of	triethylammonium	salt;	yield:	190	mg	(91.3	%);	TLC	(MeOH/CH2Cl2,	1:10	with	1%	triethylamine)	Rf	=	0;	1H	NMR	(400	MHz,	CD3OD)	δ	8.05-	7.89	(m,	3H),	7.64-7.50	(m,	3H),	6.47	(s,	1H),	5.66	(s,	1H),	4.40	(brs,	2H),	3.33-3.26	(m,	2H),	2.53	
175		
(s,	2H),	1.96	(s,	3H);	13C	NMR	(125.8	MHz,	CD3OD)	δ	168.1,167.3,	153.4,	138.9,	135.3,	131.8,	131.4,	130.5,	113.2,	86.9,	86.3,	78.8,	67.0,	48.2,	39.3,	13.4;	31P	NMR	(162	MHz,	CD3OD)	δ	1.02	;	HRMS	(ESI-TOF)	calcd.	for	C10H14N2O8P	[M-H]-	321.0488;	found	321.0493.		
3’-Benzoyl-2’-deoxy-L-thymidine-5’-phosphor-2-methylimidazolide	(5.29)	General	procedure	C	with	180	mg	(0.42	mmol)	of	5.28,	8	mL	of	anhydrous	DMF,	300	μL	(2.1	mmol)	of	triethylamine,	86	mg	(1.0	mmol)	of	2-methylimidazole,	275	mg	(1.0	mmol)	of	triphenylphosphine,	242	mg	(1.0	mmol)	of	dipyridyl	disulfide	for	2	hours	reaction	at	room	temperature.	First	precipitation	was	achieved	with	50	mL	of	diethyl	ether.	The	product	was	resuspended	with	10	mL	of	DMF	and	dropwise	added	to	the	solution	containing	700	mg	of	sodium	 perchlorate,	 15	 mL	 of	 triethylamine	 in	 100	 mL	 of	 ethyl	 acetate	 for	 the	 second	precipitation.	The	product	was	afforded	as	a	white	solid	5.29;	yield:	145	mg	(96.9%);	31P	NMR	(162	MHz,	CD3OD)	δ	-7.85;	HRMS	(ESI-TOF)	C21H23N4O8PNa	[M+Na]+	513.1151;	found	513.1146		
3’-Benzoyl-2’-deoxy-L-thymidine-5’-(γ-(2-(pyrenesulfonyl)ethyl))triphosphate	
(5.30)	General	 procedure	 D	 with	 170	 mg	 (0.44	 mmol)	 of	 5.29,	 248	 mg	 (0.53	 mmol)	 of	 2-	(pyrenesulfonyl)ethyl]-pyrophosphate	(7)	and	3	mL	(4.40	mmol)	of	ZnCl2	solution	(1.5	M	in	anhydrous	DMF)	for	3	hours	stirring.	After	the	reaction,	the	solution	was	precipitated	by	150	mL	of	ether.	Silica	column	chromatography	with	eluents	(H2O/(isopropanol-MeCN	1:1)	from	2%	 to	 7%	 containing	 1%	 diisopropylethylamine	 (DIPEA)	 to	 afford	 the	white	 solid	5.30;	yield:	150	mg	(46.7%);	TLC	(H2O/isopropanol	1:10	containing	2%	DIPEA):	Rf	=	0.35;	1H	NMR	
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(400	MHz,	DMSO-d6+	D2O	(1:2))	δ	:	8.99	(brs,	1H),	8.65	(d,1H,	J	=	8	Hz),	8.32-	8.21	(m,	5	H),	8.15-8.09	(m,	2H),	7.98-7.87	(m,	2H),	7.70	(s,	1H),	7.56-7.55	(m,	1H),	7.41	(s,	1H),	6.22	(t,	1H,	J	=	4	Hz)	,	5.10	(s,	1H),	4.35	(s,	2H),	4.22	(s,	1H),	4.11	(s,	1H),	3.92	(t,	2H,	J	=	4	Hz),	2.33	(s,	1H),	1.88	(s,	1H);	31P	NMR	(162	MHz,	DMSO-d6	+	D2O	(1:2))	δ	-10.99	(brs,	1P),	-11.26	(brs,	1P)	-20.94	(brs,	1P);	HRMS	(ESI-TOF)	calcd.	For	C35H31N2O17P3SNa	[M-2H+Na]-	899.0459;	found	899.0454.	
	
L-2’-deoxythymidine-5’-triphosphate	(5.31).	General	procedure	E	with	20	mg	(0.04	mmol)	of	5.30,	10	mL	of	33%	NH4OH(aq)	for	15	hours	stirring	at	room	temperature.	The	product	5.31	was	afforded	as	a	white	solid;	yield:	8	mg	(83.2%);	1H	NMR	(400	MHz,	D2O)	δ	7.84	(s,	1H),	6.28	(t,	1H,	J	=	6.0	Hz),	5.17	(s,	1H),	4.54	(s,	1H),	4.15	(d,	1H,	J	=	10.4	Hz),	2.83-2.77	(m,	1H),	2.49	(s,	1H),	2.45	(s,	2H),	2.00	(s,	3H);	31P	NMR	(162	MHz,	D2O)	δ	-4.38	(d,	J	=	16.2	Hz),	-10.65	(d,	J	=	16.2	Hz),	-19.74	(brs).		
Analytical	Reverse-Phase	HPLC	Analysis.	2	μL	of	reaction	crude	(5.10-5.11a-d,	and	5.16-5.17,	and	5.22-5.23a-d,	and	5.28-5.29)	in	DMF	or	1	μL	of	purified	pyrene	substituted	nucleoside	triphosphates	(5.12a-d,	and	5.18,	and	5.24a-d,	and	5.30)	in	methanol	or	3	μL	of	nucleoside	triphosphates	(5.13a-d,	and	5.19,	and	5.25a-d,	and	5.31)	in	H2O	was	added	to	50	μL	of	0.1	M	triethylammonium	acetate	(TEAA)	buffer	pH	7.0.	The	solution	was	centrifuged	by	4000	rpm	for	2	minutes	at	room	temperature	and	30	μL	of	supernatant	was	injected	for	HPLC	analysis.	Reaction	progress	of	the	synthesis	of	 nucleoside	 monophosphates	 (5.10a-d,	 and	 5.16,	 and	 5.22a-d,	 and	 5.28),	 nucleoside	phosphor-	 2-methylimidazolides	 (5.11a-d,	 and	 5.17,	 and	 5.23a-d,	 and	 5.29),	 pyrene	
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substituted	 nucleoside	 triphosphates	 (5.12a-d,	 and	 5.18,	 and	 5.24a-d,	 and	 5.30)	 and	nucleoside	triphosphates	(5.13a-d,	and	5.19,	and	5.25a-d,	and	5.31)	in	figure	5.1	to	5.10	was	monitored	 by	 analytical	 HPLC	 chromatography	 with	 the	 gradient	 from	 0%	 to	 50	 %	 of	acetonitrile	 in	 0.1	M	 triethylammonium	 acetate	 buffer	 pH	 7.0	 over	 forty	minutes.	 Purity	determination	of	synthesized	5’-dNTPs	(5.13a-d)	was	monitored	by	the	co-injection	with	the	commercial	5’-	dNTPs	purchased	from	Sigma-Aldrich	by	analytical	HPLC	chromatography	in	figure	 S11	 to	 S14	 with	 the	 gradient	 from	 0%	 to	 10	 %	 of	 acetonitrile	 in	 0.1	 M	triethylammonium	acetate	buffer	pH	7.0	over	forty	minutes	of	analytical	run.		
PCR	Fidelity	Assay.	A	100	μl	PCR	reaction	was	performed	in	1x	ThermoPol	buffer	(20	mM	Tris-HCl,	10	mM	(NH4)2SO4,	 10	 mM	 KCl,	 2	 mM	MgSO4,	 0.1%	 Triton	 X-100,	 pH	 8.8,	 NEB),	 0.5	 μM	 of	 Fwd	[CAACCGGTCCCCACGTTGCC]	 and	 Rev	 [AACGGCTGGGAGAACCTGGTTCTCAATGTA]	 PCR	primers,	400	μM	dNTPs	(Chemically	Synthesized	vs	Life	Technologies),	4.4	ng	of	pGDR11	KOD-RS	 plasmid	 [Target	 sequence:	CAACCGGTCCCCACGTTGCCGTTGCCAAGAGGTTGGCCGCGAGAGGAGTCAAAATACGCCCTGGAACGGTGATAAGCTACATCGTGCTCAAGGGCTCTGGGAGGATAGGCGACAGGGCGATACCGTTCGACGAGTTCGACCCGACGAAGCACAAGTACGACGCCGAGTACTACATTGAGAACCAGGTTCTCCCAGCCGTT]	 with	 final	 concentration	 of	 5	 units/100	 μL	 Taq	 polymerase	 (NEB).	 The	 PCR	conditions	were:	95	oC,	2.5	min	(melt),	95	oC,	30	sec,	62	oC,	45	sec,	72	oC,	30	sec	for	20	cycles	and	an	additional	72	oC,	2	min.	The	amplified	amplicon	(200bp)	was	agarose	purified,	ligated	into	 a	 TOPO-TA	 vector,	 and	 subsequently	 cloned	 into	 NEB	 DH5a	 E.	 coli	 competent	 cells	following	the	manufacturer’s	instructions.	Individual	colonies	were	grown	in	liquid	media	
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and	sequenced	using	 the	M13F	primer	by	Retrogen,	San	Diego,	CA.	DNA	sequences	were	aligned	and	analyzed	using	MEGA7	software.	Five	sequences	clones	were	analyzed	for	each	condition	to	give	a	total	of	750	nucleotide	positions.		
	
	
TNA	Transcription	Assay.	Primer-extension	reactions	were	performed	in	a	final	volume	of	20	μl.	Each	reaction	contained	10	pmol	of	primer	[IR680	-	5'-GTCCCCTTGGGGATACCACC-3']	annealed	to	10	pmol	of	template	[5’ATCGAGTACAGTCAGATCGATATGATCTATATATTAATTAGGTGGTATCCCCAAGGGGAC-3’],	1x	ThermoPol	buffer,	0.5	μM	KOD-RS,	100	μM	of	each	tNTP.	Reactions	were	incubated	for	120	min	at	55ÅãC,	quenched	with	stop	buffer	(40%	Formamide	and	1x	TBE	buffer,	10	mM	EDTA),	and	analyzed	by	10%	denaturing	urea	PAGE.		
Table	5.1.	Crystal	data	and	structure	refinement	for	pyrene	pyrophosphate	(5.7).	Identification	code																																																																									jcc7	(Liao	Jen-Yu)	Empirical	formula																																																																																	C24H31NO9P2S	Formula	weight																																																																																																			571.50	Temperature																																																																																																				133(2)	K	Wavelength																																																																																																								0.71073	.	Crystal	system																																																																																							Orthorhombic	Space	group																																																																																																														Pbca	Unit	cell	dimensions																																																													a	=	9.0890(17)	.	a=	90Å.																																																																																																								b	=	17.092(3)	.	b=	90Å.																																																																																																								c	=	34.022(6)	.	g	=	90Å.	
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Volume																																																																																																									5285.2(17)	.3	Z																																																																																																																																													8	Density	(calculated)																																																																																			1.436	Mg/m3	Absorption	coefficient																																																																																		0.297	mm-1	F(000)																																																																																																																												2400	Crystal	color																																																																																																										colorless	Crystal	size																																																																											0.585	x	0.353	x	0.044	mm3	Theta	range	for	data	collection																																																									1.197	to	26.372Å	Index	ranges																																																				-11	≤	h	≤	11,	-21	≤	k	≤	21,	-42	≤	l	≤	42	Reflections	collected																																																																																																	52512	Independent	reflections																																																												5402	[R(int)	=	0.0393]	Completeness	to	theta	=	25.500Å																																																																									99.9	%	Absorption	correction																																												Semi-empirical	from	equivalents	Max.	and	min.	transmission																																																														0.8621	and	0.7124	Refinement	method																																																					Full-matrix	least-squares	on	F2	Data	/	restraints	/	parameters																																																																	5402	/	0	/	349	Goodness-of-fit	on	F2																																																																																																				1.213	Final	R	indices	[I>2sigma(I)	=	4887	data]																					R1	=	0.0569,	wR2	=	0.1343	R	indices	(all	data,	0.80	.)																																																				R1	=	0.0628,	wR2	=	0.1370	Largest	diff.	peak	and	hole																																																												0.611	and	-0.388	e-3	
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Table	5.2.	PCR	Fidelity.	
Commercial	dNTPs	 Chemically	synthesized	dNTPs	
Expected	 Mutation	 Count	
	
Expected	 Mutation	 Count	
	A	 C	G	T	
0	2	0	
	
A	 C	G	T	
0	1	0	
	C	 A	G	T	
0	0	0	
	
C	 A	G	T	
0	0	0	
	G	 A	C	T	
0	0	0	
	
G	 A	C	T	
0	0	0	
	T	 A	C	G	
0	0	0	
	
T	 A	C	G	
0	0	0	
	Total	nucleotide	positions	=	750	 Total	nucleotide	positions	=	750	
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184		
Chapter	6	
Conclusions		
	The	research	accomplishments	presented	in	this	thesis	have	described	optimal	synthetic	strategies	 for	 α-L-threofuranosyl	 (TNA)	 monomers,	 nucleoside	 phosphoramdites,	 and	nucleoside	 triphosphates	synthesis	with	high	scalability.	Those	molecular	building	blocks	are	 used	 as	 immediate	 substrates	 to	 construct	 the	 TNA	 oligonucleotides	 chemically	 or	enzymatically	 for	 functional	 property	 evaluation	 and	 therapeutic	 application	 toward	 the	selected	biological	targets.		Here	we	have	developed	a	ten-step	synthetic	strategy	for	the	synthesis	of	TNA	nucleoside	monomers	and	phosphoramidites	in	quantitative	scale.	Key	challenges	have	been		resolved	and	purification	steps	were	minimized	 to	 increase	 the	yield	of	product	synthesis.	Several	TNA	nucleoside	intermediates	were	also	prepared	to	be	used	as	the	immediate	precursors	for	the	following	modified	TNA	nucleoside	and	nucleotide	synthesis.			Then	a	stepwise	synthetic	strategy	was	developed	to	construct	the	α-L-threofuranosyl	nucleoside	 monophosphates	 and	 nucleoside	 triphosphates.	 This	 method	 overcame	 the	challenge	of	poor	phosphorylation	efficiency	on	3’-OH	of	TNA	nucleoside	by	introducing	the	combined	 phosphitylation-oxidation	 reaction.	 The	 resulting	 TNA	 nucleoside	monophosphate	 precursors	 were	 subjected	 to	 a	 silica	 gel	 chromatography	 and	hydrogenation	reaction	to	generated	high	purity	of	TNA	nucleoside	monophosphates	that	preclude	 the	 HPLC	 purification.	 Then	 the	 stepwise	 high	 yield	 conversion	 from	 α-L-
185		
threofuranosyl	nucleoside	3’-monophosphates	to	nucleoside	3’-monophosphate	derivatives	to	nucleoside	3’-triphosphates	 facilitated	a	 throughput	HPLC	chromatography	of	 the	 final	products.	 This	 synthetic	 strategy	 was	 extensively	 applied	 to	 the	 2’-deoxy	 TNA	 nucleoside	triphosphates	 (Chapter	 4),	 and	 7-deaza-7-phenyl	 TNA-Guanosine	 nucleoside	 triphosphate,	Fluorescence	 activated	 tricyclic	 TNA-cytosine	 nucleoside	 triphosphate	 and	 several	 modified	TNA-Uracil	nucleoside	triphosphates	synthesis.		We	used	this	idea	for	the	chemical	synthesis	of	2′-deoxy-α-L-threofuranosyl	nucleoside	3′-triphosphates	 (dtNTPs).	 The	 key	 synthetic	 challenge	 was	 resolved	 by	 introducing	 the	triethylborane	as	the	radical	initiator	for	room	temperature	2’-deoxygenation	reaction	of	TNA	nucleosides.	Stepwise	phosphorylation	strategy	developed	in	chapter	4	allows	the	synthesis	of	2′-deoxy-α-L-threofuranosyl	nucleoside	3′-triphosphates	bearing	all	four	genetic	bases.	Looking	into	 future,	we	 suggested	 these	molecules	 can	be	used	as	 the	 chain	 terminators	 to	 study	 the	mechanism	of	TNA	synthesis	by	a	TNA	polymerase.	The	information	gained	from	this	studies	will	allow	 us	 to	 engineer	 the	 polymerase	 variants	 with	 better	 efficiency	 and	 faithful	 genetic	information	delivery.		Finally,	we	developed	 	a	novel	pyrophosphate	reagent	and	described	a	 fundamentally	different	 approach	 to	 generate	 triphosphate	 derivatives	 that	 are	 purified	 by	 silica	 gel	chromatography	and	converted	to	the	desired	compounds	on	scales	vastly	exceeding	those	achievable	by	HPLC.	The	power	of	this	approach	is	demonstrated	through	the	synthesis	of	a	broad	range	of	natural	and	unnatural	nucleoside	triphosphates	(dNTPs	and	xNTPs)	using	protocols	that	are	efficient,	inexpensive,	and	operationally	straightforward.		
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Current	development	of	a	P(V)	pyrophosphate	reagents	in	the	lab	has	made	it	possible	to	synthesize	the	gram	scale	of	natural/modified	nucleoside	triphosphate	using	a	silica	gel	chromatography	 instead	 of	 using	 HPLC	 purification.	 Extensive	 applications	 on	 the	 other	phosphorylated	 reagent	 analogues	 are	 under	 consideration.	 Look	 into	 future	 prospect,	installation	of	solid	support	on	monophosphate	or	pyrophosphate	reagents	are	feasible	idea	to	improve	the	purification	process	of	phosphorylated	molecules.	And	this	kind	of	reagents	could	be	used	as	a	substrate	for	our	engineered	polymerases	for	checking	their	mechanism.			 														
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